Clinical Investigations Kft

Planning - Monitoring - Evaluation - Reporting

Clinical Trial Report

Prospective multicentric open clinical study comparing the efficacy and safety of PIASCLEDINE® 300 plus standard treatment versus standard treatment only in patients with osteoarthritis of the knee

Protocol No. PIAS005/06
EudraCT No. 2007-004973-25

Final version: 06 September 2010

Sponsor:
Laboratoires Expanscience
10, Avenue de l'Arche
F-92400 Courbevoie
France

Study Coordinator:
Professor Dr. Ruxandra Ionescu
St. Maria Hospital
37-39 Ion Michalache Blvd.
Bucharest
Romania

Scientific Advisor:
Renée-Liliane Dreiser, MD
4, rue Chauveau Lagarde
75008 Paris,
France

Contract Research Organisations:

ZAK-PHARMA Dienstleistung GES.M.B.H.
Amalienstrasse 48/8
A-1130 Vienna Austria

M&M CRE
Calea Plevnei 141, Apt. 33
060011 Bucharest, Romania
Until August 2009

Clinical Investigations Services S.r.l.
Calea Plevnei 141, Apt. 33
060011 Bucharest, Romania
From September 2009

1 TITLE PAGE

Clinical Study Report

Report title	Prospective multicentric open clinical study comparing the efficacy and safety of PIASCLEDINE® 300 plus standard treatment versus standard treatment only in patients with osteoarthritis of the knee
Name of test drug	Piascledine 300 mg capsules
Indication studied	Osteoarthritis of the Knee
Name of the sponsor Address:	Laboratoire Expanscience 10, Avenue de l'Arche F-92400 Courbevoie France
Protocol Number	PIAS005/06
Drug Development Phase	IV
Study Initiation Date	08 September 2008 (first patient in)
Study Completion Date	02 November 2009 (last patient out)
Coordinating Investigator	Prof. Dr. Ruxandra Ionescu
Author	Gerhard Krejci, PhD, Dr. h.c., Hon. Prof. Clinical Investigations Ltd 4 Churchill Court, 58 Station Road Harrow HA2 7ST, UK
Date	06 September 2010

This study has been performed in compliance with Good Clinical Practice regulations.

2 SYNOPSIS

Title of Study:	Prospective multicentric open clinical study comparing the efficacy and safety of PIASCLEDINE 300 plus standard treatment versus standard treatment only in patients with osteoarthritis of the knee
Phase:	IV
Investigators:	Prof. Zhaneta Georgieva, Varna Dr. Beata Kołodziejczyk, Warszawa Dr. Michal Barszczewski, Legionowo Dr. Anna Dargiewicz, Warszawa Prof. Dr. Ruxandra Ionescu, Bucharest Dr. Adrian Sărbu, Bucharest Dr. Monica Bunea, Bucharest Dr. Mihail Bogdan Jantes, Targoviste MUDr. Valeria Durdikova, Bratislava MUDr. Roman Jančovic, Bratislava
Study Centres:	University Hospital „St. Marina",Varna NZOZ Lecznica Medea, Warszawa Indywidualna Specjalistyczna Praktyka Lekarska, Legionowo NZOZ Poradnia Medicynej Rodziniej, Warszawa Sf. Maria Hospital, Bucharest, Sana Medical Center, Bucharest Fortis Medical Center, Bucharest County Hospital, Targoviste Nestatna reumatologicka ambulancia, Bratislava Romjan s.r.o., Bratislava
Publication (reference)	None
Study Period	Date of first enrolment: 08 September 2008 Date of last enrolment: 01 June 2009 Date of finishing the study: 02 November 2009
Trial Objective	To evaluate the efficacy and safety of Piascledine® 300 in the treatment of osteoarthrosis of the knee, by comparing two parallel groups: Piascledine® 300 associated with the Standard Treatment (PAST) versus Standard Treatment Only (STO). Further to evaluate the Quality of Life and the consumption of rescue medication.
Number of patients (planned and analysed)	300 (150 in each group)
Diagnosis and main criteria for inclusion	Female or male outpatients aged 45 years or more suffering from femoro-tibial osteoarthritis of the knee uni- or bi-compartmental, uni- or bilateral and/or femoro-patellar, progressing for at least 6 months, with overall pain assessed between 25 and 50 mm on the VAS, in spite of daily intake of

	DICLOFENAC 75 to 150 mg/d or equivalent for **at least 10 days** per month, for at least 3 months prior to inclusion.
Test product, dose and mode of administration, batch numbers Duration of treatment	Piascledine® 300 mg capsules Oral, once 300 mg daily Batch number according to the local distributors 180 days with 5 visits per patient D 0 – D 45 – D 90 – D 135 – D 180
Reference therapy, dose and mode of administration, batch numbers	Group 1: Standard Treatment Only (NSAIDs) = Diclofenac, Ibuprofen, Naproxen, Nimesulide, Piroxicam, in equivalent dosages (=STO) Group 2: Piascledine 300 mg once daily + Standard treatment (= PAST) Batch number according to the local distributors
Criteria for evaluation, efficacy:	Number of patients not requiring NSAIDs from visit 2 (day 45) Number of days until NSAIDs were stopped Number of days until NSAIDs were resumed Consumption of rescue medication Pain evaluation assessed on VAS Lequesne-Index Health Status Score (Quality of Life - SF12) Final evaluation of overall efficacy by patients and physicians
Criteria for evaluation, safety:	Final evaluation of patient´s and physician´s on overall tolerability Adverse events monitoring
Statistical methods:	Depending on parameters, specific graphic Exploratory Data Analysis –EDA techniques are used to visualize outlying data. Depending on parameters, averages and standard deviations, medians and extremes, number of subjects in classes are calculated. Comparison of the groups before treatment was studied on D 0 using the traditional statistical tests: Chi2 test or Friedman concordance test for the nominal variables and Mann-Whitney test for non-parametric variables have been used. The data were tested for normality with the Kolmogorov-Smirnov test. Also the repeated measures ANOVA was used to test the alterations of efficacy parameters through-out duration of the study,
Efficacy results:	The number of patients weaning off NSAIDs increased in the PAST-group continuously from Visit 2 to Visit 5. At the end of the trial 35.4% of the patients did not need NSAID any more. In the STO groups there was also a slight increase of patients stopping NSAID/medication, but on a much lower level. 7.4% of the patients did not use NSAID in the STO-group at the end of the trial. This difference between the STO- and the PAST-group is highly significant ($p<0.001$) during the entire duration of the study

	Also in all secondary efficacy criteria (Pain evaluation assessed on VAS, Lequesne-index, overall assessment of efficacy as well as in all issues of the Quality-of-life scale SF12, a significant difference between the two treatment groups has been revealed in favour of the Piascledine treatment.
Safety results:	Three SAEs have been observed during the trial in the PAST group (one death due to a lung tumour, one cholestatic icterus, one biliary colic) without or with unlikely relation to the treatment. In the PAST group 29 patients (19.3%) reported 35 Adverse Events, from which 6 have been assessed as possibly or probably related to the treatment, while 28 observations were not or unlikely related to the treatment (infections, accident etc.). In the STO-group 9 patients (6.0%) reported 14 adverse events, mostly known side effects of the NSAID. The overall tolerability of the Piascledine treatment has been assessed as excellent and good by the investigators in 98.7%, by the patients in 98.6%, in the STO-group.81.1% and 79.8%, respectively. Medium and poor tolerability for piascledine is assessed in 1.4% by investigators and patients, for STO in 18.9% by investigators, and in 20.3% by the patients.
Conclusion:	It has been proved in this investigation that the add-on therapy with Piascledine has a significant and clinically relevant positive effect on both the symptomatology of osteoarthritis and the quality of life.
Date of the report:	06 October 2010

3 TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT

3.1. LIST OF TABLES

3.2. LIST OF FIGURES

4 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

CRA	Clinical Research Associate
GCP	Good Clinical Practices
DDD	Defined Daily Dose
ASU	Avocado/Soybean Unsaponifiables
SYSADOA	Symptomatic Slow Acting Drugs of OsteoArthritis
NSAID	Non-Steroidal Anti-Inflammatory Drugs
WHO	World Health Organisation
EULAR	European League Against Rheumatism
PAST	Piascledine and Standard Therapy
S.D.	Standard Deviation
STO	Standard Therapy Only

Terminology used in the report for the visits:

V1	Visit 1, Day 0, Randomisation visit
V2	Visit 2, Study day 45 ± 15
V3	Visit 3, Study day 90 ± 15
V4	Visit 4, Study day 135 ± 15
V5	Visit 5, Study day 180 ± 15, End of Study

All other abbreviations and terms are standard and self-evident or irrelevant and therefore only explained on the appropriate site of the report.

5 ETHICS

5.1. INDEPENDENT ETHICS COMMITTEE (IEC) OR INSTITUTIONAL REVIEW BOARD (IRB)

The ethical standards adopted by the XVIII World Medical Assembly (Helsinki, 1964) and subsequent revisions have been strictly observed, as well as the European Union Good Clinical Practice standards for clinical trials. A copy is available in the investigator's study file.

Prior to the initiation of the study, the protocol, the information leaflet, the informed consent, the CRF, the chemical and pharmaceutical documentation, and the Investigator´s Brochure have been submitted to the local Ethics Committees (EC) for review and approval. A list with the members of the Ethics Committees was attached to the Ethical vote.

The study did not start until the local Ethics Committees and the Health Authorities had given their approval both to the protocol and to the associated consent and information sheets. An approval letter from the Ethics Committee was lodged in the Study File before commencement of the study. The Ethics Committee was informed of all protocol amendments likely to affect the safety of the subjects or the conduct of the trial. All serious and unexpected adverse reactions and other information that might alter the study design and/or touch the patient's risk in this study in any way were notified to this committee. A list of the Ethics Committee members, with an indication of the members that voted on the protocol, is lodged in the Study Files.

The patient's initials and birth data are used for identification purposes. A patient information sheet of each patient has been completed and kept in the hospital.

The study has been submitted to the following national authorities:

Bulgaria: Bulgarian Drug Agency at the Minister of Health (YAL)

Poland: Central Register of Clinical Trials (CRCT)

Romania: National Medicine Agency (NMA)

Slovakia: State Institute for Drug Control (SUKL)

The following local ethics committees approved the study:

Bulgaria:

Central vote: Bulgarian Drug Agency at the Minister of Health, date of submission 23 September, 2008, date of approval 23 December, 2008

Local EC: Ethic Commission in UMHAT "St. Marina", date of submission 23 September, 2008, date of approval : 23 February, 2009

Poland:

Bioethical Committee: Komisja Bioetyczna Okręgowej Izby Lekarskiej w Warszawie, date of submission: 27 February 2008, date of approval: 27 March 2008

Ministry: Centralna Ewidencja Badań Klinicznych, Warszawa, date of submission: 22 February 2008, date of approval: 28 May 2008

Romania:

Central vote: NMA (National Medicine Agency), Bucharest, Romania; date of submission 04 February 2008, date of approval 31 July 2008;

Ethics committees: National Ethics Committee, Bucharest, Romania; date of submission 04 February 2008, date of approval: 23 June 2008 for 3 sites in Bucharest (Sf. Maria Hospital, Fortis Medical Center and Sana Medical Center)

Emergency County Hospital Targoviste, date of submission 04 February 2008, date of approval: 08 September 2008.

Slovakia:

Central vote: Ethics committee of Bratislava samosprávny kraj, Sabinovská 16, 820 05 Bratislava, date of submission 25 Jan 2008, date of approval: 04 Mar 2008

5.2. ETHICAL CONDUCT OF THE STUDY

The study has been conducted in accordance with the following regulations:

- Declaration of Helsinki (Helsinki, 1964) and subsequent amendments.
- ICH. Note for guidance on good clinical practice. CPMP/ICH/135/95, 1996.
- EMEA. Notice to Marketing Authorisation Holders. Pharmacovigilance Guidelines. CPMP/PhVWP/108/99, 1999.
- Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.

5.3. PATIENT INFORMATION AND CONSENT

All patients participating in the study have been adequately informed as to the study characteristics, and their free and voluntary authorisation has been requested. Each patient selected has been informed of the nature, aim and procedures involved in the study, including the possible risks associated with the study.

Patients were informed that their participation was voluntary and that they were able to withdraw at any time, without consequences. They were also informed that the sponsor and its representatives, and the responsible authorities would have access to their clinical data.

Any patient agreeing to participate in the study signed the consent form, which is retained in the Investigator's Study Files. No patient could participate in the study until written informed consent has been signed.

The investigator also signed and personally dated the consent sheet. This indicates that informed signed consent has been gained and that the patient has had the opportunity to raise any issues or questions, and that these have been adequately answered.

The patient received a copy of the information and consent sheets, the original is retained in the Investigator's Study Files.

6 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

SPONSOR:

Laboratoires Expanscience
Dr. Philippe Coste
10, Boulevard de l'arche
92419 Courbevoie, France
+33 1 43 34 60 80

PROJECT MANAGER:

Zak Pharma Dienstleistung Ges.M.B.H.
Mag. Ingrid Hochmayer
A - 1130 Wien
Amalienstrasse 48/8
Austria
+43 1 879 38 95

SPONSOR'S MONITOR:

Zak Pharma Dienstleistung Ges.M.B.H.
A - 1130 Wien
Amalienstrasse 48/8
Austria
+43 1 879 38 95

M&M Cre
Calea Plevnei 141/33
060011 Bucharest
Romania
+40 21 310 75 80

CRO STATISTICS:

Clinical Investigations Services S.R.L.
Calea Plevnei 141/33
060011 Bucharest
Romania
+40 21 310 75 80

CLINICAL REPORT:

Clinical Investigations Ltd.
4 Churchill Court, 58 Station Road
Harrow Ha2 7st, Uk

INVESTIGATORS AND INVESTIGATIONAL SITES

BULGARIA

Prof. Dr. Zhaneta Georgieva
University Hospital „St. Marina"
9000 Varna
Phone +359 886 848379

POLAND

Dr. Beata Kołodziejczyk
NZOZ Lecznica Medea
Kleczewska 41
PL - 01-826 Warszawa
Phone +48 22 639 80 89

Dr. Anna Dargiewicz
NZOZ Poradnia Medycyny Rodziniej
Zwirki i Wigury 39
PL-02-132 Warszwawa
Phone: +48 22 823 89 45

Dr. Michal Barszczewski
Indywidualna Specjalistyczna Praktyka Lekarska, Ortopedyczna I Traumatologia
Piaskowa ½
PL-05-119 Legionowo
Phone + 48 22 686 09 10

ROMANIA

PROF. DR. RUXANDRA IONESCU
„Sf. Maria" Hospital
37 – 39, Ion Mihalache Boulevard,
1st district, Bucharest
Phone: +40 021 222 35 50, +40 21 222 35 51, +40 21 222 35 19
Fax +40 21 222 40 64, + 40 21 222 39 60

Dr. Adrian Sărbu
"Sana Medical Center"
3, „Dr. Dumitru Sergiu" Street, 2nd Apartment, 1st district, Bucharest
Mobile phone: +40 723318884
Phone/Fax: +40 21 212 8163
e-mail: adrian.sarbu@sana.ro

Dr. Monica Bunea
Fortis Medical Center
86, Constantin Sandu AldeaStreet
Bucharest
Phone +40 21 322 0107
Fax: +40 21 320 2753

Dr Mihail Bogdan Jantes
County Hospital Targoviste
78, T. Vladimirescu street,
Targoviste
Mobile phone:+40 744 242482
Phone: +40 245 631582

SLOVAK REPUBLIC

MUDr. Valeria Durdikova
Nestatna reumatologicka ambulancia
ZS Fedinova 9
SK-851 01 Bratislava
Phone :+421 2 63 81 11 63

MUDr. Roman Jančovic
Romjan s.r.o., reumatol. ambul.
Tehelná 26
SK-831 03 Bratislava
Phone: +421 911 900 330
Fax: +412 2 555 74 669

7 INTRODUCTION

Osteoarthritis (degenerative joint disease) is the most frequent condition affecting joints; osteoarthritis of the knee, in particular, is the main cause of functional incapacity in subjects aged 65+. Osteoarthritis of the knee is, indeed, a real issue of public health. It is estimated to have a 6.11% occurrence in adults aged 30+. This rate increases with age to reach over 40% after 75 years. In 2000, and then in 2003, EULAR (European League against Rheumatism) issued treatment recommendations regarding the management of osteoarthritis of the knee (1). These recommendations have been reviewed and revised according to evidence-based medicine; the recommendations are as follows:

1) Optimal management of osteoarthritis of the knee requires the combination of drug and nondrug therapies.
2) Treatment has to be adapted according to the risk factors associated to the knee (obesity, mechanical constraints, physical activity), to general risk factors (age, co-morbidity, multiple treatments), to the severity of the pain and disability, to the presence or absence of local signs of inflammation (swelling), to the location and severity of the lesions.
3) Non-pharmacological treatment should combine habitual education, physical exercise and technical aids (canes, soles, splints) and should be accompanied by weight loss. For example, significant weight loss can sometimes allow for delaying the application of a full prosthesis.
4) Paracetamol is the analgesic of choice and, if effective, long-term oral analgesic treatment is to be preferred.
5) Topical solutions (NSAID, capsaicin) are quite effective and have fewer side effects.
6) The use of NSAID must be considered in case of failure with paracetamol administered in adequate amounts (2 to 4 g per day) and over a reasonable period of time (approximately 2 weeks). In case of increased digestive risk, in particular in the age group up to 60, or in case of recent or old history of gastro-duodenal ulcers, especially if complications had developed (perforation, haemorrhages), the choice can be a traditional NSAID associated with a gastric balm or a prescription of an anti-Cox-2.
7) Opioids, alone or associated with paracetamol, are an alternative for patients with contraindications and/or low tolerance for NSAID, including Coxibs.
8) Symptomatic slow-acting drugs in osteoarthritis – SYSADOA (glucosamine sulphate, chondroitin sulphate, avocado unsaponifiables, diacerein, and, more recently, hyaluronic acid in intra-articular injection) have a symptomatic action and could have structural effects.
9) Corticoid infiltrations are indicated in case of inflammatory outbreaks, especially if there is engorgement (which has to be systematically punctured, in addition to this analgesic action; the puncture allows for the evaluation of the mechanical quality of the articular fluid).
10) Application of prostheses is to be considered for patients with radiological indications, refractory pain in spite of well-managed treatment, and functional disability. Therefore, osteoarthritis management strategies envisage the combination of pharmacological and non-pharmacological treatments.

Among the pharmacological treatments, one can distinguish:

- Symptomatic treatments, which aim at relieving the symptoms (pain and functional discomfort) during or between outbreaks; these treatments themselves are differentiated depending on their clinical kinetics of action (1)
- Fast-action symptomatic treatment: NSAID, analgesics
- Slow-action symptomatic treatments (2-6): i.e. treatments which allow for conservation of fast action treatments for acute episodes and aim at achieving long-lasting pain alleviation and reducing the discomfort and the number of outbreaks. This action includes administration of less NSAID, the adverse effects - especially digestive – of which are known, especially in cases of repeated or long-term administration.

PIASCLEDINE® 300 belongs to a class called "SYSADOA" (SYmptomatic Slow Acting Drugs in OsteoArthritis). It contains Avocado/Soybeans Unsaponifiables (ASU) in a 1:3 to 2:3 mixture (PIASCLEDINE® 300) and showed interesting properties *in vitro* and *in vivo* on animal models of experimental osteoarthritis, thus meeting the pharmacological pre-requisites one may expect for the basic treatment of osteoarthritis (7-11).

The ASU inhibit the interleukin 1 (IL-1) and stimulate the collagen synthesis on cultures of articular chondrocytes (7). The ASU can partly prevent the noxious effects of IL-1 on the synovial cells and can even abolish its effects on articular chondrocytes of rabbits (9). The anti-collagenolythic activity of the ASU and their capacity to inhibit partially the noxious effects of IL - 1 was shown in two recent studies: one on cultures of bovine articular chondrocytes (10), the other on cultures of human articular chondrocytes (11).

In clinical research, several prospective, multicentric, randomised studies, controlled versus placebo studies, double blind studies conducted on gonarthrosic and coxarthrosic patients showed delayed, prolonged symptomatic action of PIASCLEDINE® 300 in the osteoarthritis of the lower limbs (12, 13). This effect appears after approximately one to two months of treatment and persists two months after interruption.

In the study of Blotman et al. (12), patients affected by osteoarthritis of the knee and coxarthrosis were administered compulsorily an NSAID orally for 45 days (among 7 NSAID retained), associated with PIASCLEDINE® 300 or placebo. The consumption of NSAID was codified. The main evaluation criterion was the number of patients re-taking an NSAID and the period of re-administration after the interruption at D45. The results showed that withdrawal from NSAID starting with 45th day could be maintained until the end of the 3rd month in 57% of the patients treated with PIASCLEDINE® 300, versus 30% of the patients treated with placebo. The difference in patients overall (osteoarthritis of the knee) was statistically significant between the two treatment groups ($p < 0.001$). However, in several countries, a certain number of practitioners are not yet familiar with the use of slow acting drugs in osteoarthritis, in particular PIASCLEDINE® 300; in addition, there are no studies available, allowing us to evaluate the actual benefits of PIASCLEDINE® 300 in terms of saving NSAID. That was the reason this study was initiated, allowing for a comparison of two types of treatment of osteoarthritis of the knee:

- Standard treatments, namely: analgesics, NSAID (oral), prescription of physical exercise and dietetic measures
- Standard treatments associated with PIASCLEDINE® 300 CAPSULES.

These two types of therapeutic approaches to osteoarthritis of the knee were carried out by general practitioners and/or rheumatologists during the present study.

7.1. SIDE EFFECTS

Piascledine® safety could be thoroughly assessed from two categories of data:

- On one hand, the safety results obtained, in comparison with placebo during the clinical studies

- On the other hand. The post-marketing data, obtained from PSURs covering the 1002-2007 period.

Clinical safety data trend to confirm that Piascledine® 300 mg safety does not differ significantly from placebo. The results of the various presented studies are remarkably homogenous and consistent with respect to that aspect, and the AE incidences are in the same magnitude in the Piascledine® 300 mg and placebo groups, sometimes slightly lower in the placebo group (27.4% vs 25.6% in study PR292; 29.5% vs 26.1% in study PR594), sometimes slightly lower in the Piascledine® 300 mg group (11.3% vs 12.0% in study PR193; 59.3% vs 62.6% in study PR1399, and 73.6% vs 79.2% in study PR1600). In all these studies including a rather high number of patients (1085 included, from these 584 treated with Piascledine® 300 mg), no tendency towards a predominant type of adverse events or system organ was found.

The separate analysis of the most recent completed studies has confirmed the previously mentioned results versus placebo, and a comparable safety profile of Piascledine® 300 mg and Chondroitine (22).

Regarding the safety assessment through the post-marketing survey data, the crude incidence of AE remained quite low, while the calculated value over the last evaluation period (01 June 2002 to 31 May 2007) is about 0.075 cases per million treatment days.

7.2. INVESTIGATIONAL DRUG

Piascledine® 300mg is a *S*ymptomatic *S*low-*A*cting *D*rug in *O*steo*A*rthritis (SYSADOA). Its active ingredient is a combination of unsaponifiable fractions of avocado and soybean, in respective proportions of 1/3 and 2/3.

It was only in the early 1990s that preclinical work detailed the characteristics of Piascledine® 300mg concerning articular cartilage and its mechanism of action.

Pharmacological studies showed that Piascledine® 300mg had potential efficacy for the treatment of osteoarthritis. This efficacy has been acknowledged and has led to the creation of a new category of osteoarthritis treatment: *S*ymptomatic *S*low-*A*cting *D*rugs in *O*steo*A*rthritis (SYSADOA). This type of treatment is chiefly characterised by a predominant effect on pain and function, appearing a few weeks after initiation of treatment and lasting after treatment discontinuation.

7.3. COMPARATIVE DRUG

Comparators in the recent study were NSAIDs: Diclofenac, Ibuprofen, Naproxen, Nimesulide, Piroxicam.

8 STUDY OBJECTIVES

The objective of this study was to evaluate the efficacy and safety of PIASCLEDINE® 300 in the treatment of osteoarthritis of the knee, by comparing two parallel groups: PIASCLEDINE® 300 associated with the Standard Treatment (PAST) versus Standard Treatment Only (STO).

8.1. PRIMARY OBJECTIVES

The main criterion was the number of patients which do not require DICLOFENAC or equivalent NSAID from the beginning of the second visit V2 (D45) in both groups.

8.2. SECONDARY OBJECTIVES

The secondary efficacy criteria were:

- Period of NSAID interruption, in days: speed of weaning
- Duration of weaning: period of re-administering NSAID, in days
- Need for taking paracetamol: consumption in g (up to 4g/d) and period while taking paracetamol after interruption of NSAID
- Pain evaluation assessed on VAS,
- LEQUESNE index (index for osteoarthritis of the knee),
- Quality-of-life scale: SF12,
- Final evaluation of overall utility, by patient and investigator,
- Overall tolerability assessed by patient and investigator,
- Treatment compliance evaluation.

9 INVESTIGATIONAL PLAN

9.1. OVERALL STUDY DESIGN AND PLAN: DESCRIPTION

This study was a phase IV prospective, multicentre, open clinical study comparing the efficacy and safety of PIASCLEDINE® 300 plus standard treatment (PAST) versus standard treatment only (STO) in patients with osteoarthritis of the knee over a period of 180 days.

300 patients were involved in the study.

The study was conducted in the following countries: Bulgaria, Poland, Romania, and Slovakia.

9.2. TIME SCHEDULE/STUDY DURATION

The recruitment period was twelve months after study set-up. The patients were treated and followed-up for a period of 180 days, including 5 visits per patient (D 0, D 45, D 90, D 135, and D 180).

V1 (D 0) Inclusion visit

Informed consent
Demographics: date of birth, age
Complete clinical check-up: height, weight, blood pressure, general condition
Descriptive data: history, previous and concomitant treatments
Characteristics of the osteoarthritis of the knee
Control of inclusion and non-inclusion criteria
Health Status Questionnaire Score
LEQUESNE algo-functional index
VAS
Inclusion statement
Allocation of patients in one of the two treatment groups PAST/STO
Dispensing of medication
Patients' diary dispensing

V2 (D 45 ± 15)

Patients' diary return
Consumption of NSAID and consumption of analgesics
Withdrawal of NSAID and analgesics
Other treatments prescribed for gonarthrosis
Compliance
NSAID consumption check (patient's diary)
Paracetamol consumption check (patient's diary)
Adverse events
Health Status Questionnaire Score
LEQUESNE algo-functional index
VAS
Evaluation of tolerability
Handing-over of PIASCLEDINE in the PAST group
Patients' diary dispensing

V3 (D 90 ± 15) and V4 (D 135 ±15)

Patients' diary return
Data regarding NSAID and Paracetamol consumption
Other treatments prescribed for gonarthrosis
Compliance
NSAID consumption check (patient's diary)
Paracetamol consumption check (patient's diary)
Adverse events

Health Status Questionnaire Score
LEQUESNE algo-functional index
VAS
Evaluation of tolerability
Handing-over of PIASCLEDINE in the PAST group
Patients' diary dispensing

V5 (D 180 ± 15) End-of-test visit

Patients' diary return
Data regarding NSAID and Paracetamol consumption
Other treatments prescribed for gonarthrosis
Compliance
NSAID consumption check (patient's diary)
Paracetamol consumption check (patient's diary)
Adverse events
Health Status Questionnaire Score
LEQUESNE algo-functional index
VAS
Global assessment of efficacy
Global assessment of tolerability

A 15-days tolerance was accepted for the follow-up visits V2, V3, V4, V5, in order to match actual consultation intervals as they were carried out in ordinary practices.

In case of premature interruption of the study or incompleted intermediate consultation, a final visit was needed for clarifying in detail the reasons for interruption.

9.3. DISCUSSION OF STUDY DESIGN

9.3.1. Randomisation, Stratification

The randomisation to the two treatment groups was performed in a ratio of 1:1 (PAST-STO).

The randomisation was performed by ZAK-PHARMA Dienstleistung GES.M.B.H. using the computer program Rancode 1.0 (idv München, Gauting). The CRO kept the randomisation code under lock and key.

9.4. SELECTION OF STUDY POPULATION

To be included into the study the patients had to satisfy **all inclusion criteria** and **none of the exclusion criteria**.

9.4.1. Inclusion Criteria

- Female or male outpatients at least 45 years old,
- Affected by osteoarthritis of the knee, femoral-tibial joint single or double-compartment, one side or bilateral and/or femoral-patellar joint, meeting the criteria of the American College of Rheumatology progressing for at least 6 months, with overall spontaneous pain assessed between 25 and 50 mm on the VAS, in spite of daily intake of DICLOFENAC or equivalent 75 to 150 mg/d for at least 10 days per month, for at least 3 months prior to inclusion.
- Osteoarthritis of the knee confirmed radiologically, radiographies being not older than 12 months.
- The patient has a Lequesne-index over 5.
- The patient is capable to understand and comply with the study instructions.

9.4.2. Exclusion Criteria

Criteria regarding the underlying pathology:

- Articular chondrocalcinosis known in advance or defined by the presence of a calcic edging on at least one femoral-tibial articular space,
- Ochronoses, haemochromatoses, chondromatosis, villo-nodular synovitis, PAGET's disease, haemophilia, psoriasis
- Known symptomatic hip osteoarthritis (coxarthrosis), homolateral to the osteoarthritis of the knee,
- Osteoarthritis of the knee indicating for a surgical intervention within the presumed research time,
- Surgery (osteoectomy, meniscectomy, synoviorthesis) on the evaluated knee

Criteria concerning the patient:

- Contraindications for NSAID (history of gastro-duodenal ulcer, renal insufficiency or significant hepatic-cellular insufficiency or serious haematologic disease, history of allergy, insulin dependent diabetes),
- Severe progressive cardiac, pulmonary, renal, hepatic, haematologic, neoplastic or infectious condition,
- Leucopenia,
- Severe hereditary disease,
- Intolerance for PIASCLEDINE® 300,

Criteria regarding previous and associated treatments:

- Has taken slow-acting treatment for OA (SYSADOA) or received hyaluronic acid injections, within the 3 months prior to inclusion,
- Does not require drug treatment for OA,
- Has been involved in some other therapeutic study within three months preceding inclusion,

- Participating in some concomitant trial,
- Pregnant woman, or susceptible to become pregnant during the study period,
- Breast-feeding woman.

9.4.3. Removal of Patients From Therapy or Assessment

Every patient had the right at any time to withdraw his/her consent to participate. The investigator could also decide to interrupt treatment for any patient at any time.

9.4.4. Premature study discontinuation

Patients may withdraw or be withdrawn from the clinical study at any time without prejudice to their future treatment. In addition, patients may be withdrawn from the study by the investigator for any of the following reasons:

- Any adverse event after which a continuation of treatment would constitute an unacceptable high risk for the patient, including pathologic laboratory parameters.
- Any new or intercurrent disease likely to interfere with the conduct of the study.
- Patient is unwilling to adhere to the study requirement e.g. non-compliance or no cooperation.
- Occurrence of an exclusion criterion.

Whenever a patient discontinued the study, the circumstances of the withdrawal or discontinuation were recorded in detail in the CRF. The examinations of visit 5 (180 days) had to be performed in case of patient withdrawal or premature study discontinuation visit.

The study was planned to be terminated prematurely if:

- New toxicological or pharmacological findings or serious adverse events invalidate the earlier positive benefit-risk assessment.
- Adverse events occur in such severity and frequency that the proposed schedule can no longer be adhered to.
- The Sponsor decides to discontinue the further development of Piascledine®.

A study centre was to be closed if:

- It would have become apparent that patient enrolment is ineffective with respect to quality and/or quantity.
- Data recording was inaccurate and/or incomplete on a chronic basis.

9.5. TREATMENTS

9.5.1. Products Administered

The administered treatments were as follows:

- PIASCLEDINE 300, 1 capsule per day and standard treatment strategies or
- Standard treatment strategies only.

PIASCLEDINE 300 has been dispensed by the investigators.
The standard treatment included NSAIDs, analgesics, associated or not with gastric protectors, intraarticular corticoid injections, prescription of exercise and diet, use of canes.

9.5.2. Identity of Investigational Product(s)

Formula PIASCLEDINE® 300
Avocado/Soybeans unsaponifiables (ASU),
Total extract: 300mg/capsule
corresponding to : Avocado oil unsaponifiable: 100mg/capsule
Soybean oil unsaponifiable: 200mg/capsule
Excipients: colloidal anhydrous silica (Aerosil 200), butylhydroxytoluene.
Wrap: gelatine, titanium dioxide, erythrosin, yellow iron oxide
Calibration: n°1
Generic name: PIASCLEDINE
Galenic form: Capsule
Dosage: 1 capsule per day
Dosing: 300 mg
Administration route: oral
Batch number: according to the local distribution
Packaging: 10.8g (36 capsules) /month
Expiry date: according to the local distribution
Manufacturer/Country LABORATORIES EXPANSCIENCE/FRANCE

9.5.3. Treatment scheme

The standard treatment strategies allowed in the two groups were:

- NSAIDs (oral),
- Analgesics – Paracetamol
- Therapeutic means to correct NSAID iatrogenic effects, e.g. gastroprotective medication
- Intra-articular corticoid injections (if hydarthrosis develops after puncture),
- Use of canes,
- Prescription of exercise at home and/or kinesitherapy sessions,
- Prescription of diet if overweight,

Due to the lack of homogeneity between products and the absence of indication for osteoarthritis in different countries, topical NSAIDs should not be prescribed.

Several NSAIDs may be prescribed, according to DRUGDEX® System comparison table for different products (16).

For the same reasons of lack of homogeneity between products in different countries, opiate analgesics should not be prescribed.

9.5.3.1 Packaging and labelling

Marketed packaging of PIASCLEDINE® in each country.
Labelling was performed according to GCP specification.

9.5.3.2 Storage and management of the investigational medicinal products

The required investigational products were distributed to investigators at the initiation visit.

The investigational products were stored in a safe, secure and controlled area, with access only for investigator(s), study assistants participating in the trial-

The investigator dispensed Piascledine to the patients of the PAST group at each visit separately and at Visit 1 informed them verbally, how, when and how much should be taken and the remaining blisters should be taken back to the next visit (even in case of empty blisters).

Piascledine dispatched by the investigators might be used only within the study duration. For that period monitors had access to the investigational drugs for inspection purposes. At the end of the trial, all investigational medication, used or not used, should be returned to the CRO for final accountability and to be destroyed according to the national regulations.

Final accountability has been made by the CROs on site. Not used medication has been left with the investigators to be used up by former study patients with a minimum of 3 months expiry. Empty boxex and blisters have been destroyed on site with appropriate documentation.

9.5.4. Selection of Doses in the Study

The dosing was performed according to the recommendations in the Summary of Product Characteristics.

9.5.5. Prior and Concomitant Therapy

9.5.5.1 Concomitant medication
All concomitant medication with no relation to osteoarthritis have been recorded in the case report form.

9.5.5.2 Allowed (permitted) treatments
All treatment applied for a different pathology and not included among not allowed treatment forms was accepted and described in detail in the case report form.

9.5.5.3 Allowed NSAIDs
All NSAIDs considered as standard treatment for osteoarthritis in the various countries are allowed such as Diclofenac, Ibuprofen, Piroxicam, Nimesulide, Naproxen.

9.5.5.4 Forbidden (prohibited) treatments
No patient was allowed to receive any symptomatic slow acting drugs in osteoarthritis (SYSADOA), other than PIASCLEDINE 300 in the PAST group. No patient was allowed to receive topical NSAID, due to the non-homogeneity of products and the absence of indication for osteoarthritis of the knee in the different countries. For the same reasons (lack of homogeneity between products in different countries), opiate analgesics were not permitted to be prescribed.

9.5.6. Treatment Compliance

Patients belonging to the PAST group were profoundly informed by the investigators concerning the dosage of PIASCLEDINE .

Compliance evaluation was conducted in the following way:

- Patients returned the boxes and the used and unused blisters on V2, V3, V4, V5
- Investigators counted the remaining capsules,
- The amount of used and returned capsules was recorded in the case report form,
- Compliance evaluation calculated with the exact duration of the intervals V1/V2, V2/V3,V3/V4, V4/V5
- Compliance was calculated as follows:

$$\frac{(\text{No of capsules delivered} - \text{No of capsules returned}) \times 100}{\text{No of capsules per day} \times \text{No of days}}$$

- Differences between theoretical and effective consumption of capsules between visits, in %

In case of drop-outs or no show, the same calculation formula has been applied between V 0 and date of drop-out or date of last visit.
Compliance of the PAST group patients was evaluated as:

- Excellent: difference ± 10%,
- Very good: difference ± 20%,
- Good: difference ± 30%,
- Medium: difference ± 40%,
- Poor: difference equal to or higher than 40%.

9.6. ASSESSMENT OF EFFICACY, TOLERABILITY AND COMPLIANCE

9.6.1 Evaluation criteria

9.6.1.1 Main evaluation criterion

Number of patients not requiring DICLOFENAC or equivalent NSAID from the beginning of the second visit V2 (D45) in both groups

9.6.1.2 Secondary evaluation criteria

9.6.1.2.1. Efficacy

The secondary criteria for efficacy were:

- Number of days until NSAID was stopped
- Number of days until NSAID was resumed
- Paracetamol intake in g (maximum dosage allowed in each country) and duration of paracetamol intake,
- Pain evaluation, assessed on VAS,
- LEQUESNE index, (index for osteoarthritis of the knee),
- Health Status Questionnaire Score,
- The overall efficacy was assessed by the patient and the investigator at the final visit, by answering the following question: "How do you appreciate the overall efficacy of the treatment?" Variants of answers are: excellent, good, average, poor.

9.6.1.2.2. Tolerability

- The tolerability was evaluated on V2, V3, V4, V5, by recording the existence of adverse events. All the side effects that emerge during this study were recorded in the case report form.
- The overall tolerability was assessed by the patient and the investigator at the final visit, by answering the following question: "How do you appreciate the overall tolerance with the treatment?" Variants of answers are: excellent, good, average, poor.

9.6.2 CLINICAL TOLERABILITY EVALUATION CRITERIA

9.6.2.1 ADVERSE EVENTS

Definition of an AE

An adverse event or adverse experience (AE) is any untoward medical occurrence in a patient or clinical investigation subject who was administered a pharmaceutical product, and that does not necessarily have a causal relationship to this treatment.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal product.

This definition includes intercurrent illnesses or injuries, exacerbation of pre-existing conditions, and AEs occurring as a result of drug withdrawal, abuse, misuse or overdose. AEs observed during all periods of a clinical trial are to be recorded, including AEs occurring during a period without trial medication.

This also includes AEs which are reported after a patient has completed the clinical study.

Therapeutic failures during clinical trials are not considered to be AEs.

Therapeutic failures equivalent to lack of efficacy or symptom improvement or progression of symptoms at any time point during the study period, are not considered to be AEs.

For each AE, the investigator was obliged to provide sufficient information whether the AE was consequent to the progression of symptoms or not.

Definition of an SAE

A serious adverse event (SAE) is any event that suggests a significant hazard, contraindication, side effect, or precaution, whether or not it is considered to be associated with the trial product.

An SAE is one that meets any of the following criteria:

1. Results in death;
2. Is life-threatening;
3. Requires inpatient hospitalization or prolongation of existing hospitalization;
4. Results in persistent or significant disability/incapacity;
5. Is a congenital anomaly/birth defect;
6. Other important medical conditions:

Any other medical important events that, based upon appropriate medical judgment, are thought to jeopardize the patient or subject and/or require medical or surgical intervention to prevent one of the outcomes listed in the definition above, should also be reported in the same way as an SAE.

An **unexpected adverse event** is any experience not previously reported in nature, severity or incidence in the current Investigator's Brochure / SPC for Piascledine.

A planned hospitalization during the course of the study due to pre-existing conditions will not be considered an SAE.

Definition of an Adverse Drug Reaction (ADR)

The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out.

Regarding *marketed medicinal products* an ADR is a response to a drug which is noxious and unintended and which occurs at doses normally used in prophylaxis, diagnosis, or therapy of disease or for modification of physiological function.

Severity Classification of Adverse Events

For this study, the severity of an AE will be rated according to the following definitions:

Mild

Symptom barely noticeable to subject; it does not influence performance of daily activities or functioning. Prescription drug is not usually needed for relief of symptom but may be given on demand of the subject (because of personality of subject).

Moderate

Symptom of sufficient severity to cause subject uncomfortable feeling; performance of daily activities influenced; subject is able to continue the study; treatment for symptom may be needed.

Severe

Symptom causes severe discomfort. Maybe subject cannot continue the study: treatment with test drug has to be stopped. Treatment for symptom may be given and/or subject hospitalized.

Follow up Period for Serious and Non-Serious Adverse Events

Follow-up of all SAEs will be done until the outcome is resolved, has reached a stable condition in the investigator's opinion, or until the patient is lost to follow-up.

Based on the medical judgment of the investigator, all non-serious AEs (including the abnormal laboratory values identified as AEs by the investigators) had to be followed until 14 days after the patient completed the study. All non-resolved, non-serious AEs beyond such date were recorded as "ongoing" without further follow-up.

Any medical-related issues or questions requiring immediate resolution or action should be directed to the medical supervisor.

Relationship to Study Drug

For this study, the AE cause and effect relationship to the study drug have been classified in accordance with the WHO Causality Criteria as follows:

Causality term	Assessment criteria *
Certain	Event or laboratory test abnormality, with plausible time relationship to drug intake Cannot be explained by disease or other drug Response to withdrawal plausible (pharmacologically, pathologically) Event definite phrmacologically or phenomenologically (i.e. an objective and specific medical disorder or a recognised pharmacological phenomenon Rechallenge satisfactory, if necessary
Probable, likely	Event or laboratory test abnormality, with reasonable time relationship to drug intake Unlikely to be attributed to disease or other drugs Response to withdrawal clinically reasonable Rechallenge not required

Possible	Event or laboratory test abnormality, with reasonable time relationship to drug intake Could also be explained by disease or other drug Information on drug withdrawal may be lacking or unclear
Unlikely	Event or laboratory test abnormality, with a time to drug intake that makes a relationship improbable (but not impossible) Disease or other drugs provide plausible explanation
Unassessable / Unclassifiable	Report suggesting an adverse reaction Cannot be judged because information is insufficient or contradictory Data cannot be supplemented or verified
Not related	Sufficient information to indicate that the etiology is unrelated to the study medication

* All points should be reasonably complied with

Reporting Adverse Events

During the course of the study, all AEs (including SAEs), irrespective of the relation to the study drug, have been recorded on the adverse event pages of the CRF. During each monitoring visit, the investigator and the clinical monitor reviewed all AEs. The investigator was responsible for ensuring that correct information concerning all AEs were included on the appropriate CRF pages.

All Serious Adverse Events occurring within 30 days post study drug administration had to be reported immediately to the sponsors safety department.

The EC should be notified of any serious adverse event which is unexpected and at least possibly related to the study drug according to the policies of the respective institution's EC. The EC should also be notified of any safety letters which the site will receive from the sponsor's safety department.

Follow up Period for Serious and Non-Serious Adverse Events

Follow-up of all SAEs have been done until the outcome is resolved, has reached a stable condition in the investigator's opinion, or until the patient is lost to follow-up.

Based on the medical judgment of the investigator, all non-serious AEs (including the abnormal laboratory values identified as AEs by the investigators) have been followed until 14 days after the patient completes the study. All non-resolved, non-serious AEs beyond such date have been recorded as "ongoing" without further follow-up.

9.6.3 Final safety report

When the statistical analysis was issued, a full report of the study was drafted to be signed, following their agreement, by the co-ordinator, the promoter, the statistical investigator, the scientific advisor, and the manager of the test.

The promoter, the company in charge of the monitoring, the national co-ordinator and the investigators are forbidden to disclose, in any manner whatsoever, the complete results of the study without the formal authorisation of each party.

9.7. DATA QUALITY ASSURANCE

All CRFs were checked for completeness and plausibility by the clinical investigator and the local monitor (manually), by a central monitor at Clinical Investigations as well as by the data management (manually and computer-supported).

Each correction on a CRF was made in such a manner that the first original entry remains legible. The corrected values were noted along with the reason for the correction, date of correction and the investigator's initials.

All data were entered twice (double data entry) by two different persons on two different sites at Clinical Investigations kft using Microsoft Excel 2007. Both data sets were compared automatically to check for errors with Microsoft Excel 2007.

Programmed validation and plausibility checks were run to check the data, and queries were generated in case of any doubtful findings. In addition, a manual/visual check was performed for medical plausibility. Queries from both processes were forwarded to the monitor for clarification with the Investigator. The data were corrected according to the results of the queries. A hard copy of the query form was attached to and archived together with the original CRF.

9.8. STATISTICAL METHODS PLANNED IN THE PROTOCOL AND DETERMINATION OF SAMPLE SIZE

9.8.1 Methodology

The methodology associates a composite criterion that has to take into account all decisional factors and a specific analysis which does not formally require a statistical test, but which allows determining which strategy to choose as compared to another.

This methodology relies on the principle that one should not choose the least effective treatment (third-rank risk), and that if the two treatments are equivalent, selecting one or the other is equal. The number of patients needed is calculated based on the 3rd rank risk and can be done with a calculation according to the main clinical criterion, taking into account the absence of information regarding the other criteria.

9.8.2 Sample of patients

Data are not available here, regarding the main criterion envisaged: percentage of patients on NSAID only since at least three months and obtaining under treatment (or in the absence of treatment: reference group) a weaning off the NSAID or their replacement by paracetamol.

However, in a previous clinical trial comparing the PIASCLEDINE 300 with placebo in patients affected by osteoarthritis of the lower limbs in which NSAID interruption was required in the 45th day of Piascledine treatment (12), it was noted that weaning was maintained 90 days later in 57% of the patients in the Piascledine group, versus only 30% of patients in the placebo group, that is a difference of 27%, highly significant (osteoarthritis of the knee and coxarthrosis together).

For the present study, we retained this percentage of 30% success in the group without treatment, which appears to be a high estimate, as there is no use of placebo here.

Taking: Success of the reference product (here reference group with no treatment): 30%

Gamma risk selected: 0.005

Difference to be highlighted: 15% of patients put off NSAID either completely, or replaced by paracetamol, in the PAST group, compared to the STO group.

The theoretical sample calculated by group was 135 subjects, with a total of 270 patients – number increased by 10% to cover the possibility of unusable files, that gives a total of 300 patients.

9.8.3 Statistical methods used

Review of blind data

- Depending on parameters, specific graphic Exploratory Data Analysis –EDA techniques were used to visualize outlying data.
- Requests for decisions to the scientific advisor in the trial, especially with regard to the classification of protocol violations as "major" (exclusion of the effectiveness evaluation per protocol) and "minor".

Description of the samples

Depending on parameters, averages and standard deviations, medians and extremes, number of subjects in classes.

Comparison of the groups before treatment

Have been studied on D 0 using the traditional statistical tests: Chi2 test or Friedman concordance test for the qualitative variable, Student test for the quantitative variables

Efficacy evaluation

For the efficacy evaluation, all randomized patients in the PAST group and in the STO group have been kept.

Efficacy was tested based on the a Schuirmann type method using a two sided proportion test with D=0.15 and a risk 2a = 0.01.

The conclusion could point to the superiority of the PAST strategies if the delta observed is D=0.15, in favor of the PAST strategies, and if the theoretical number of subjects required has been complied with (270).

The other effectiveness parameters have been analyzed.

The variation of the secondary efficacy criteria will be evaluated by a test appropriate to the nature of variable with a risk a = 0.05

Data analysis:

Main criterion:

- The main criterion is the number of patients weaned off NSAID at each visit starting with V2.

Additional criteria:
The secondary efficacy criteria are:

- Period of NSAID interruption, in days: speed of weaning
- Duration of weaning: period of re-administering NSAID, in days
- Need for taking paracetamol: consumption in g (up to 4 g/d) and period while taking paracetamol after interruption of NSAID
- Pain evaluation assessed on VAS,
- LEQUESNE index (APPENDIX 3), (index for osteoarthritis of the knee),
- Quality-of-life scale: SF12 (APPENDIX 4),
- Final evaluation of overall utility, by patient and investigator,
- Overall tolerability assessed by patient and investigator,
- Treatment compliance evaluation.

Compliance evaluation

For the (PIASCLEDINE 300 plus standard treatment strategies) group,

Difference between theoretical and real consumption of capsules between V1 and V5 expressed in percents

Compliance to the treatment within the study was assessed as:

- Excellent: difference ± 10%,
- Very good: difference ± 20%,
- Good: difference ± 30%,
- Average: difference ± 40%,
- Poor: difference equal to or higher than 40%.

In case of test dropping or no show, the same calculation formula has been applied between D 0 and date of drop-out or date of last visit.

Tolerability evaluation:

For tolerability evaluation, all randomized patients having received treatment with PIASCLEDINE 300 have been evaluated.

The percentages of research subjects presenting or not one or more adverse effects during the tested period have been tested.

These were evaluated on V2, V3, V4, V5, by recording the existence of adverse effects, spontaneous or reported as an answer to the question: "has there been any undesirable event?"

Number of subjects with undesirable effect(s), number of undesirable effects, number of interruptions of treatment due to undesirable effect(s) have been reported.

9.9. CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED ANALYSES

The study was planned to be performed in Bulgaria (2 sites), Lithuania (4 sites), Poland (3 sites), Romania (4 sites), and Slovakia (3 sites).

The study has been finally performed in Bulgaria (1 site), Poland (3 sites), Romania (4 sites), and Slovakia (2 sites).

The defined secondary criteria: speed of weaning (period of NSAID interruption in days), duration of weaning (period of re-administering NSAID, in days), and need for taking paracetamol: (consumption in g (up to 4g/d) and period while taking paracetamol after interruption of NSAID) could not be evaluated in the way described in the protocol, as these data have not been registered in the CRF. An evaluation of the patient diaries has not been foreseen, and as it has been calculated from the database that these parameters would be evaluable in only approx. 25% of the patients, it has been decided to omit the report of these parameters and replace it by the numbers of tablets taken by the patient.

10 STUDY PATIENTS

10.1. DISPOSITION OF PATIENTS

This report deals with 300 patients taken up into the trial between 8 September 2008 and 1 June 2009 in10 centres in Bulgaria, Poland, Romania and Slovakia.

Table 1: Distribution of patients according to centres

Centre Nr	Centre	No of patients	%	Piascledine	Chondroitin
1	Georgieva	60	20,0	30	30
3	Kołodziejczyk	12	4,0	6	6
4	Barszczewski	32	10,7	15	17
5	Dargiewicz	16	5,3	9	7
6	Ionescu	36	12,0	18	18
7	Sărbu	30	10,0	15	15
8	Bunea	36	12,0	18	18
9	Jantes	36	12,0	18	18
10	Durdikova	18	6,0	9	9
12	Jančovic	24	8,0	12	12

The centres treated in median 31 patients (minimum 12, maximum 60 patients).

10.2. PROTOCOL DEVIATIONS

Table 2 shows the protocol violations observed. These violations have not been used to generate subgroups. Table 3 shows the early terminations. Patients listed in this table may also appear in Table 2.

Table 2: Protocol violations

Criteria	**Not fulfilled, Random No:**
Female or male outpatients at least 45 years old	None
Affected by osteoarthritis of the knee, femoral-tibial joint single or double-compartment, one side or bilateral and/or femoral-patellar joint, meeting the criteria of the American College of Rheumatology progressing for at least 6 months,	4, 265, 267, 282, 283, 285, 286, 287, 290, 296, 297, 298, 299, 300, (less than 6 months from the diagnosis)
with overall spontaneous pain assessed between 25 and 50 mm on the VAS in spite of daily intake of DICLOFENAC or equivalent 75 to 150 mg/d for at least 10 days per month, for at least 3 months prior to inclusion.	57, 63 (VAS < 25 mm at visit 1) 102 (no dosage/ daily dosage)

Criteria	Not fulfilled, Random No:
Osteoarthritis of the knee confirmed radiological, radiographies being not older than 12 months.	None
The patient has a Lequesne-index over 5.	None
The patient is capable to understand and comply with the study instructions	None
The patient suffers from articular chondrocalcinosis known in advance or defined by the presence of a calcic edging on at least one femoral-tibial articular space	None
Ochronoses, hemochromatoses, chondromatosis, villo-nodular synovitis, paget's disease, haemophilia, psoriasis	None
Known symptomatic hip osteoarthritis (coxarthrose), homolateral to the osteoarthritis of the knee	None
Osteoarthritis of the knee indicating for a surgical intervention within the presumed research time	None
Surgery (osteoectomy, meniscectomy, sinoviorthesis) on the evaluated knee	None
Contraindications for NSAID (history of gastro-duodenal ulcer, renal insufficiency or significant hepatic-cellular insufficiency or serious hematological disease, history of allergy, Diabetic insulin dependant)	147 (gastritis), 35 (duodenal ulcer), 210(chronic gastritis), 145 (gastritis), 70 (chronic gastritis), 120 (peptic ulcer), 245 (allergic rhino-sinusitis), 273 (gastro-duodenitis)
Severe progressive cardiac, pulmonary, renal, hepatic, hematological, neoplasic or infectious condition	50 (uterine cancer), 119(macrocytosis)
Leucopenia	None
Severe hereditary disease	None
Intolerance for piascledine 300	None
Has taken slow-acting treatment for OA or received hyaluronic acid injections (SYSADOA), within the 3 months prior to inclusion	None
Does not require drug treatment for OA	None
Has been involved in some other therapeutic study within the three months preceding inclusion	None
Participating in some concomitant trial	None
Pregnant woman, or susceptible to become pregnant during the study period	None
Breast- feeding woman	None
Drop outs or not all visits done	129, 215, 51, 53, 99, 22, 41, 201, 210
Visit 2 not 45 ± 15	**5** (61 days), **94** (78 days)
Visit 3 not 90 ± 15	**19** (70 days), **2** (71 days), **84** (106 days), **104** (106 days), **6** (106 days), **154** (107 days), **83** (107 days), **82** (108 days), **47** (109 days), **85** (110 days), **149** (111 days), **150** (111 days), **151** (111 days), **146** (118 days)
Visit 4 not 135 ± 15	**19** (103 days), **101** (107 days), **4**

Criteria	Not fulfilled, Random No:
	(110 days), **203** (111 days), **221** (151 days), **191** (152 days), **192** (152 days), **72** (154 days), **6** (155 days), **49** (164 days), **47** (165 days)
Visit 5 not 180 ± 15	**101** (140 days), **50** (154 days), **102** (154 days), **8** (155 days), **54** (156 days), **223** (157 days), **48** (160 days), **203** (160 days), **220** (162 days), **75** (162 days), **98** (163 days)

Table 3: Early terminations

Random No	Initials	No of final examination	Date of final examination	Date of last dose PAST group	Treatment stopped by	Reason	Remarks
22	BB	5 (compulsory final visit, treatment stopped before V2)	20.02.09	19.02.09	patient	AE – suspicion of lung tumor	SAE, death in 2009 (date unknown)
41	MG	2	04.05.09	24.04.09	patient	Lack of efficacy, AE worsening pain of knee	AE between 20.04.09 – 04.05.09
51	EK	2	17.06.09	17.06.09	patient	Lack of efficacy, AE pain in the knees and left brachialgia reported on 17.06.09	AE ongoing since 08.06.09
53	DS	2	08.06.09	25.05.09	patient	AE abdominal pain	AE completely recovered
99	TEW	2	27.04.09	05.04.09	patient	AE –rash between 02.04.09 – 10.04,09	AE completely recovered

Ran-dom No	Initials	No of final examination	Date of final examination	Date of last dose PAST group	Treatment stopped by	Reason	Remarks
128	MA	3	17.12.08	-	patient	Failure to follow appointment schedule, withdrawn informed consent	AE nausea on 25.09.08, ongoing
201	RDS	2	17.03.09	14.02.09	other physicians	AE - icterus cholestatic syndrom	AE between 15.02.09 – 06.03.09
210	EED	2	22.05.09	03.05.09	other physicians	AE - biliary colic	AE between 01.05.09 – 08.05.09
215	EJ	3	04.03.09	-	patient	Lack of efficacy, withdrawn IC,	lost for follow-up

11 EFFICACY EVALUATION

11.1. DATA SETS ANALYZED

300 patients have been included into the study and were eligible for evaluation. From these 150 received Piasciedine, and 150 remained with standard treatment.

11.2. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

11.2.1. Demography

300 patients have been taken up into the study in 10 centres. From these there were 256 females (85.3%) and 44 males (14.7%). In both groups there were 128 females and 22 men.

Table 4 shows the demographic data of the patients, Table 5 for male patients, Table 6 for female patients.

Table 4: Demographic data (all patients)

Parameter	Mean	SD	Minimum	Maximum
Age (years)	61,83	9,09	45	86
Height (cm)	163,21	8,01	140	202
Weight (kg)	77,78	14,67	45	147
Body-Mass-Index	29,20	5,21	19,81	56,01

Table 5: Demographic data (males)

Parameter	Mean	SD	Minimum	Maximum
Age (years)	60,34	9,82	46	85
Height (cm)	174,73	8,06	160	202
Weight (kg)	84,34	12,89	61	110
Body-Mass-Index	27,62	3,87	20,15	38,57

Table 6: Demographic data (females)

Parameter	Mean	SD	Minimum	Maximum
Age (years)	62,09	8,95	45	86
Height (cm)	161,23	6,12	140	180
Weight (kg)	76,65	14,69	45	147
Body-Mass-Index	29,48	5,37	19,81	56,01

There is no relevant difference between the two treatment groups (Table 7 and Table 8).

Table 7: Demographic data (PAST)

Parameter	Mean	SD	Minimum	Maximum
Age (years)	61,36	8,97	46	86
Height (cm)	163,11	8,60	140	202
Weight (kg)	77,03	15,00	48	147
Body-Mass-Index	28,94	5,22	19,81	56,01

Table 8: Demographic data (STO)

Parameter	Mean	SD	Minimum	Maximum
Age (years)	62,30	9,22	45	85
Height (cm)	163,32	7,40	145	190
Weight (kg)	78,53	14,35	45	130
Body-Mass-Index	29,46	5,22	20,00	46,88

The patient population was homogeneous between the groups (Table 47 - Table 56). All patients have been informed on the nature of the trial and gave their informed consent. All patients confirmed to have been given the patient information as well as a copy of the informed consent sheet.

The general physical examination revealed the following pathologic observations (Table 9): The observations are listed in detail in Table 42.

Table 9: General physical examination

Organ system	Number of pathologic
Integumentary system	31
Sensory system	8
Respiratory system	5
Cardiovascular system	31
Gastrointestinal system	3
Metabolism/Endocrine system	101
Nervous system	1
Musculoskeletal system	32
Urinary	1
Genital	5
Other	4

The vital signs did not show any abnormalities (Table 10).

Table 10: Vital signs

Parameter	Mean	SD	Minimum	Maximum
Blood pressure systolic (mm Hg)	129,58	12,64	100	180
Blood pressure diastolic (mm Hg)	76,65	7,54	60	120
Pulse rate (min^{-1})	73,71	6,57	54	95
Breath rate (min^{-1})	16,83	2,70	12	28

The concomitant diseases and medications are listed in detail in Table 43.

11.2.2. History and Diagnosis of Osteoarthritis of the Knee

In 195 cases both knees have been x-rayed, in 105 cases only one knee. In 291 cases the x-ray has been performed in extension, in 5 cases in flexion, and in 4 cases in both positions.

The x-ray has been performed on the day of the examination in 41 (13.7%) cases. In 95 patients (31.7%), the x-ray has been recorded in the week prior to the inclusion, in 63 cases (21.0%) maximum 1 month before. In 99 cases (33.0%) the x-ray was older than 1 month. In one case the examination has been done more than 2 months before, in 2 cases the date has been given one day after the examination date.

The osteoarthritis has been classified according to a modified Kellgren-scale (Table 11). 60% of the patients belonged to class II.

Table 11: Classification according to Kellgren

Classification	Number of patients	%
I	66	22,0
II	180	60,0
III	54	18,0

In 64 cases other known and radiologically confirmed arthritic localisations have been diagnosed (Table 12).

Table 12: Localisations of other osteoarthritic findings

Localisation	Number of patients
Spine	40
Lower extremities	2
Upper extremities	11
Generalised	3
Hip	8

All patients have been qualified to enter the study concerning inclusion and exclusion criteria.

11.3. MEASUREMENTS OF TREATMENT COMPLIANCE

The patients of the PAST-group were instructed to return the empty or partially empty blisters to the study centre at visit 2, 3, 4 and 5. The investigators counted the returned capsules and documented the respective numbers in the CRF.

Compliance with the research treatment was evaluated as:

- Excellent: difference ± 10%,
- Very good: difference ± 20%,
- Good: difference ± 30%,
- Medium: difference ± 40%,
- Poor: difference equal to or higher than 40%.

Almost all patients proved an excellent to very good compliance during the study period.

Remarkably enough, the percentage of patients showing an excellent compliance increases during the trial (Table 13). There were two patients showing poor compliance (201 and 210). Both terminated the study prematurely.

Table 13: Compliance

Classification	Visit 2		Visit 3		Visit 4		Visit 5	
	N	%	N	%	N	%	N	%
Excellent	137	95,1	135	95,7	139	97,2	142	97,3
Very good	5	3,5	1	0,3	2	1,4	1	0,7
Good	1	0,7	3	1,0	1	0,7	0	0,0
Medium	0	0,0	2	0,7	1	0,7	2	1,4
Poor	1	0,7	0	0,0	0	0,0	1	0,7
Valid number	144	48,0	141	47,0	143	47,0	146	48,7

11.4. EFFICACY RESULTS AND TABULATIONS OF INDIVIDUAL PATIENT DATA

11.4.1. Primary variable

The primary variable was the number of patients weaned off NSAID at each visit starting with V2. The number of patients not taking NSAIDs increased in the PAST-group continuously from Visit 2 to Visit 5. At the end of the trial 35.4% of the patients did not need NSAID any more. In the STO groups there was also a slight increase of patients stopping NSAID/medication, but on a much lower level. 7.4% of the patients did not use NSAID in the STO-group at the end of the trial. This difference between the STO- and the PAST-group is highly significant ($p<0.001$) during the entire duration of the study

Table 14: Patients weaning off from NSAID from Visit 2

Treatment	Visit 2		Visit 3		Visit 4		Visit 5	
	N	%	N	%	N	%	N	%
PAST	24	16.1	25	17.5	42	29.4	52	35.4
STO	2	1.3	7	4.7	7	4.7	11	7.4

N: Number of patients
%: Percent of patients in the study

Figure 1: Patients weaning off from NSAID from Visit 2



In the PAST group 80 patients took NSAIDs during the entire study period. 13 patients did not take NSAIDs from Visit 2, 11 from Visit 3, 12 from Visit 4. 2 Patients resumed NSAID at Visit 3, 11 patients did not take NSAID at all, 23 patients took NSAID irregularly.

The tablet intake of patients that were taking NSAID at a visit, showed a relevant decrease in the PAST-group, while the decrease in the STO group was much less pronounced (Table 15, Figure 16).

Table 15: Number of dosages taken by patients that took NSAID (mean values)

Number of tablets	Visit 2	Visit 3	Visit 4	Visit 5
PAST	21.7	16.4	15.1	12.3
STO	27.5	24.0	22.9	21.6

The NSAIDs prescribed during the study period are listed in Table 45:

11.4.2. Secondary variables

The secondary efficacy criteria were:

- Pain evaluation assessed on VAS,
- LEQUESNE index
- Quality-of-life scale: SF12,
- Final evaluation of overall utility, by patient and investigator,
- Overall tolerability assessed by patient and investigator,
- Treatment compliance evaluation.

11.4.3. Pain (VAS)

Table 16 shows the statistical characteristics of the pain measurement. Pain decreases to less than 50% of the initial value in the PAST group, while in the STO-group there was only a slight decrease of pain (Figure 2). This result is highly significant during the entire study (Table 61).

Table 16: Pain (VAS)

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Mean	40.31	33.97	31.83	21.87	18.82
	SD	7.05	12.26	13.47	14.24	15.23
	Median	41	34.5	31	20	16
	Minimum	25	2	2	0	0
	Maximum	50	78	78	50	52
STO	Mean	39.56	34.72	36.84	33.89	33.38
	SD	7.10	13.70	12.01	14.56	15.80
	Median	40	35	38	33.5	32.5
	Minimum	23	6	8	3	0
	Maximum	50	78	75	78	75

Figure 2: Pain on VAS (mean values)



11.4.4. Lequesne-Index

Table 17 shows the statistical characteristics of the Lequesne-index. The Lequesne-index decreases in both groups, but more pronounced in the PAST group, in which, from Visit 1 to Visit 5, the index decreased for more than 50%. (Table 17, Figure 3). This result is highly significant (Table 60).

Table 17: Lequesne-Index

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Mean	12,41	9,52	8,03	6,83	6,02
	SD	3,91	3,84	3,81	3,53	3,55
	Median	12,50	9,00	7,50	6,50	5,50
	Minimum	5,0	1,5	0,5	0,0	0,0
	Maximum	21,0	19,0	19,0	18,5	16,5
STO	Mean	12,79	11,52	11,01	10,38	10,12
	SD	4,29	3,99	4,22	4,32	4,53
	Median	12,00	11,50	10,75	10,00	10,00
	Minimum	5,5	3,5	2,0	1,5	0,5
	Maximum	22,0	20,0	21,5	21,5	21,5

Figure 3: Lequesne-Index (mean values)



11.4.5. Quality of Life (SF12 – Questionnaire)

The SF12 Quality of life questionnaire consists of 12 questions that have to be answered individually.

For all 12 questions the initial situation was comparable; i.e. the differences between the groups were not significant (Table 65 to Table 76). For all questions an improvement of the initial situation has been observed in both groups. The improvement was, also for all 12 questions, remarkably better in the PAST-group. At visit 5 the groups differed significantly in all issues (Table 80 to Table 91).

In the following the results are presented in tabular form as well as in graphs.

For a better visualisation of the questions the answers have been coded, where graduations have been assessed. The worst value has been coded with 1, the second best with 2 etc.

Then mean values have been calculated from the coded frequencies, and divided by the number of observations.

The following results have been obtained in detail:

Table 18: In general, would you say your health is…

		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Excellent	0	2	4	7	6
	Very good	8	14	22	33	57
	Good	46	82	79	70	52
	Fair	79	38	30	26	24
	Poor	17	13	8	7	7
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	Excellent	0	1	0	0	0
	Very good	6	8	11	16	18
	Good	51	64	77	79	76
	Fair	75	64	51	40	41
	Poor	18	13	11	13	13
	Total	150	150	150	148	148

There was no difference at Visit 1. At Visit 5 there is a statistically significant difference in favour of the Piascledine treatment (Table 18, Figure 4).

Figure 4: Health status



Table 19: Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Limited a lot	54	23	13	12	8
	Limited a little	80	93	86	76	77
	Not limited at all	16	33	44	55	61
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	Limited a lot	58	39	38	28	24
	Limited a little	76	91	93	103	106
	Not limited at all	16	20	19	17	18
	Total	150	150	150	148	148

Figure 5: Limitation in moderate physical efforts



Table 20: Does your health now limit you in climbing several flights of stairs?

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Limited a lot	76	38	22	22	22
	Limited a little	71	105	104	94	92
	Not limited at all	3	6	17	27	32
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	Limited a lot	83	69	62	55	46
	Limited a little	65	78	83	90	98
	Not limited at all	2	3	5	3	4
	Total	150	150	150	148	148

Figure 6: Limitation in climbing stairs



Table 21: During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	No	42	87	100	110	113
	Yes	108	62	43	33	33
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	No	49	61	65	68	74
	Yes	101	89	85	80	74
	Total	150	150	150	148	148

Figure 7: Number of patients accomplishing less than expected as a result of physical health



Table 22: During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	No	46	87	97	102	102
	Yes	104	62	46	41	44
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	No	43	59	63	63	67
	Yes	107	91	87	85	81
	Total	150	150	150	148	148

Figure 8: Number of patients limitated in work and regular activities



Table 23: During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Yes	73	111	119	125	128
	No	77	38	24	18	18
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	Yes	74	85	80	81	90
	No	76	65	70	67	58
	Total	150	150	150	148	148

Figure 9: Number of patients accomplishing less due to emotional problems



Table 24: During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?

Treatment group	Parameter	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Yes	75	114	115	122	120
	No	75	35	28	21	26
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	Yes	70	78	75	83	87
	No	80	72	75	65	61
	Total	150	150	150	148	148

Figure 10: Number of patients not working as usual due to emotional problems



Table 25: During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?

		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	Not at all	0	2	7	23	28
	Slightly	24	55	70	65	72
	Moderately	83	68	53	46	39
	Quite a bit	43	23	13	9	7
	Extremely	0	1	0	0	0
	Total	150	149	143	143	146
		p<0.05				*p<0.01*
STO	Not at all	0	2	4	6	8
	Slightly	18	32	29	29	29
	Moderately	71	73	76	74	80
	Quite a bit	59	39	40	36	29
	Extremely	2	4	1	3	2
	Total	150	150	150	148	148

Figure 11: Pain interfering with normal work



Table 26: How much time during the past 4 weeks have you felt calm and peaceful?

		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	All of the time	5	9	13	17	32
	Most of the time	14	29	43	50	47
	A good bit of the time	33	46	42	30	24
	Some of the time	71	56	36	30	25
	A little of the time	26	8	7	12	14
	None of the time	1	1	2	4	4
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	All of the time	1	5	2	7	3
	Most of the time	26	25	29	29	31
	A good bit of the time	26	35	47	42	45
	Some of the time	55	56	52	53	53
	A little of the time	40	28	19	16	15
	None of the time	2	1	1	1	1
	Total	150	150	150	148	148

Figure 12: Feeling calm and peaceful



Table 27: How much time during the past 4 weeks did you have a lot of energy?

		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	All of the time	5	7	11	16	25
	Most of the time	11	22	39	47	54
	A good bit of the time	32	52	39	37	33
	Some of the time	63	55	42	34	24
	A little of the time	35	12	11	9	9
	None of the time	4	1	1	0	1
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	All of the time	2	0	0	0	1
	Most of the time	8	15	17	20	23
	A good bit of the time	20	44	47	49	50
	Some of the time	78	65	64	62	56
	A little of the time	39	25	19	15	15
	None of the time	3	1	3	2	3
	Total	150	150	150	148	148

Figure 13: Having a lot of energy



Table 28: How much time during the past 4 weeks did you feel down?

		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	All of the time	0	2	2	1	1
	Most of the time	12	5	2	3	0
	A good bit of the time	32	20	12	10	10
	Some of the time	57	39	37	32	24
	A little of the time	35	52	51	51	60
	None of the time	14	31	39	46	51
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	All of the time	1	2	1	2	0
	Most of the time	19	13	10	5	9
	A good bit of the time	21	33	24	21	23
	Some of the time	58	45	43	47	42
	A little of the time	43	38	39	40	35
	None of the time	8	19	33	33	39
	Total	150	150	150	148	148

Figure 14: Feeling down



Table 29: How much time during the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities like visiting with friends, relatives, etc. ?

		Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
PAST	All of the time	0	0	2	3	0
	Most of the time	22	7	5	3	3
	A good bit of the time	27	22	15	10	5
	Some of the time	59	42	33	33	37
	A little of the time	20	52	63	49	37
	None of the time	22	26	25	45	64
	Total	150	149	143	143	146
		n.s.				*p<0.01*
STO	All of the time	1	1	0	0	1
	Most of the time	22	14	14	12	15
	A good bit of the time	35	35	31	30	24
	Some of the time	54	56	50	53	55
	A little of the time	23	24	35	35	35
	None of the time	15	20	20	18	18
	Total	150	150	150	148	148

Figure 15: Interference with social activities



11.4.6. Overall efficacy

Overall efficacy has been evaluated by both patient and investigator in 146 cases in the PAST-group, and in 148 cases in the STO-group. Investigator and patient rated almost identically in both groups. The assessments were excellent and good in 95.2% by the investigator, and 91.8% by the patient in the PAST-group, while it was 50.6 % versus 50.0% in the STO-group. Poor efficacy was assigned to PAST treatment in 2.1 and 2.7%, resp., while 10.1 and 14.2%, resp. for the STO-group (Table 30).

Table 30: Overall efficacy

Treatment group	assessment	Investigator		Patient	
		N	%	N	%
PAST	Excellent	84	57,5	85	58,2
	Good	55	37,7	49	33,6
	Average	4	2,7	8	5,5
	Poor	3	2,1	4	2,7
	No of assessments	146		146	
STO	Excellent	19	12,8	19	12,8
	Good	56	37,8	55	37,2
	Average	58	39,2	53	35,8
	Poor	15	10,1	21	14,2
	No of assessments	148		148	

11.4.7. Rescue medication

The intake of rescue medication has been assessed from the diary entries, in which the patients had to record their daily NSAID and paracetamol-tablets intake. As the intake periods were different from patient to patient (due to different intervals between the examinations), the daily average intake has been calculated.

It could be demonstrated that the daily intake of rescue medication was always lower in the PAST-group. The intake of NSAID decreased in both groups during the observation period, but the decrease was more pronounced in the PAST-group as well (See also chapter 11.4.1)

Also the average intake of paracetamol was considerable lower in the PAST-group. While in the STO group the intake during the observation period was almost constant, the amount of paracetamol in the PAST group decreased between visit 2 an 4, and remained on this level until Visit 5.

Figure 16: Average daily intake of NSAID



Figure 17: Average daily intake of paracetamol



11.4.8. Statistical/Analytical Issues

All efficacy and safety parameters have been assessed for all included patients. For missing values, there was no LOCF technique applied – missing values have been treated in all evaluations as missing values.

For the primary efficacy variable, number of patients weaned off NSAID at each visit starting with V2 to the end of the therapy and the percentage of valid values were computed. Moreover the structure of the number of patients taking NSAID during the study period, has been evaluated. For those patients who took NSAID during the treatment the number of tablets has been assessed.

For the secondary variables, Pain Evaluation assessed on VAS, LEQUESNE index, Global assessment of knee osteoarthritis, SF 12 Quality-of-life scale and vital signs basic statistical characteristics have been computed, and graphs have been done.

Overall efficacy and tolerance, number of patients at each visit starting with V2 to the end of the therapy, and the percentage of valid values were computed.

For all efficacy and acceptability data, descriptive statistics (n, mean, standard deviation, median, upper and lower quartile, and extreme values for continuous data, counts and frequencies for categorical and ordinal values) were given per visit and per treatment group (test, comparator).

Test for normality distributions and homogenicity of the initial observations have been done for height, weight, BMI, Kellgren-Lawrence-score, systolic and diastolic blood pressure, heart rate, breath rate, Lequesne-Index, VAS, QoL, in both groups by means of Kolmogorov-Smirnov and Shapiro-Wilk and Mann, Whitney-test, respectively.

For the primary efficacy variable, repeated between groups comparison of number of patients weaning off from NSAID has been done by chi-square test for all visits between 2 and 5.

Statistical differences have been computed for Visit 5 for Lequesne-Index, VAS, QoL.

For the Lequesne-index, VAS, and QoL, repeated ANOVA calculations have been done for visit 2 to visit 5.

For adverse events, frequency tables are given.

Patient listings were generated for all data items collected on the CRF and presented in the appendices of the report.

11.5.13. Tabulation of Individual Response Data

See Chapter 14.

11.5.14. Drug Dose, Drug Concentration, and Relationships to Response

Not applicable.

11.5.15. Drug-Drug and Drug-Disease Interactions

Not applicable.

11.5.16. By-Patient Displays

See chapter 14.

11.5. EFFICACY CONCLUSIONS

The primary variable was the number of patients weaned off NSAID at each visit starting with V2. The number of patients not taking NSAIDs increased in the PAST-group continuously from Visit 2 to Visit 5. At the end of the trial 35.4% of the patients did not need NSAID any more. In the STO groups there was also a slight increase of patients stopping NSAID/medication, but on a much lower level. 7.4% of the patients did not use NSAID in the STO-group at the end of the trial. This difference between the STO- and the PAST-group is highly significant ($p<0.001$) during the entire duration of the study

Also in all secondary efficacy criteria (Pain evaluation assessed on VAS, Lequesne-index, overall assessment of efficacy as well as in all issues of the Quality-of-life scale SF12, a significant difference between the two treatment groups has been revealed in favour of the Piascledine treatment.

The average daily intake of NSAID has been reduced in both groups during the observation time, but more pronounced in the PAST-group. The intake of paracetamol and paracetamol has been reduced in both groups from visit 1 to visit 4, but also more pronounced in the PAST group. From visit 4 to visit 5 the intake of paracetamol increased slightly in both groups.

It has been proved in this investigation that the add-on therapy with Piascledine has a significant and clinically relevant positive effect on both the symptomatology of osteoarthritis and the quality of life.

12 SAFETY EVALUATION

12.1. EXTENT OF EXPOSURE

The maximum extent of study medication a patient could have taken is 180 ± 15 daily dosages of Piascledine, which means maximum 58.5 g of Piascledine.

The compliance has been assessed as excellent in 142 cases (97.3% of 146 valid assessments), as very good in 1 case (0.7%), as good in 0 cases, as medium in 1 case (0.7%), and as poor in 2 cases (1.4%).

12.2. ADVERSE EVENTS

12.2.1. Brief Summary of Adverse Events

Altogether 49 not serious adverse events in 38 patients have been reported (PAST-group: 35 adverse events in 29 patients (71.4% of all AEs), STO-group: 14 adverse events in 9 patients (28.6% of all AEs). During the observation time, 19.3% of the patients in the PAST-group reported adverse events, and 6% of the patients in the STO-group.

From these where approximately 80% not or unlikely related to the test drugs.

A probable relationship to Piascledine has been assessed in 1 case, a possible relationship in 5 cases. No definite relationship has been recorded.

Table 31: Relationship of Adverse events to the test drug

Relationship to test drug	N	%
Not related	21	56,66
Unlikely	7	23,33
Possible	6	16,66
Probable	1	3,33
Definite	0	0,00
Total	35	100

Table 32: Adverse events with probable relationship to the test drugs

Random No	Initials	Visit no	AE	Onset	End
105	MD	3	Gastric pain	25.12.08	26.12.08

Table 33: Adverse events with possible relationship to the test drugs

Random no	Initials	Visit no	AE	Onset	End
128	MA	2	Nausea	25.09.08	ongoing
53	DS	2	Abdominal pain	27.05.09	29.05.09
110	MS	4	Gastric pain after diclofenac ingestion	22.01.09	23.01.09
41	MG	2	Worsening of pain of knee	20.04.09	04.05.09
47	TEW	1	Rash	02.04.09	10.04.09

12.2.2. Display of Adverse Events

In Table 34 all reported adverse events are listed.

Table 34: Display of adverse events, PAST-group

Rand. Nr	Initials	AE reported at visit no:	Description of AE	AE Status	Date of appearance	Date ended	AE Intensity:	Outcome of AE	Causal relationship to study drug	Expectation	Comment
7	MN		bradycardia	1	20.01.09	20.01.09	1	1	1	1	
8	AS	3	diarrhoe after aulin from gp doctor	1	1.01.09	1.01.09	1	1	1	2	
41	MG	2	worsening of pain of knee	1	20.04.09		2	2	3	2	
41	MG	2		2	20.04.09	4.05.09	1	1	3	2	
44	AL	4	operation of varices of legs	1	18.12.08	18.12.08	1	1	1	1	planned operation
48	WBK	3	bronchitis		17.03.09	23.03.09	2	1	1	2	
48	WBK	4	stomatitis	1	2.04.09	9.04.09	1	1	1 2		
48	WBK	5	urinary infection	1	14.05.09	24.05.09	2	1	2	2	
51	EK	2	for the last ten days patient suffered increased pain of knees and left brachialgia	1	8.06.09		2	2	2	2	intermittant knee pains
52	MK	2	hyperglycemia 312mg% fasting	1	10.06.09		2	2	1	2	hyperglycemia-accidental finding during routine blood test
53	DS	2	abdominal pain	1	27.05.09	29.05.09	2	1	3	2	
59	TJS	3	viral infection of airways	1,2	1.12.08	7.12.08	1	1	1	2	
69	JAF	5	common cold	1 and 2	21.03.09	26.03.09	1	1	1	2	
73	MAP	3	common cold1,2		28.02.09	6.03.09		2	1	2	
99	TEW	1	rash	1,2	2.04.09	10.04.09	2	1	3	2	
100	KMI	5	ischias	1,2	15.09.09	15.10.09	2	1	1	2	
105	MD	4	low urinary tract infection	1	1.02.09	3.02.09	1	1	1	2	

Rand. Nr	Initials	AE reported at visit no:	Description of AE	AE Status	Date of appearance	Date ended	AE Intensity:	Outcome of AE	Causal relationship to study drug	Expectation	Comment
105	MD	3	gastric pain	1	25.12.08	26.12.08	2	1	4	1	
110	MS	4	gastric pain after diclofenac ingestion	2	22.01.09	23.01.09	1	1	3	1	
116	EE	4	acute pyelonephritis	1	15.02.09		2	2	1	2	
116	EE	5	acute pyelonephritis	2	15.02.09	26.02.09	2	1	1	2	
117	MG	3	fracture of radial epifiza left forearm	1	15.01.09		2	2	1	2	
117	MG	4	fracture of radial epifiza left forearm	2	15.01.09	12.02.09	2	1	1	2	
120	ET	3	epigastralgia	1	9.12.08	15.12.08	2	1	2	2	the patient discovered a concomitent gastric infection with helicobacter pylori and she took the antibiotic treatment
128	MA	2	nausea	1	25.09.08		1	2	3	1	
132	MG	2	nausea	1	3.11.08	6.11.08	2	1	2	1	
134	MLM	2	vascular prophylaxis	1	3.11.08		1	3	1	2	at the reccomandation of general practicioner the patient started the vascular prophylaxis with diosminum
136	MCB	4	flue syndrome	1	15.01.09	24.01.09	1	1	2	2	
138	PN	3	nausea	1	25.12.08	30.12.08	2	1	2	2	
142	INL	2	muscular cramps in lower limbs	1	8.11.08	12.11.08	3	1	2	2	
143	MB	4	flu	1	2.02.09	12.02.09	2	1	1	2	
143	MB	5	flu	1	7.04.09	13.04.09	1	1	1	2	
181	EM	3	new medication for	1	29.01.09		1	3	1	2	acidum acetyl

Rand. Nr	Initials	AE reported at visit no:	Description of AE	AE Status	Date of appearance	Date ended	AE Intensity:	Outcome of AE	Causal relationship to study drug	Expectation	Comment
			ischemic heart disease								salicilicum 75mg/day, metoprololum 50mg/day at the indication of general practitioner
194	ES	2	osteoporosis	1	19.11.08		2	2	1	2	
194	ES	5	osteoporosis	2	19.11.08		2	2	1	2	the patient is under gp observation

Table 35: Display of adverse events, STO-group

Rand. Nr	Initials	AE reported at visit no:	Description of AE	AE Status	Date of appearance	Date ended	AE Intensity	Outcome of AE	Causal relationship to study drug	Expectation	Comment
49	JS	4	pain in cervical and lumbar spine	1	21.08.09		2	2	NA	2	
49	JS	4	pain in cervical and lumbar spine	1	21.08.09	22.10.09	2	1	NA	2	
50	KS	2	abdominal pain	1	10.04.09	13.04.09	1	1	NA	1	
98	CZZ	2	depression	1	29.04.09		1	2	NA	2	
98	CZZ	4	depression	2	29.04.09	31.07.09	1	1	NA	2	
111	MI	4	low urinary tract infection	1	31.01.09	3.02.09	1	1	NA	NA	
122	CS	2	epigastralgias	1	5.11.08	7.11.08	2	1	NA	1	AE is considered expected and related to diclofenac
122	CS	2	epigastralgias	1	19.11.08	19.11.08	1	1	NA	1	AE is considered related to diclofenac and expected
202	EC	4	gastric pain	1,2	15.05.09	16.05.09	1	1	NA	NA	AE is expected and related to diclofenac
211	MID	3	flu	1	7.01.09	15.01.09	1	1	NA	2	
218	MA	4	epigastralgias	1	26.05.09		2	2	NA	NA	AE is related and expected with nimesulidum
218	MA	5	epigastralgias	2	26.05.09	31.05.09	2	1	NA	NA	AE is related and expected with nimesulidum
220	MV	3	epigastralgias	1	18.04.09		2	2	NA	NA	AE is related and

Rand. Nr	Initials	AE reported at visit no:	Description of AE	AE Status	Date of appearance	Date ended	AE Intensity	Outcome of AE	Causal relationship to study drug	Expectation	Comment
											expected with diclofenacum and meloxicamum
220	MV	4	epigastralgias	2	18.04.09	5.05.09	2	1	NA	NA	AE is related and expected with diclofenacum and meloxicamum

Explanation of Adverse Events Qualities

Code	Intensity	Relationship	Outcome
0		Not related	
1	Mild	Unlikely	Complete recovery
2	Moderate	Possible	Still present in the time of reporting
3	Severe	Probable	Still present in the final examination
4		Definite	Chronic condition

12.2.3. Analysis of Adverse Events

In the PAST-group 35 patients developed adverse events, while in the STO-group 9 patients developed adverse events.

Six adverse events in the PAST-group were probably or possibly related to the test drug.

12.3. DEATHS, OTHER SERIOUS ADVERSE EVENTS, AND OTHER SIGNIFICANT ADVERSE EVENTS

There were 3 serious adverse events reported.

Patient No 22 from centre No 10 (Durdikova), initials BB, female, born on 02 February 1930, 156 cm, 56 kg,in the PAST-group, since 16 February 2009 under therapy with Piascledine, died during the year 2009 on a lung tumor. No further information is available.

Patient No 201 from centre 6 (Ionescu), initials RSD, male, born on 24 July 1931, 180 cm, 79 kg, in the PAST group, was hospitalized for icterus (cholestatic syndrome) on 15 February 2009. The patient has been discontinued from the medication, and recovered completely. The connection with the study drug has been assessed as unlikely.

Patient No 210 from centre 6 (Ionescu), initials EED, female, born on 12 May 1944, 162 cm, 65 kg, in the PAST-group, was hospitalized for a biliary colic on 1 May 2009. The patient has been discontinued from the medication, and recovered completely. The connection with the study drug has been assessed as unlikely.

12.3.1. Listing of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

12.3.1.1 Deaths

Table 36: Serious Adverse Events – Death

Serious adverse events – death

Centre Nr.	10
Investigator	Durdikova
Patient no	22
Initials	BB
DOB	02.02.30
Weight	56
Height	156
Sex	F
Onset	2009
Description	Death
Pat died	Yes
Life threatening	Yes
Hospitalization	No
Disabling	No
Overdose	No
Cancer	Yes
Abnorm	No

Unexpected	Yes
Relevant tests	
Symptom 1	Death
Onset date	01.01.09
Onset time	
Duration	
Severity	Severe
Causality with drug	Not related
Causality with condition	No
Causality with other therapy	No
Action	None
Outcome	Death
Treatment	None
Symptom abated after dechallange	NA
Symptom abated after dose reduction	NA
Symptom reappeared at rechallange	NA
Symptom worsened after dose increase	NA
Batch no of study drug	NA
Amount	NA
Units	NA
Frequency	NA
Route	NA
Start date	NA
Stop date	NA
Administration	NA
Drug previously received	NA
Patient status	NA
Relevant medical history (1)	Osteopenia
Concomitant drug	Osteocentron
Amount	nk
Units	nk
Frequency	nk
Route	nk
Start date	01.01.06
Stop date	og
Relevant medical history (2)	lumbalgiae
Concomitant drug	
Amount	
Units	
Frequency	
Route	
Start date	01.01.98
Stop date	og
Patient seen by investigator	no
Additional information	now, I don't know another informations about her illness and death

12.3.1.2 Other Serious Adverse Events

Table 37: Serious Adverse Events - Others

Serious adverse events – others

Centre Nr.	6	6
Investigator	Ionescu	Ionescu
Patient no	201	210
Initials	RSD	EED
DOB	24.07.1931	12.05.1944
Weight	79	65
Height	180	162
Sex	M	F
Onset	15.02.09	01.05.09
Description	icterus cholestatic syndrom	Biliary colic
Pat died	No	No
Life threatening	No	No
Hospitalization	Yes	Yes
Disabling	No	No
Overdose	No	No
Cancer	No	No
Abnorm	No	No
Unexpected	Yes	Yes
Relevant tests		
Symptom 1		
Onset date	15.02.09	01.05.09
Onset time	06.03.09	08.05.09
Duration	-	-
Severity	-	Moderate
Causality with drug	Unlikely	Unlikely
Causality with condition	No	No
Causality with other therapy	No	No
Action	Permanent discontinuation, medication, hospitalization	Permanent discontinuation, medication, hospitalization, surgery
Outcome	Complete recovery	Complete recovery
Treatment	Hospitalization	Hospitalization, surgery
Symptom abated after dechallange	NA	NA
Symptom abated after dose reduction	NA	NA
Symptom reappeared at rechallange	NA	NA
Symptom worsened after dose increase	NA	NA
Batch no of study drug		
Amount	300	300
Units	mg	mg
Frequency	1/day	1/day

Route	po	po
Start date	15.12.08	17.02.09
Stop date	15.02.09	01.05.09
Administration		
Drug previously received		
Patient status	outpatient	outpatient
Relevant medical history	Lumbar column spondylopaty (1980), ischemic heart disease (2007), prostate adenoma (1990), inguinal hernia (1980), hypertension (2007)	ischemic heart disease (2002), arterial hypertension (2002), chronic gastritis (1995),
Concomitant drug	Metoprolol	Metoprolol
Amount	50	50
Units	mg	mg
Frequency	/day	/day
Route	po	po
Start date	1.01.07	1.01.02
Stop date		
Concomitant drug (2)	Simvastatin	Perindopril
Amount	20	10
Units	mg	mg
Frequency	/day	/ day
Route	po	po
Start date	1.01.07	1.01.02
Stop date		
Concomitant drug (3)	Perindopril	Indapamidum
Amount	5	1,5
Units	mg	mg
Frequency	/ day	/ day
Route	po	po
Start date	1.01.07	1.01.02
Stop date		
Concomitant drug (4)	Doxazosinum	Omeprazolum
Amount	4	10
Units	mg	mg
Frequency	/ day	/ day
Route	po	po
Start date	1.07.08	1.02.09
Stop date		10.02.09

12.3.1.3 Other Significant Adverse Events

In this section the patients early terminating the study due to adverse events are listed.

Patient No 41 and 53 (PAST-group) terminated the study prematurely due to adverse events, patient 41 due to worsening of pain in the knee at Visit 2, patient 53 due to abdominal pain at Visit 2.

12.3.2. Narratives of Deaths, Other Serious Adverse Events, and Certain Other Significant Adverse Events

All information obtained is contained in Table 36 and Table 37. No additional information has been provided.

12.3.3. Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

All information obtained is contained in Table 36 and Table 37. No additional information has been provided.

12.4. VITAL SIGNS, PHYSICAL FINDINGS, AND OTHER OBSERVATIONS RELATED TO SAFETY

12.4.1. Vital signs

Neither systolic or diastolic blood nor heart rate pressure changed during the treatment phase in one of the treatment groups (Table 38).

Table 38: Blood pressure at visits 1 and 5

Group	Parameter	Systolic blood pressure		Diastolic blood pressure	
		Visit 1	Visit 5	Visit 1	Visit 5
PAST	Mean	128,62	128,88	76,47	75,69
	SD	12,02	9,48	7,22	7,79
	Median	130	130,00	80,00	75,00
	Minimum	100	110	60	60
	Maximum	180	150	95	100
STO	Mean	130,53	128,91	76,83	75,30
	SD	13,21	10,58	7,86	8,59
	Median	130,00	130,00	80,00	75,00
	Minimum	100	100	60	50
	Maximum	180	160	120	100

Table 39: Heart and breath rate at visits 1 and 5

Group	Parameter	Heart Rate		Breath rate	
		Visit 1	Visit 5	Visit 1	Visit 5
PAST	Mean	73,67	73,64	16,75	16,45
	SD	6,46	5,54	2,80	1,89
	Median	74,00	74,00	16,50	17,00
	Minimum	60	60	12	12
	Maximum	92	88	26	20
STO	Mean	73,76	73,99	16,90	16,58
	SD	6,70	5,67	2,61	1,81
	Median	72,50	74,00	17,00	17,00
	Minimum	54	60	12	12
	Maximum	95	90	28	21

12.4.2. Physical examination

There were 6 patients, whose result of the physical examination changed at Visit 2, 0 at Visit 3, 4 at Visit 4, and 5 at Visit 5.

12.4.3. Concomitant treatment

In 26 patients the concomitant medication (not NSAID and paracetamol) changed at Visit 2, in 17 at Visit 3, in 14 at Visit 4 and 5, respectively. These changes are listed in **Table 45**

12.4.4. Overall tolerability

Overall tolerability was assessed by investigator and patient in 146 cases for the PAST-group, and in 148 for the STO-group. The tolerability in the PAST group is considerably higher than the reports in the STO-group. The tolerability of the Piascledine treatment is assessed as excellent and good by the investigators in 98.7%, by the patients in 98.6%, in the STO-group.81.1% and 79.8%, respectively. Medium and poor tolerability for piascledine is assessed in 1.4% by investigators and patients, for STO in 18.9% by investigators, and in 20.3% by the patients.

Table 40: Overall tolerability

Treatment	Assessment	Investigator		Patient	
		N	%	N	%
PAST	Excellent	129	88,4	124	84,9
	Good	15	10,3	20	13,7
	Medium	0	0	0	0
	Poor	2	1,4	2	1,4
	No of assessments	146		146	
STO	Excellent	39	26,4	38	25,7
	Good	81	54,7	80	54,1
	Medium	27	18,2	30	20,3
	Poor	1	0,7	0	0
	No of assessments	148		148	

12.5. SAFETY CONCLUSIONS

Three Serious Adverse Events have been observed during the trial in the PAST group (one death due to a lung tumour, one cholestatic icterus, one biliary colic) without or with unlikely relation to the treatment.

In the PAST group 29 patients (19.3%) reported 35 Adverse Events, from which 6 have been assessed as possibly or probably related to the treatment, while 28 observations were not or unlikely related to the treatment (infections, accident etc.).

In the STO-group 9 patients (6.0%) reported 14 adverse events, mostly known side effects of the NSAID.

The overall tolerability of the Piascledine treatment has been assessed as excellent and good by the investigators in 98.7%, by the patients in 98.6%, in the STO-group.81.1% and 79.8%, respectively. Medium and poor tolerability for piascledine is assessed in 1.4% by investigators and patients, for STO in 18.9% by investigators, and in 20.3% by the patients.

The vital signs did not reveal any changes in both groups during the observation time.

Not only that the add-on therapy with Piascledine does not have a negative influence on the tolerability of osteoarthritis, the tolerability seems to be even increased by the piascledine treatment.

13 DISCUSSION AND OVERALL CONCLUSIONS

This prospective multinational multicentric open clinical study comparing the efficacy and safety of PIASCLEDINE® 300 plus standard treatment versus standard treatment only in 300 patients with knee osteoarthritis over a 6 months period confirms the high efficacy and good tolerance of Piascledine.

Osteoarthritis is major public health problem in the world due to its prevalence, its impact of quality of life and its huge direct cost. Therefore the diagnosis and treatment of OA should be based on solid scientific evidences and cost-effective practice.Several international and national treatment recommendations has been developed to influence medical practice. In this respect it is important to clarify the position of Piascledine in the recommended treatment of osteoarthritis.

In 2000 the EULAR recommendation for the management of knee osteoarthritis the authors stated that „SYSADOA may possess structure modifying properties, but more studies using standardised methods required." In this recommendation Piascledine was not mentioned among the drugs belonging to the SYSADOA group. (1)

3 years later in a new recommendation the authors go further stating that the drugs belonging to SYSADOA – in this case including Piascledine too – have symptomatic effects and may modify structure. For Piascledine they calculated an effect size of 0.32-1.72 which is comparable to the traditional NSAIDs (0.47-0.96)and this recommendation based on 1B level of evidence (23).

Piascledine produced varying degree of symptomatic efficacy in several clinical studies in patients with osteoarthritis of the knee and hip.

In the study conducted by Blotman et al. 163 patients with osteoarthritis of the knee or hip received compulsory oral doses of NSAID for 3 months (one of the 7 predefined NSAID) and 300 mg/daily Piascledine or placebo. The main evaluation criterion was the ratio of patients who returned to NSAID and the time elapsed between day 45 and the resumption. The difference for the whole set of patients was statistically significant between the two treatment groups ($P < 0.001$). Other assessment criteria (patient and physician global assessment, Lequesne functional index and severity of pain) showed the same trend with the exception of pain measured by a VAS scale. (12Erreur ! Source du renvoi introuvable.)

Maheu et al. treated 164 patients with osteoarthritis of the knee (114) and hip (50) for 6 months and followed them for an additional 2 months Piascledine 300 (85 patients) or placebo (79 patients). The primary endpoints were the Lequesne index, pain, overall disability (rated on the visual analogue scale) and intake of NSAIDs. In this study all parameters ameliorated significantly better in the Piascledine treated group than in the placebo group, except NSAIDs intake reduction. The Lequesne score decreased from 9.7+/-0.3 to 6.8+/-0.4 in the avocade and from 9.4+/-0.3 to 8.9+/-0.4 in the placebo group. Less patient requiered NSAID treatment in the Piascledine arm (48 %) than in the placebo group (63%). The subgroup analysis showed a more marked improvement in patients with hip osteoarthritis. (13)

Lequesne et al. in a placebo controlled trial treated 163 patients with hip osteoarthritis with Piascledine for 2 years to evaluate the structure modifying effect. 108patients were

radiologically evaluable at the end of the study but there was no difference in the joint space loss between the two groups.In a post-hoc analysis the were able to demonstrate that Piascledine significantly reduced the joint space loss compared to placebo in the patient with advanced joint space narrowing. (24)

In a study comparing Piascledine 300 mg once daily and chondroitin sulfate 1200 mg three times daily directly for efficacy, safety and carry-over effect it has been demonstrated that there is no difference in efficacy or in safety aspects between Piascledine and chondroitin sulfate. Also the compliance was identical under these test conditions, in which all patients had to take 4 capsules daily over 6 months (22).

The results of this open, randomized trial can add a further evidence on the effectiveness of Piascledine 300 mg in the treatement of osteoarthritis:

The primary variable was the number of patients weaned off NSAID at each visit starting with V2. The number of patients not taking NSAIDs increased in the PAST-group continuously from Visit 2 to Visit 5. At the end of the trial 35.4% of the patients did not need NSAID any more. In the STO groups there was also a slight increase of patients stopping NSAID/medication, but on a much lower level. 7.4% of the patients did not use NSAID in the STO-group at the end of the trial. This difference between the STO- and the PAST-group is highly significant ($p<0.001$) during the entire duration of the study

Also in all secondary efficacy criteria (Pain evaluation assessed on VAS, Lequesne-index, overall assessment of efficacy as well as in all issues of the Quality-of-life scale SF12, a significant difference between the two treatment groups has been revealed in favour of the Piascledine treatment.

The tolerability of the treatments has been assessed higher in the group receiveing Piascledine. It seems that the tolerability of NSAID treatment is increased by adding piascledine to the standard treatment.

It has been proved in this investigation that the add-on therapy with Piascledine has a significant and clinically relevant positive effect on both the symptomatology of osteoarthritis and the quality of life.

14 TABLES, FIGURES, AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT

Table 41: Demographic data

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
1	HT	Valeria Durdikova	10	female	13.08.37	71	175	70
2	LT	Valeria Durdikova	10	female	3.09.55	54	160	85
3	NM	Valeria Durdikova	10	female	3.09.60	48	168	70
4	AU	Valeria Durdikova	10	female	15.02.60	48	155	68
5	VM	Valeria Durdikova	10	female	16.09.30	78	158	60
6	LL	Valeria Durdikova	10	male	12.06.44	64	170	70
7	MN	Valeria Durdikova	10	female	10.03.44	64	162	68
8	AS	Valeria Durdikova	10	female	13.10.33	75	150	48
9	OT	Valeria Durdikova	10	female	4.07.60	48	156	52
10	HJ	Valeria Durdikova	10	female	15.04.59	49	154	66
11	MS	Valeria Durdikova	10	female	27.05.58	51	160	60
12	AP	Valeria Durdikova	10	female	3.06.42	66	175	106
13	JW	Roman Jancovic	12	male	12.01.50	59	170	72
14	PK	Roman Jancovic	12	male	9.09.57	51	174	61
15	RM	Roman Jancovic	12	female	22.03.51	58	168	91
16	AP	Roman Jancovic	12	female	29.03.57	52	164	79
17	BS	Roman Jancovic	12	female	8.05.61	48	171	63
18	JB	Roman Jancovic	12	female	16.11.43	65	180	79
19	EL	Valeria Durdikova	10	female	18.10.51	58	166	73
20	JP	Valeria Durdikova	10	female	3.04.40	69	156	68
21	MB	Valeria Durdikova	10	female	11.05.62	47	168	58
22	BB	Valeria Durdikova	10	female	2.02.30	79	156	56
23	VV	Valeria Durdikova	10	female	30.05.58	51	170	120
24	DR	Valeria Durdikova	10	female	11.01.55	54	164	87
25	AG	Roman Jancovic	12	female	21.01.33	75	156	80
26	RS	Roman Jancovic	12	male	28.07.29	79	160	70
27	MB	Roman Jancovic	12	female	13.05.30	78	160	60
28	NJ	Roman Jancovic	12	female	5.12.44	64	168	104
29	JC	Roman Jancovic	12	male	23.02.46	62	173	79
30	VC	Roman Jancovic	12	female	7.12.48	60	167	74
31	IC	Roman Jancovic	12	female	1.07.58	50	164	90
32	DM	Roman Jancovic	12	male	21.03.59	49	179	102
33	ZM	Roman Jancovic	12	female	1.07.49	59	167	59
34	GH	Roman Jancovic	12	female	22.02.32	76	162	65
35	IS	Roman Jancovic	12	female	22.01.57	52	170	86
36	JZ	Roman Jancovic	12	female	30.03.25	84	158	56
37	MB	Roman Jancovic	12	female	18.10.58	50	172	70
38	DM	Roman Jancovic	12	female	15.04.47	61	165	81
39	AZ	Roman Jancovic	12	female	23.04.53	55	166	77

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
40	OH	Roman Jancovic	12	female	22.09.53	55	166	81
41	MG	Roman Jancovic	12	female	5.07.41	68	168	78
42	JG	Roman Jancovic	12	male	25.04.44	64	176	103
43	TBK	Beata Kotodziejczyk	3	female	8.09.40	68	158	71
44	AL	Beata Kotodziejczyk	3	female	6.05.42	66	158	72
45	WS	Beata Kotodziejczyk	3	female	27.06.47	61	158	80
46	ZJ	Beata Kotodziejczyk	3	female	23.10.29	79	156	70
47	AS	Beata Kotodziejczyk	3	male	28.01.34	74	167	72
48	WBK	Beata Kotodziejczyk	3	female	27.03.45	63	158	78
49	JS	Beata Kotodziejczyk	3	female	26.09.41	67	160	63
50	KS	Beata Kotodziejczyk	3	female	12.09.40	69	162	87
51	EK	Beata Kotodziejczyk	3	female	3.12.47	61	160	66
52	MK	Beata Kotodziejczyk	3	male	26.02.38	71	172	85
53	DS	Beata Kotodziejczyk	3	female	2.04.42	67	159	86
54	AEK	Beata Kotodziejczyk	3	female	2.01.32	77	162	79
55	AD	Michal Barszczewski	4	male	7.08.51	57	168	72
56	KG	Michal Barszczewski	4	male	21.04.50	58	171	79
57	JD	Michal Barszczewski	4	male	18.02.55	53	178	84
58	KK	Michal Barszczewski	4	female	19.12.52	55	167	69
59	TJS	Michal Barszczewski	4	female	18.08.52	56	168	72
60	BAF	Michal Barszczewski	4	female	18.06.39	69	160	60
61	RB	Michal Barszczewski	4	female	18.07.30	78	160	52
62	DB	Michal Barszczewski	4	female	4.09.32	76	163	70
63	AF	Michal Barszczewski	4	male	20.10.53	54	181	96
64	JS	Michal Barszczewski	4	female	22.02.42	66	164	72
65	UBH	Michal Barszczewski	4	female	13.05.36	72	158	90
66	DB	Michal Barszczewski	4	male	19.04.62	46	187	97
67	KRM	Inga Dlugon	5	female	26.05.38	70	168	90
68	JAA	Inga Dlugon	5	female	9.04.46	62	158	57
69	JAF	Inga Dlugon	5	female	24.04.27	81	156	72
70	URG	Inga Dlugon	5	female	29.06.43	65	162	69
71	STK	Inga Dlugon	5	male	3.07.40	68	174	76
72	MAK	Inga Dlugon	5	female	10.07.30	78	157	65
73	MAP	Inga Dlugon	5	female	22.05.44	64	170	107
74	JRM	Inga Dlugon	5	female	21.06.33	75	159	62
75	MAZ	Inga Dlugon	5	female	2.07.24	84	154	66
76	MEW	Inga Dlugon	5	female	8.08.48	60	164	72
77	FEP	Inga Dlugon	5	female	20.11.32	76	158	69
78	WIG	Inga Dlugon	5	male	14.12.37	71	176	95
79	PJ	Michal Barszczewski	4	male	8.08.54	54	188	90
80	WC	Michal Barszczewski	4	female	18.02.36	72	159	69
81	AK	Michal Barszczewski	4	female	30.01.36	72	158	70
82	IR	Michal Barszczewski	4	female	1.11.33	74	160	60
83	WW	Michal Barszczewski	4	female	7.02.25	83	150	45
84	ITR	Michal Barszczewski	4	female	7.08.34	74	160	88
85	SP	Michal Barszczewski	4	female	20.08.38	70	165	55

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
86	AL	Michal Barszczewski	4	female	17.10.39	69	163	71
87	RS	Michal Barszczewski	4	male	6.02.54	54	175	80
88	KMR	Michal Barszczewski	4	female	9.04.52	56	170	64
89	MR	Michal Barszczewski	4	male	1.11.53	54	177	77
90	SB	Michal Barszczewski	4	female	15.09.40	68	162	100
91	KR	Michal Barszczewski	4	female	22.07.51	57	170	67
92	AM	Michal Barszczewski	4	male	25.10.57	51	190	97
93	JS	Michal Barszczewski	4	male	3.09.46	62	175	72
94	DN	Michal Barszczewski	4	male	3.05.58	50	165	65
95	ZMJ	Michal Barszczewski	4	male	11.03.61	47	178	80
96	CJW	Michal Barszczewski	4	male	12.08.57	51	175	87
97	NOZ	Inga Dlugon	5	female	14.02.44	65	161	87
98	CZZ	Inga Dlugon	5	female	20.07.46	62	160	80
99	TEW	Inga Dlugon	5	female	23.09.50	58	162	65
100	KMI	Inga Dlugon	5	female	6.04.23	86	165	80
101	BJC	Michal Barszczewski	4	female	16.01.63	46	176	72
102	MIL	Michal Barszczewski	4	female	16.11.63	45	162	96
103	FS	Ruxandra Ionescu	6	female	1.05.63	45	163	115
104	MC	Ruxandra Ionescu	6	female	18.05.52	56	167	110
105	MD	Ruxandra Ionescu	6	female	20.09.52	56	159	65
106	VM	Ruxandra Ionescu	6	female	19.06.36	72	158	82
107	MC	Ruxandra Ionescu	6	female	3.04.55	53	160	78
108	FN	Ruxandra Ionescu	6	female	4.11.46	61	156	58
109	LM	Ruxandra Ionescu	6	female	28.11.57	50	161	65
110	MS	Ruxandra Ionescu	6	female	12.06.52	56	155	75
111	MI	Ruxandra Ionescu	6	female	5.05.43	65	156	80
112	AG	Ruxandra Ionescu	6	female	28.07.50	58	160	68
113	VI	Ruxandra Ionescu	6	female	10.10.57	50	155	78
114	EL	Ruxandra Ionescu	6	female	13.12.50	57	155	62
115	FP	Ruxandra Ionescu	6	female	24.04.56	52	170	120
116	EE	Ruxandra Ionescu	6	female	16.01.38	70	158	69
117	MG	Ruxandra Ionescu	6	female	11.02.58	50	173	100
118	ES	Ruxandra Ionescu	6	female	25.01.52	56	163	65
119	MV	Ruxandra Ionescu	6	female	2.05.53	55	162	68
120	ET	Ruxandra Ionescu	6	female	1.08.47	61	155	60
121	MR	Ruxandra Ionescu	6	female	13.04.36	72	158	69
122	CS	Ruxandra Ionescu	6	female	26.05.45	63	165	85
123	EGM	Ruxandra Ionescu	6	female	1.11.54	54	170	82
124	PR	Ruxandra Ionescu	6	female	15.06.50	58	168	88
125	AMG	Ruxandra Ionescu	6	female	26.10.46	62	165	72
126	MV	Ruxandra Ionescu	6	female	4.03.58	50	156	68
127	PVT	Adrian Sarbu	7	female	26.04.33	75	163	72
128	MA	Adrian Sarbu	7	female	26.03.55	53	165	77
129	IF	Adrian Sarbu	7	female	31.03.59	49	164	91
130	MI	Adrian Sarbu	7	female	5.06.59	49	165	82
131	IC	Adrian Sarbu	7	female	16.11.56	52	162	75

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
132	MG	Adrian Sarbu	7	female	23.01.40	68	165	59
133	DAR	Adrian Sarbu	7	female	18.12.45	63	150	67
134	MLM	Adrian Sarbu	7	female	27.09.44	64	170	70
135	NP	Adrian Sarbu	7	female	16.05.37	71	156	67
136	MCB	Adrian Sarbu	7	female	15.08.43	65	162	63
137	LS	Adrian Sarbu	7	female	15.07.51	57	165	68
138	PN	Adrian Sarbu	7	female	19.02.37	71	155	65
139	VF	Adrian Sarbu	7	female	15.06.42	66	159	71
140	MB	Adrian Sarbu	7	female	14.04.42	66	164	80
141	GIM	Adrian Sarbu	7	female	6.10.41	67	166	76
142	INL	Adrian Sarbu	7	male	21.07.40	68	165	105
143	MB	Adrian Sarbu	7	female	17.12.40	68	160	79
144	ET	Adrian Sarbu	7	female	10.01.54	54	158	95
145	CA	Monica Bunea	8	female	11.03.47	61	160	118
146	LS	Monica Bunea	8	female	22.02.37	71	160	68
147	ADP	Monica Bunea	8	female	25.05.50	58	160	79
148	VAA	Monica Bunea	8	female	20.10.35	72	166	73
149	ED	Monica Bunea	8	female	27.02.40	68	153	76
150	SS	Monica Bunea	8	female	21.07.30	78	167	78
151	IDA	Monica Bunea	8	male	14.09.53	55	174	110
152	RT	Monica Bunea	8	female	4.07.41	67	156	64
153	EC	Monica Bunea	8	female	15.05.55	53	165	84
154	MAM	Monica Bunea	8	female	8.12.44	63	165	75
155	VN	Monica Bunea	8	female	27.03.38	70	156	65
156	PS	Monica Bunea	8	female	17.03.46	62	169	68
157	GB	Monica Bunea	8	female	17.12.44	63	164	86
158	STP	Monica Bunea	8	female	13.04.33	75	163	85
159	CC	Monica Bunea	8	female	14.08.50	58	170	95
160	SC	Monica Bunea	8	male	8.07.46	62	168	70
161	DO	Monica Bunea	8	female	1.02.55	53	165	77
162	MC	Monica Bunea	8	female	25.08.55	53	150	70
163	NB	Bogdan Mihail Jantes	9	female	14.07.53	55	162	75
164	MM	Bogdan Mihail Jantes	9	female	10.02.59	49	164	60
165	EN	Bogdan Mihail Jantes	9	female	17.08.48	60	160	70
166	IP	Bogdan Mihail Jantes	9	female	6.04.40	68	150	70
167	MD	Bogdan Mihail Jantes	9	female	7.11.36	71	155	68
168	IN	Bogdan Mihail Jantes	9	female	19.06.39	69	162	79
169	ID	Bogdan Mihail Jantes	9	male	30.11.60	47	170	62
170	AA	Bogdan Mihail Jantes	9	female	18.03.44	64	154	62
171	EL	Bogdan Mihail Jantes	9	female	2.11.46	61	165	80
172	GT	Bogdan Mihail Jantes	9	female	16.05.45	63	150	80
173	VM	Bogdan Mihail Jantes	9	female	19.03.33	75	165	80
174	EO	Bogdan Mihail Jantes	9	female	8.03.48	60	164	65
175	ES	Bogdan Mihail Jantes	9	female	28.05.48	60	140	58
176	MI	Bogdan Mihail Jantes	9	female	13.10.37	71	162	60
177	GU	Bogdan Mihail Jantes	9	female	1.09.52	56	163	70

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
178	GC	Bogdan Mihail Jantes	9	female	4.03.41	67	150	62
179	GB	Bogdan Mihail Jantes	9	female	21.09.51	57	165	57
180	MC	Bogdan Mihail Jantes	9	female	9.08.34	74	170	73
181	EM	Adrian Sarbu	7	female	22.10.46	62	149	86
182	MD	Adrian Sarbu	7	female	1.06.51	57	164	85
183	SB	Adrian Sarbu	7	female	1.05.34	74	151	82
184	FI	Adrian Sarbu	7	female	23.12.46	62	150	78
185	FD	Adrian Sarbu	7	male	22.10.48	60	180	102
186	TD	Adrian Sarbu	7	female	7.04.44	64	154	94
187	MT	Monica Bunea	8	female	12.04.50	58	164	70
188	EP	Monica Bunea	8	female	4.10.51	57	165	65
189	MD	Monica Bunea	8	female	1.05.38	70	165	72
190	SE	Monica Bunea	8	female	30.11.52	55	168	92
191	IV	Monica Bunea	8	female	9.09.57	51	162	105
192	GC	Monica Bunea	8	female	9.04.59	49	150	53
193	MN	Bogdan Mihail Jantes	9	female	8.11.53	54	153	51
194	ES	Bogdan Mihail Jantes	9	female	21.06.48	60	167	82
195	ID	Bogdan Mihail Jantes	9	male	2.06.59	49	170	86
196	FD	Bogdan Mihail Jantes	9	female	17.03.41	67	155	76
197	GG	Bogdan Mihail Jantes	9	male	23.04.43	65	175	81
198	MA	Bogdan Mihail Jantes	9	female	28.06.41	67	155	74
199	MP	Ruxandra Ionescu	6	female	11.07.40	68	160	80
200	NB	Ruxandra Ionescu	6	female	6.05.44	64	162	68
201	RSD	Ruxandra Ionescu	6	male	24.07.31	77	180	79
202	EC	Ruxandra Ionescu	6	female	1.08.45	63	164	84
203	EB	Ruxandra Ionescu	6	female	25.11.44	64	152	60
204	IF	Ruxandra Ionescu	6	male	21.09.60	48	185	104
205	ES	Ruxandra Ionescu	6	female	16.07.46	62	160	80
206	ME	Ruxandra Ionescu	6	female	24.03.63	45	170	74
207	IU	Ruxandra Ionescu	6	female	27.11.47	61	150	65
208	EN	Ruxandra Ionescu	6	female	25.10.52	56	160	75
209	FS	Ruxandra Ionescu	6	female	4.08.51	57	162	52
210	EED	Ruxandra Ionescu	6	female	12.05.44	64	162	65
211	MID	Adrian Sarbu	7	male	3.07.23	85	164	78
212	MRB	Adrian Sarbu	7	male	17.11.62	46	190	90
213	AA	Adrian Sarbu	7	female	2.02.48	60	153	68
214	IB	Adrian Sarbu	7	female	7.06.56	52	156	82
215	EJ	Adrian Sarbu	7	female	18.01.49	59	151	88
216	MAR	Adrian Sarbu	7	female	8.12.55	53	163	71
217	EB	Monica Bunea	8	female	14.01.56	52	165	80
218	MA	Monica Bunea	8	female	15.03.44	64	161	79
219	VM	Monica Bunea	8	female	29.05.45	63	164	90
220	MV	Monica Bunea	8	female	1.03.49	59	160	80
221	VT	Monica Bunea	8	female	13.04.54	54	161	78
222	IC	Monica Bunea	8	female	26.02.39	69	164	84
223	TC	Monica Bunea	8	male	22.09.33	75	165	71

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
224	DV	Monica Bunea	8	male	16.09.44	64	175	93
225	AV	Monica Bunea	8	female	19.06.48	60	159	90
226	FB	Monica Bunea	8	female	6.11.34	74	165	75
227	AE	Monica Bunea	8	female	28.09.41	67	152	71
228	IS	Monica Bunea	8	female	21.04.55	53	157	66
229	IJ	Bogdan Mihail Jantes	9	female	8.02.52	56	180	86
230	MC	Bogdan Mihail Jantes	9	female	22.10.58	50	153	48
231	ED	Bogdan Mihail Jantes	9	female	21.03.47	61	154	61
232	EP	Bogdan Mihail Jantes	9	female	27.03.53	55	172	96
233	AS	Bogdan Mihail Jantes	9	female	28.03.40	68	178	78
234	ES	Bogdan Mihail Jantes	9	female	22.07.48	60	158	80
235	TT	Bogdan Mihail Jantes	9	male	8.05.46	62	173	83
236	PO	Bogdan Mihail Jantes	9	female	26.08.44	64	160	72
237	VS	Bogdan Mihail Jantes	9	female	17.08.55	53	165	72
238	IN	Bogdan Mihail Jantes	9	female	22.10.53	55	160	88
239	EN	Bogdan Mihail Jantes	9	female	15.10.39	69	162	58
240	IS	Bogdan Mihail Jantes	9	female	24.08.45	63	157	63
241	ISH	Zhaneta Georgieva	1	female	19.01.34	75	156	72
242	IKV	Zhaneta Georgieva	1	female	19.02.55	54	160	95
243	MJJ	Zhaneta Georgieva	1	female	24.07.48	60	160	90
244	RDA	Zhaneta Georgieva	1	female	27.03.56	51	162	147
245	MSM	Zhaneta Georgieva	1	female	29.07.43	65	164	95
246	PDT	Zhaneta Georgieva	1	female	6.07.30	78	165	63
247	BSJ	Zhaneta Georgieva	1	female	23.11.47	61	167	73
248	LVK	Zhaneta Georgieva	1	female	17.10.36	72	170	70
249	KJP	Zhaneta Georgieva	1	female	20.07.36	72	158	86
250	KSA	Zhaneta Georgieva	1	female	12.07.61	47	165	102
251	DIS	Zhaneta Georgieva	1	male	13.08.51	57	171	110
252	VPV	Zhaneta Georgieva	1	female	7.06.48	60	170	90
253	PPS	Zhaneta Georgieva	1	female	25.02.31	78	155	85
254	ZAI	Zhaneta Georgieva	1	female	20.05.45	63	163	95
255	PDI	Zhaneta Georgieva	1	female	31.01.53	56	167	103
256	EFM	Zhaneta Georgieva	1	female	5.01.53	56	150	80
257	DKD	Zhaneta Georgieva	1	female	22.09.32	76	166	87
258	IBT	Zhaneta Georgieva	1	female	21.10.50	58	164	70
259	IHG	Zhaneta Georgieva	1	female	9.02.41	68	160	85
260	RTC	Zhaneta Georgieva	1	male	29.05.33	75	173	76
261	MSD	Zhaneta Georgieva	1	female	21.07.48	60	159	90
262	RSC	Zhaneta Georgieva	1	female	21.01.59	50	156	61
263	KSI	Zhaneta Georgieva	1	female	29.05.46	62	158	68
264	NDG	Zhaneta Georgieva	1	female	27.04.57	51	157	106
265	KAK	Zhaneta Georgieva	1	female	24.07.41	67	160	120
266	TST	Zhaneta Georgieva	1	female	2.09.51	57	167	87
267	ZSM	Zhaneta Georgieva	1	female	7.09.56	52	157	95
268	DDJ	Zhaneta Georgieva	1	female	27.11.60	48	156	78
269	JBP	Zhaneta Georgieva	1	female	17.10.48	60	160	97

Random Nr	Initials	Investigator	Centre	Sex	Date of birth	Age	Height	Weight
270	VKP	Zhaneta Georgieva	1	female	24.06.57	51	158	87
271	VYY	Zhaneta Georgieva	1	female	16.01.52	57	167	81
272	DGA	Zhaneta Georgieva	1	female	20.02.39	70	158	85
273	SAP	Zhaneta Georgieva	1	female	7.07.37	71	164	90
274	VIV	Zhaneta Georgieva	1	male	8.04.43	65	202	95
275	PZZ	Zhaneta Georgieva	1	female	22.02.49	60	160	78
276	AGV	Zhaneta Georgieva	1	female	15.12.45	63	168	80
277	GMS	Zhaneta Georgieva	1	female	4.05.41	67	170	82
278	PMT	Zhaneta Georgieva	1	female	4.02.35	74	160	64
279	RPP	Zhaneta Georgieva	1	female	27.11.47	61	162	92
280	JAR	Zhaneta Georgieva	1	male	3.09.46	62	165	83
281	BHZ	Zhaneta Georgieva	1	female	30.05.40	68	156	85
282	SDM	Zhaneta Georgieva	1	female	17.11.50	58	162	73
283	ZPI	Zhaneta Georgieva	1	female	5.07.58	50	160	85
284	MID	Zhaneta Georgieva	1	female	25.07.52	56	162	75
285	PTA	Zhaneta Georgieva	1	female	26.04.34	74	168	70
286	SIH	Zhaneta Georgieva	1	female	30.03.58	51	165	105
287	ZGZ	Zhaneta Georgieva	1	male	29.06.43	65	172	89
288	EEM	Zhaneta Georgieva	1	female	20.10.61	47	150	65
289	TIG	Zhaneta Georgieva	1	female	19.03.41	68	155	80
290	MIN	Zhaneta Georgieva	1	female	12.09.55	53	168	75
291	FRI	Zhaneta Georgieva	1	female	18.09.55	53	145	67
292	NAD	Zhaneta Georgieva	1	female	23.03.57	52	152	88
293	ZIR	Zhaneta Georgieva	1	female	25.04.39	69	165	69
294	NAT	Zhaneta Georgieva	1	female	14.03.49	60	154	65
295	EAK	Zhaneta Georgieva	1	female	7.07.43	65	157	80
296	KBK	Zhaneta Georgieva	1	male	29.12.43	65	172	83
297	ASS	Zhaneta Georgieva	1	female	15.07.30	79	160	67
298	IMK	Zhaneta Georgieva	1	female	17.06.49	59	162	88
299	NIP	Zhaneta Georgieva	1	female	26.04.53	55	168	130
300	BIN	Zhaneta Georgieva	1	female	2.10.53	55	152	62

Table 42: General physical examination at V1

Random Nr	Pathologic finding
1	hyperkyphosis
5	ischemic cardiac disease
	osteoporosis
11	hypertension
12	mild obesity
14	right partial rupture biceps brachii
15	obesity
18	varices cruris
	scoliosis
19	thyreoiditis chronica
20	arterial hypertension

Random Nr	Pathologic finding
	lumbalgiae
22	osteopenia syndroma lumboischiadicum chronica
23	hypothyreosis obesity
	osteoarthritis of the hand
24	sicca sy eyes
	coxarthrosis
25	kyphoscoliosis hallux valgus
26	scoliosis
	prostate hypertrophy
27	scoliosis hallux valgus bilateral
30	scoliosis
34	scoliosis
35	obesity
36	scoliosis hallux valgus
38	varices cruris
39	varices cruris
41	varices cruris
43	goiter
44	varices of legs
	glasses
	crepitatio
	scoliosis limited flexion of knees
45	glasses
	Crepitatio dex
	pain in abdomen
	scoliosis limited flexion of knees
47	skin irritation of shanks
48	glasses
	dyscopathy scoliosis limited flexion of knees
49	cataract of left eye
50	glasses
	dyscopathy scoliosis limited flexion of knees
51	rhonchi
	swelling of left wrist joint
52	palmary eczema
53	glasses
	obesity
	dyscopathy limited flexion of knees
54	varices of legs
	glasses
	dyscopathy limited flexion of knees
56	crepitations of femoral patella joint
58	pain of full flexion of right knee
60	varices of legs
62	crepitations of patella femoral joint
65	obesity

Random Nr	Pathologic finding
67	crural varices arterial hypertension
	obesity
68	crural varices
69	arterial hypertension
	obesity
72	scar after cholecystectomy
73	scar after cholecystectomy
	arterial hypertension
	obesity
75	atrial fibrillation crural varices
87	shortening of the right leg
98	arterial hypertension
100	fremitus
102	obesity
103	post surgical apendicecthomy cholecisthectomy abdominal scars
103	second degree obesity
104	obesity
107	abdominal scar post hystherecthomy
110	polinodular goiter
	tender lumbar area
115	post surgical abdominal scar
116	low limbs varix
117	abdominal tegumentary scar post hysterectomy
	hypotiroidism
	hysterectomy
119	tender paravertebral area (lumbar)
123	tender lumbar area
124	hands vitiligo
125	abdominal scar post hysterectomy
127	overweight
128	overweight
129	obesity II grade
130	stage I obesity
131	overweight
133	chronic constipation
134	postoperative median abdominal scar
135	overweight
137	left internal menislectomy
138	overweight
139	overweight
140	overweight
141	overweight
142	stage II obesity
143	stage I obesity
144	obesity gr II

Random Nr	Pathologic finding
145	scar post apendicectomie scar post cholecystectomy scar post hysterectomy varicose veins of legs
	stage III obesity
146	scar post apendicectomy scar post hysterectomy
	overweight
147	st I obesity
148	varicose vein of legs scar post hysterectomy
	overweight
149	stage I obesity
150	overweight
151	stage II obesity
152	overweight
153	overweight
154	overweight
155	overweight
	scar post apendicectomia scar post hysterectomia
	stage I obesity
158	scar post hysterectomia
	stage I obesity
159	stage I obesity
161	scar post hysterectomia
	overweight
162	stage I obesity
163	osteoporosis
164	osteoporosis
165	osteoporosis
170	osteoporosis
172	atrial fibrillation, blood hypertension
	diabet mellitus (on diet) hypercolesterolemy
174	osteoporosis
175	osteoporosis
177	osteoporosis
178	osteoporosis
179	osteoporosis
180	abdominal scar post apendicectomy
181	stage II obesity, post thyroidectomy scar
182	varicose veins at lower limbs
	stage I obesity, post thyroidectomy scar
183	stage II obesity
184	stage I obesity
185	stage I obesity
186	stage II obesity
	post colecistectomy scar
187	overweight
189	overweight
190	stage III obesity

Random Nr	Pathologic finding
191	stage III obesity
193	abdominal scar post apendicectomy
	osteoporosis
195	abdominal scar post splenectomy
197	hypercholesterolemy
199	obesity
199	right convex scoliosis
200	abdominal scar post surgical
	pulsless pediosus tibial posterior&popliteal artherie
	tender cervical area
201	post surgery's inguinal scar
204	postsurgery inguinal scar
206	varicosity of lower limbs
	uterus fibroma
211	emphysematous thorax
	irregular heart sounds
	overweight
213	varicose veins in lower limbs
	overweight
214	Left knee postoperatory scar
	Stage I obesity
215	stage II obesity
	abdominal scar post hysterectomy
216	overweight
217	overweight
218	obesity I
219	obesity I
220	obesity I
221	obesity I
222	obesity grd I
223	overweight
224	obesity grd I
225	stage II obesity
226	overweight
227	stage I obesity
228	overweight
232	abdominal scar post histerectomy
232	hysterectomy
233	diabetes mellitus
235	abdominal scar post apendicectomy
236	diabetes mellitus
237	abdominal scar post apendicectomy
238	osteoporosis
239	abdominal scar post colecistectomy
239	osteoporosis
240	abdominal scar post apendicectomy

Random Nr	Pathologic finding
	osteoporosis
243	high blood pressure
	obesitas II gr
244	obesitas III gr
245	long expirium
	enlargement of the thyroid gland
249	obesitas
	positive succusio renalis
250	obesitas
251	obesitas
253	obesitas
254	rush on the abdomen
	obesitas I gr
255	obesitas II gr
263	high systolic blood pressure
265	high blood pressure ischemic illnes
265	diabetes mellitus
267	high blood pressure
273	high blood pressure
282	high blood pressure
285	high blood pressure
285	dislipidemia
286	obesitas III gr
287	high blood pressure
287	cholelitiasis
287	diabetes mellitus
289	obesitas
296	morbus hypertonicus
297	morbus hypertonicus
299	high blood pressure
299	diabetus mellitus

Table 43: Concomitant diseases and medications at visit 1

Rand Nr	Concomitant disease	Date of onset	Date of end	Name of the treatment	Indication	Dosage and units	Route	Start date	Stop date
1	arter. hypertenzia	01.01.2005	ongoing	calcium eff.	osteoporosis	500mg (1)	po	01.01.2005	ongoing
	osteoporosis	01.01.2005	ongoing	actonel 35	osteoporosis	35mg once weekly	po	01.01.2005	ongoing
				accuzide	arter.hypertenzia	10mg (1)	po	01.01.2005	ongoing
3	arthritis rheumatoides	12.11.2008	ongoing	diclofenac	arthritis	150mg	po	08.10.2000	ongoing
				plaquenil	arthritis rheum.	200mg	po	13.11.2008	ongoing
4	status post cholecystectomiam	01.01.1997	01.01.1997						
5	osteoporosis	28.07.2006	ongoing	chondrosulf	osteoarthritis	400mg (2)	po	01.01.2006	01.01.2006
	ischemic cardiac disease	01.01.1988	ongoing	nitropelet	ischemic cardiac disease	2,5mg (2)	po	01.01.1988	ongoing
	status post cholecystectomiam	01.01.1988	ongoing	calcium	osteoporosis	500mg (1)	po	01.01.2000	ongoing
	status post fract. radii I.dx from 02	28.07.2006	ongoing						
6	status post artrostopiam flirus	01.02.2008	ongoing						
7	arterial hypertenzia	01.01.2005	ongoing	lozap h=losartan potassium and hydrochlorothiazide	arterial hypertension	50mg and 12,5mg	po	01.01.2005	ongoing
7	osteoporosis	01.01.2007	ongoing	tevalen	osteoporosis	70mg 1 weekly	po	10.09.2008	ongoing
8	osteoporosis	01.01.2007	ongoing	tonocalcin 200	osteoporosis	200mg 1x	nasal	01.01.2007	ongoing
9	arterial hypertension	01.01.2000	ongoing	atenobene	arterial hypertension	50mg	po	01.01.2000	ongoing

11	status post ovarectomiam l.dx.	01.01.2003	ongoing	condrosulf	osteoarthrosis	400mg 2x	po	01.01.2004	01.01.2004
	hepatopatia	01.01.2006	ongoing	sylimarinum	hepatopatia	300mg 3x	po	01.01.2005	ongoing
	lumbalgiae	01.01.1998	ongoing	xanax	insomnia	0,25mg if needed	po	01.01.2005	ongoing
	osteopenia	01.01.2004	ongoing						
14	apendectomy	01.01.2005	01.01.2005						
15	obesity	nknknk	ongoing	levothyroxin	hypothyreosis	50ug	po 1x	01.01.2008	ongoing
	cholecystectomy	01.06.2005	01.06.2005						
	right strumectomy	01.11.2007	01.11.2007						
	hypothyreosis	nknknk	ongoing						
16	apendectomy	01.01.1978	01.01.1978						
17	tonsilectomy	01.01.1981	01.01.1981	varfarinum natrium	phlebotrombosis	5mg	oral	01.01.2006	01.01.2007
	apendectomy	01.01.1985	01.01.1985						
	phlebotrombosis post sclerotisation of varices crusis of left leg	01.01.2006	01.01.2006						
18	osteopenia	01.03.2005	ongoing	calcii carbonas	osteopenia	1250mg	oral	01.01.2007	ongoing
	scoliosis	01.01.1983	ongoing	cholecalciferol	osteopenia	400iu	oral	01.07.2007	ongoing
	apendectomy	01.01.1976	01.01.1976						
	cholecystectomy	01.01.1976	01.01.1976						
	fracture of ankle	01.01.1984	01.01.1984						
	hypercholesterole mia	01.01.2009	ongoing						
	low back pain	01.01.1983	ongoing						
	varices cruris	01.01.1963	ongoing						
19				condrosulf	omarthrosis	400mg 2x		01.03.2008	01.05.2008

	thyreopathia chron.thyreoiditis	01.01.2000	ongoing	euthyrox	chron.thyreoiditis	75mg		01.01.2000	ongoing
20	arterial hypertension	01.01.2000	ongoing	tritazide	arterial hypertension	5mg	po	01.01.2007	ongoing
	chronic vertebrogenous lumboischiadical syndrome	01.12.2008	ongoing						
	state after total endoprothesis of the right hip (2006)	01.01.2006	ongoing						
22	osteopenia	01.01.2006	ongoing	osteocenon	osteopenia	nk		01.01.2006	ongoing
	lumbalgiae	01.01.1998	ongoing						
23	diabetes mellitus diet	01.01.2008	ongoing	novalgin	gonalgiae	500mg	po	06.04.2009	ongoing
	hypothyreosis	01.01.2005	ongoing	euthyrox	hypothyreosis	150ug	po	01.01.2005	ongoing
	status after punct. from the left knee	01.01.2004	ongoing						
24	sjögren's sy.	17.12.2003	ongoing						
25	hypertension	01.01.1998	ongoing	perindopril	hypertension	4mg	po	01.01.2006	ongoing
	hypercholesterolemia	01.01.2000	ongoing						
	varices cruris	01.01.1976	ongoing						
26				hyaluronic acid	osteoarthritis	2ml	ia	03.06.2008	09.07.2008
	stomach resection propter adenoma	01.10.2000	01.10.2000	dutasterid	prostate hypertrophy	0,5mg	po	01.09.2007	ongoing
	hypertension	01.01.1996	ongoing	amlodipin	hypertension	5mg	po	01.02.2008	ongoing
	prostate hypertrophy	01.01.2005	ongoing	trandolapril	hypertension	2mg	po	01.06.2005	ongoing
27	osteopenia	01.07.2007	ongoing	caltrate plus ca+vitamin d	osteopenia	600mg ca	po	01.07.2007	ongoing

28	hypertension	01.01.1998	ongoing	bisoprolol	hypertension	5mg	po	01.01.2002	ongoing
29	hypertension	01.01.1996	ongoing	nitrendipin	hypertension	20mg	po	01.01.2004	ongoing
30	hypertension	01.01.2001	ongoing	perindopril	hypertension	2mg	po	01.01.2007	ongoing
	hyperlipidemia	01.01.2003	ongoing						
	plinus flat foot	nknknk	ongoing						
32	hypertension	01.01.2002	ongoing	perindopril	hypertension	2mg	po	01.01.2006	ongoing
	status post colica renalis 2004	01.01.2004	01.01.2004						
	hyperlipidemia	01.01.2005	ongoing						
	obesity	nknknk	ongoing						
34	hypothyroidism	01.01.1995	ongoing	calcium+dvit.	osteopenia	600mg	po	01.01.2003	ongoing
	osteopenia	01.01.2003	ongoing	levothyroxinum	hypothyroidism	50mg	po	01.01.1995	ongoing
35	hypertension	01.10.2004	ongoing	bisoprolol	hypertension	5mg	po	01.10.2004	ongoing
	tonsilectomy	01.01.1999	01.01.1999						
	duodenal ulcer	01.01.2006	01.01.2006						
36	chronic bronchitis	01.01.2001	ongoing	amlodipin	hypertension	5mg	po	01.01.2006	ongoing
	hypertension	01.01.1990	ongoing	calcium	osteoporosis	500mg	po	13.06.2007	ongoing
	ischaemic heart disease	01.01.1994	ongoing	isosorbit dinitrat	ischaemia	60mg	po	01.07.2008	ongoing
	osteoporosis	01.01.2002	ongoing	ibandronat	osteoporosis	100mg	po	13.06.2007	ongoing
37	low back pain	01.01.2006	01.01.2006						
38	hypertension	01.01.1988	ongoing	diltiazem	hypertension	120mg	po	01.01.1999	ongoing
	tonsilectomy	01.01.1974	01.01.1974						
	apendectomy	01.01.1981	01.01.1981						
39	tonsilectomy	01.01.1969	01.01.1969						
	hysterectomy	01.01.2002	01.01.2002						
40	hypertension	01.01.2008	ongoing	taloxifen	osteoporosis	60mg	po	01.10.2007	ongoing

	osteoporosis	01.10.2007	ongoing	calcium+dvit	osteoporosis	600mg	po	01.10.2007	ongoing
	cholecystectomy	01.01.1994	01.01.1994						
41	hypertension	01.01.1995	ongoing	acid acetylosalicylic	myocardial ischaemia	100mg	po	01.01.1995	ongoing
	myocardial ischaemia	01.01.1995	ongoing	trimetazidin	myocardial ischaemia	35mg	po	01.01.1997	ongoing
				ramipril	hypertension	2,5mg	po	01.01.2006	ongoing
42	hyperlipidemia	01.12.2007	ongoing						
	obesity	nknknk	ongoing						
43	arterial hypertension	01.10.1980	ongoing	ezetimibum	hypercholesterolemia	10ug 1tab	1x orally	01.04.2008	ongoing
	coronary disease	01.04.2003	ongoing	magnesii lactas	coronary disease	48mg 1tab	1x orally	04.05.2008	ongoing
	narrow angle glaucoma	01.11.1985	ongoing	losartanum kalicum	arterial hypertension	50mg 1tab	1x orally	30.03.2007	ongoing
	nodular goiter	01.02.2002	ongoing	aspirin	coronary disease	100ug 1tab	1x orally	20.04.2003	ongoing
				latanoprostum brimoniti tartas+timolol	glaucoma	0,05mg/ml	topical	15.02.2007	ongoing
					glaucoma	1,3mg/ml+6,8 mg/ml	topical	15.02.2007	ongoing
44	cerebral insufficientia	01.10.2004	01.10.2004	atoris atorvastatinum	atherosclerosis	20mg	po	23.01.2004	ongoing
	coronary disease	01.01.2003	ongoing	diuresin indapamide	hypertonia arterialis	1,5mg	po	01.10.2007	ongoing
	hyperlipidemia	01.01.2004	ongoing	kalipoz potassium K+10meq	potassium suplementation K+	10mEq	po	01.10.2007	ongoing
	hypertonia arterialis	01.01.1991	ongoing	accurenal quinapril	hypertonia arterialis	20mg	po	13.09.2006	ongoing

	scoliosis and dyscopathy	01.01.2005	ongoing	bisocard bisoprolol	coronary disease	2,5mg	po	01.02.2008	ongoing
	varices of legs	nknknk	ongoing	lacipil lacidypina	hypertonia arterialis	4mg	po	26.03.2008	ongoing
				acard acetylsalicilic acid	coronary disease	75mg	po	10.12.2004	ongoing
				helicid omeprazol	protection	10mg	po	22.11.2007	ongoing
45	cholecystectomy	nknknk	nknknk	metoprolol metocard	hypertonia arterialis	25mg 2x	po	03.10.2008	ongoing
	diabetes mellitus I.II	01.02.2008	ongoing	lacidipin lacipil 4mg	hypertonia arterialis	4mg 1x	po	01.10.2006	ongoing
	dyscopathy	01.01.1993	ongoing	ramipril axtil 5mg	hypertonia arterialis	5mg 2x	po	08.10.2008	ongoing
	hyperlipidemia	nknknk	ongoing	potassium kali poz	suplementatio	K+10mEq 1tab	po	23.09.2002	ongoing
	hypertonia arterialis	01.01.1987	ongoing	losartan loristia	hypertonia arterialis	50mg 2x	po	01.10.2006	ongoing
	incontinentio urinae	01.01.2000	ongoing	indapamide ipres long	hypertonia arterialis	1,5mg 1x	po	23.09.2002	ongoing
				metformin metformax	diabetes mellitus	850mg 3x	po	11.02.2008	ongoing
				omeprazole helicid	protection	20mg 1x	po	03.08.2005	ongoing
				oxybutinin driptane	incontinentio urine	5mg 2x	po	01.12.2001	ongoing
				simvastatin simvacard	hyperlipidemia	10mg 1x	po	01.02.2007	ongoing
46	hypercholesterolemia	18.12.2000	ongoing	lovastatin	hypercholesterolemie	10mg 1x	oral	16.05.2007	03.05.2008
	osteoporosis	12.09.2001	ongoing	alendronate sodium	osteoporosis	70mg 1tab 1x/week	oral	04.10.2006	ongoing

	vertigo	01.11.2008	ongoing	betahistin	vertigo	8mg 1tab 2x	oral	06.11.2008	ongoing
				amilorid	osteoporosis	2,5mg 1tab/two times/week	oral	04.10.2006	ongoing
				aspirin	prophilactic	75mg 1tab 1x	oral	18.07.2007	ongoing
				hydrochlorotiazyd	osteoporosis	25mg 1tab two times/week	oral	04.10.2006	ongoing
47				pentoxifylline	feeling of cold in limbs	300mg 2x	orally	23.01.2004	29.11.2008
	arterial hypertension	01.03.2005	ongoing	metoprolol succinate	arterial hypertension	100mg 1tab 1x	orally	01.10.2005	ongoing
	hypercholesterolemia	29.01.2004	ongoing	perindopril	arterial hypertension	5mg 1x	orally	16.03.2005	ongoing
				aspirin	prophylactic	75mg 1x	orally	29.11.2008	ongoing
				simvastatin	hypercholesterolemie	10mg 1x	orally	18.03.2005	ongoing
48	hyperlipidemia	01.01.2001	ongoing	simvastatin	artherosclerosis	10mg	po	01.09.2005	ongoing
	hypertonia arterialis	01.01.2005	ongoing	metoprolol	hypertonia arterialis	25mg	po	01.09.2005	ongoing
	scoliosis and discopathy	01.01.1990	ongoing	indapamid	hypertonia arterialis	1,5mg	po	01.06.2008	ongoing
				acard	hyperlipidemia	75mg	po	01.09.2005	ongoing
				kalipoz	potassium suplementatio	20MEq	po	01.06.2008	ongoing
				omeprazol helicid	protection	20mg	po	01.06.2007	ongoing
				ranitydinum ranigast	protection	150mg	po	01.05.2004	ongoing
49	arterial hypertension	29.10.2004	ongoing	levothyroxine sodium	hypothyroidism	25ug	orally	01.01.2004	ongoing

	chronic panuveitis oculi sinistri granulometose	01.03.2006	ongoing	omeprazole	protection mucosa of stomach	10mg	orally	29.06.2005	ongoing
	hypercholesterolemia	11.02.2003	ongoing	simvastatin	hypercholesterolemie	20mg	orally	28.11.2003	ongoing
	hypothyroidism	28.11.2003	ongoing	bisoprolol	arterial hypertension	5mg	orally	28.03.2006	ongoing
	osteoporosis	01.01.2000	ongoing	vinpocetine	improvement of celebres circulation	5mg 2x	orally	23.03.2005	ongoing
				diosmina	improvement of venous circulation	500mg 2x	orally	23.05.2006	ongoing
50	cancer uteri	01.12.1993	01.12.1993	aspirin	coronary disease	75mg	po	01.01.1999	ongoing
	nephrolithiasis	01.01.1967	18.01.2007	chlortalidone	osteopenia	50mg 2x for week	po	01.03.2009	ongoing
	coronary disease	01.01.1999	ongoing	sorbonit isosorbid dinitrate	coronary disease	5mg	po	01.01.2008	ongoing
	hyperlipidemia	01.01.1999	ongoing	telmisartan	hypertonia arterialis	40mg	po	01.01.2004	ongoing
	hypertonia arterialis	01.01.1990	ongoing	metoprolol	hypertonia arterialis	100mg	po	01.01.2008	ongoing
	osteopenia	01.01.1993	ongoing	simvastatin	hyperlipidemia	20mg	po	01.11.2002	ongoing
	scoliosis and dyscopathy	01.01.1979	ongoing	amlodipine	hypertonia arterialis	2,5mg	po	01.08.2000	ongoing
				omeprazol	protection	20mg	po	01.01.2008	ongoing
				potassium	potassium suplementatio	315mg	po	01.12.2005	ongoing
51	after operation of thyroid gland cause by nodula goiter	01.09.1987	01.09.1987	lorazepam	depresive neurosis	1mg	orally	12.10.1999	ongoing
	radiculitis	04.09.2005	16.09.2005	omeprazole	protection mucosa of stomach	20mg	orally	21.08.2005	ongoing
	depresive neurosis	01.10.1999	ongoing	paroxetine	depresive neurosis	20mg	orally	20.06.2000	ongoing

	after operation cause by intestine oclusion	01.03.2000	01.03.2000						
	recurrent bronchitis	19.04.2008	26.04.2008						
	reflux disease	21.08.2005	ongoing						
52	eczema of palms	30.06.2006	ongoing	triderm (betametazon+klotymezol+gentamycyna)	palmary eczema	one time a day	external ointment	06.03.2009	16.03.2009
	spondylosis deformans	05.01.2000	ongoing						
53	coronary disease	01.01.2003	ongoing	bisoprolol bisocard	hypertonia arterialis	25mg	po	01.12.2006	ongoing
	hyperlipidemia	01.01.2004	ongoing	aspirin acard	coronary disease	75mg	po	01.12.2006	ongoing
	hypertonia arterialis	01.11.2005	ongoing	simvastatin vasilip	hyperlipidemia	20mg	po	08.01.2004	ongoing
	dyscopathy	01.01.2005	ongoing						
54	asthma	nknknk	ongoing	simvastatin	hyperlipidemia	10mg	po	01.01.2004	ongoing
	coronary disease	01.01.2003	ongoing	aspirin	coronary disease	75mg	po	01.01.2004	ongoing
	discopathy	01.01.1999	ongoing	propafenone	arythmia	150mg	po	01.01.2004	ongoing
	hyperlipidemia	01.01.2002	ongoing	trimetazidyne	arythmia	35mg	po	01.01.2004	ongoing
	hypertonia arterialis	01.01.1999	ongoing	bisoprolol	hypertonia arterialis	2,5mg	po	01.01.2004	ongoing
	varices of legs	01.01.1999	ongoing	indapamide	hypertonia arterialis	1,5mg	po	01.01.2004	ongoing
	arythmia	01.01.2004	ongoing						
55	hypertension	01.07.2003	ongoing	perindopril	hypertension	5mg	po	01.07.2003	ongoing
				acetylosalicylic acid	artheriosclerosis	75mg	po	01.07.2003	ongoing
				indapamide	hypertension	1,5mg	po	01.07.2003	ongoing

56	hypertension	01.01.2005	ongoing	lisinopril	hypertension	5mg	po	01.02.2008	ongoing
				omeprazol	protection	20mg	po	25.08.2008	ongoing
				paracetamol	pain of knee	1000-3000mg	po	01.04.2008	ongoing
60	cholecystectomy	01.01.1999	ongoing	detralex:diosmi num+hesperidin um	varices of legs	450mg+50mg	po	01.01.2000	ongoing
	hypertension	01.01.1995	ongoing	enalapril	hypertension	5mg	po	01.01.2005	ongoing
	ischias	01.01.1980	ongoing	paracetamol	osteoarthritis of the knee	1000-3000mg	po	nknknk	ongoing
	varicosity	nknknk	ongoing	hydrochlorothia zid	hypertension	12,5mg	po	01.01.2005	ongoing
61				paracetamol	arthritis of the knee	1000mg-2000mg	po	nknknk	ongoing
	brachialgia	01.01.1995	ongoing	tetrazepam	brachialgia	50mg	po	07.04.2008	25.04.2008
	ischias	01.01.1995	ongoing	tolperison	brachialgia	300mg	po	07.04.2008	25.04.2008
				paracetamol 500 + codeinum 30 (talvosilen forte)	brachialgia	500mg+30mg	po	07.04.2008	25.04.2008
63				pantoprazol	protection	20mg	po	25.08.2008	ongoing
64	hypertension	01.01.2007	ongoing	perindopril	hypertension	5mg	po	01.01.2007	ongoing
				indapamid	hypertension	1,5mg	po	01.01.2007	ongoing
65	diabetes I.II.	01.01.2007	ongoing	carvediol	hypertension	6,25mg	po	01.01.2008	ongoing
	hypertension	01.01.1980	ongoing	glimepiride	diabetes	3mg	po	01.01.2007	ongoing
				indapamid	hypertension	1,5mg	po	01.01.2004	ongoing
				paracetamol	osteoarthritis of knee	1000-2000mg	po	several years	ongoing
67	arterial hypertension	01.01.2000	ongoing	otrex 600	crural varices	600mg	po	05.05.2008	ongoing

	crural varices	01.01.1990	ongoing	simvastatinum simvahexal	hiperlipidemia	20mg	po	05.05.2008	ongoing
	hiperlipidemia	01.01.2000	ongoing	betaloc zok	arterial hypertension	100mg	po	11.03.2008	ongoing
	left renal cyst	01.01.2006	ongoing	heparinum lioton 1000	crural varices	bid	topical	05.05.2008	ongoing
	obesity	01.01.1980	ongoing	losartanum lorista	arterial hypertension	50mg	po	01.01.2005	ongoing
				furosemidum	arterial hypertension	40mg	po	06.03.2008	ongoing
				potassium kaldyum	substytution	0,6g	po	06.03.2008	ongoing
68	crural varices	01.01.1990	ongoing	hesperidinum detralex diosminum	crural varices	0,5g	po	14.10.2008	ongoing
	hiperlipidemia	01.11.2004	ongoing						
69				fenofibratum lipanthyl 267 M	hiperlipidemia	267mg	po	09.07.2008	31.08.2008
				pantoprazolum anesteloc	abdominal pain	40mg	po	28.10.2008	06.11.2008
	appendectomy	01.01.1980	01.01.1980	opipramolum pramolan	depression	50mg	po	01.01.2000	ongoing
	arrhythmia extrasystolic	01.01.1980	ongoing	indapamidum tertensif sr	arterial hypertension	1,5mg	po	01.01.2000	ongoing
	arterial hypertension	01.01.1980	ongoing	potassium kalipoz	substitution	0,391g	po	01.01.2000	ongoing
	depression	01.01.2000	ongoing	estazolam	insomnia	2mg	po	01.01.2000	ongoing
	hiperlipidemia	01.07.2000	ongoing	propafenon polfenon	arrhythmia	150mg	po	01.01.2000	ongoing
	osteoarthrosis	01.01.2000	ongoing	doxazosinum doxanorm	arterial hypertension	2mg	po	01.05.2004	ongoing
	osteopenia	01.01.2001	ongoing	bisoprolol bisocard	arrhythmia	5mg	po	13.01.2005	ongoing

				atorvastatinum sortis	hiperlipidemia	40mg	po	01.01.2002	ongoing
70	chronic gastritis	01.01.2005	ongoing	phospholipids	abdominal pain	nk	po	03.09.2008	30.09.2008
	arterial hypertension	01.01.1995	ongoing	bisoprolol	arterial hypertension	10mg	po	01.01.2008	ongoing
	arthritis urica	01.01.2000	ongoing	pantoprazol	gastritis	20mg	po	03.09.2008	ongoing
	diabetes mellitus type 2	01.03.2000	ongoing	fenofibrate	hiperlipidemia	267mg	po	01.03.2008	ongoing
	hiperlipidemia	01.01.1990	ongoing	gliklazyd	diabetes mellitus	30mg	po	01.08.2008	ongoing
				allopurinol	uric acidaemia	100mg	po	01.01.2000	ongoing
72	cholecystectomy	01.03.1998	01.03.1998	nicergoline	vertigo	10mg	po	24.11.2008	ongoing
	arterial hypertension	01.01.2000	ongoing	indapamide	arterial hypertension	1,5mg	po	05.05.2006	ongoing
	hiperlipidemia	01.01.1999	ongoing	potassium kaldyum	substitution	315mg	po	01.01.2007	ongoing
	osteoporosis	01.01.1999	ongoing	piracetam	vertigo	1200mg	po	21.03.2007	ongoing
	varices ani	01.01.1995	ongoing	betahistine	vertigo	8mg	po	24.11.2008	ongoing
	vertebral osteoarthropathy	01.01.1990	ongoing	levothyroxine	hypothyreosis	50ug	po	01.05.2006	ongoing
	hypothyreosis	01.01.2006	ongoing						
73	appendectomy	01.01.1975	01.01.1975	furosemid	arterial hypertension	40mg	po	01.01.2007	ongoing
	cholecystectomy	01.01.1980	01.01.1980	betozk/metoprol ol	arterial hypertension	100mg	po	01.03.2008	ongoing
	thyrotoxicosis	01.01.2003	01.01.2003	lisinopril	arterial hypertension	20mg	po	01.02.2008	ongoing
	arterial hypertension	01.01.1990	ongoing	glimepiride	diabetes mellitus	3mg	po	01.02.2008	ongoing
	chronic obstructive pulmonary disease	01.01.2007	ongoing	losartan	arterial hypertension	50mg	po	01.01.2007	ongoing

	diabetes mellitus type 2	01.01.2000	ongoing	metformin	diabetes mellitus	850mg	po	01.01.2001	ongoing
	hiperlipidemia	01.01.2000	ongoing	spironol	arterial hypertension	25mg	po	01.01.2007	ongoing
	obesity	01.01.1980	ongoing	nitrendypine	arterial hypertension	20mg	po	01.02.2008	ongoing
				fenofibrate	hiperlipidemia	100mg	po	01.01.2006	ongoing
				salmeterol	pochp	50ug	inh	01.03.2008	ongoing
74	cataract	01.01.2000	ongoing	molsidomine	mitral prolapse	2mg	po	01.01.2007	ongoing
	extrasystolic arrhythmia	01.01.1998	ongoing	trimetazidine	mitral prolapse	35mg	po	01.01.2007	ongoing
	glaucoma	01.01.2000	ongoing	simvastatine	hiperlipidemia	10mg	po	01.01.2001	ongoing
	hiperlipidemia	01.01.2001	ongoing	acetylsalicylic acid	prophilaxis	75mg	po	01.01.2007	ongoing
	mitral prolapse	01.01.1998	ongoing	bisoprolol	arrhythmia	2,5mg	po	01.07.2005	ongoing
				kalium potassium	substitution	315mg	po	01.01.2005	ongoing
				magnezium	substitution	500mg	po	01.01.2005	ongoing
75	atrial fibrillation	01.01.2000	ongoing	betaloc zoc metoprolol	hypertension arterials+chronic coronary disease	100mg	po	01.01.2000	ongoing
	chronic coronary disease	01.01.2000	ongoing	acenocumarol	atrial fibrillation	2mg	po	01.01.2000	ongoing
	crural varices	01.01.2000	ongoing	ranigast ranitydyna	protection	150mg	po	01.01.2000	ongoing
	hypertension arterialis	01.01.2000	ongoing	tritace ramipril	hypertension arterials	10mg	po	01.01.2000	ongoing
				kalipoz potassium	substitution	391mg	po	01.01.2000	ongoing
				milurit allopurinol	hyperuricaemia	100mg	po	01.01.2000	ongoing

				tialorid amilorid hydrochlorothiazid	hypertension arterialis	5mg+50mg	po	01.01.2000	ongoing
76	hiperlipidemia	01.07.2008	ongoing	ambroxol	common cold	30ml	po	09.12.2008	20.12.2008
				cetirizine+pseudoephedrine	common cold	5mg+120mg	po	09.12.2008	14.12.2008
77	arterial hypertension	01.01.2000	ongoing	metildigoxin	myocardial insufficiency	100mg	po	01.01.2001	ongoing
	coronary disease	01.01.2002	ongoing	nicergoline	vertigo	30mg	po	01.01.2001	ongoing
	myocardial insufficiency	01.01.2001	ongoing	amilorid hydrochlorothiazid	arterial hypertension	2,5mg 25mg	po	01.01.2001	ongoing
				enalapril	arterial hypertension	5mg	po	01.01.2001	ongoing
				glyceryl trinitrate	coronary disease	6,5mg	po	01.03.2006	ongoing
				vitaminum pp	prophilaxis	200mg	po	01.01.2001	ongoing
78	crural varices	01.01.1970	ongoing	fenofibrat	hiperlipemia	100mg	po	02.12.2008	ongoing
	diabetes mellitus type 2	01.01.1999	ongoing	gliclazyde	diabetes	30mg	po	04.04.2007	ongoing
	glaucoma	01.01.1990	ongoing	metformina	diabetes	1500mg	po	14.03.2007	ongoing
	myopia	01.01.1950	ongoing	azopt	glaucoma		eye drops	02.07.2008	ongoing
	cholecystectomy cholelithiasis	01.01.2000	01.01.2000						
	hiperlipidemy	01.01.1999	ongoing						
79				paracetamol	osteoarthritis	1g	po	15.07.2008	ongoing
80	hypertension	01.01.2003	ongoing	rampiril	hypertension	2,5mg	po	01.01.2006	ongoing
				paracetamol	osteoarthritis of knee	1000mg	po	01.06.2008	ongoing

81	radiculopathy-ischias	01.08.2008	15.08.2008	tolperisone	ischias	300mg	po	01.08.2008	15.08.2008
				paracetamol	ischias	2g	po	01.08.2008	15.08.2008
82	ischias	01.01.2000	ongoing	paracetamol	ischias	2g	po	01.06.2008	ongoing
				lanzoprazolum	protection	15mg	po	01.05.2008	ongoing
84	appendectomy	01.01.1969	01.01.1969	acetylosalicylic acid	hypertension	70mg	po	01.04.2008	ongoing
	cholecystectomy	01.01.1982	01.01.1982	indapamidum	hypertension	1,5mg	po	01.04.2008	ongoing
	obese	nknknk	ongoing	bisoprolol fumarate	hypertension	2,5mg	po	01.04.2008	ongoing
	hypertension	nknknk	ongoing						
85	antebrachii right fracture	01.01.2000	01.01.2000	indapamide	hypertension	1,5mg	po	01.01.2006	ongoing
	artherosclerosis	nknknk	ongoing	acetylosalicylic acid	artherosclerosis	75mg	po	05.08.2008	ongoing
	hypertension	nknknk	ongoing	perindopril	hypertension	5mg	po	01.01.2006	ongoing
87	right femoral fracture	02.02.2001	01.05.2001	omeprazole	protection	20mg	po	04.07.2008	ongoing
88				pantoprazole	protection	20mg	po	01.09.2008	ongoing
				tibolone	hormonal substitution	2,5mg	po	01.01.2004	ongoing
89				pantoprazole	protection	20mg	po	10.06.2008	ongoing
90	diabetes	01.01.2005	ongoing	rampiril	hypertension	2,5mg	po	01.01.2007	ongoing
	hypertensio	01.01.1995	ongoing	glipiride	diabetes	10mg	po	01.01.2007	ongoing
	obesity	nknknk	ongoing	acetylosalicylic acid	atherosclerosis	75mg	po	01.08.2009	ongoing
91	menislectomy of left knee	22.02.2002	22.02.2002	omeprazole	protection	20mg	po	01.09.2008	15.09.2008
				omeprazole	protection	20mg	po	03.11.2008	16.11.2008
				omeprazole	protection	20mg	po	01.10.2008	10.10.2008

93				pantoprazole	protection	20mg	po	01.11.2008	15.11.2008
				pantoprazole	protection	20mg	po	13.10.2008	31.10.2008
				pantoprazole	protection	20mg	po	15.09.2008	30.09.2008
95				omeprazole	protection	20mg	po	03.10.2008	ongoing
96				lansoprazol	protection nsaid	15mg	po	05.01.2009	ongoing
97	uterine myoma uterectomy	01.01.1998	01.01.1998	lacidipine	arterial hypertension	4mg	po	01.01.2007	ongoing
	arterial hypertension	01.01.2007	ongoing	atorvastatinum	hyperlipidemia	40mg	po	13.02.2009	ongoing
	coronary disease	01.01.2006	ongoing	indapamidum	arterial hypertension	1,5mg	po	01.01.2007	ongoing
	hyperlipidemia	01.01.2006	ongoing	bisoprolol	arterial hypertension	5mg	po	01.01.2007	ongoing
	reflux disease	01.01.2008	ongoing	tamsulosin	urinary incontinence	0,4g	po	01.11.2007	ongoing
	urinary incontinence	01.01.2007	ongoing	perindopril	arterial hypertension	5mg	po	01.01.2007	ongoing
	intolerance of glucose	01.01.2008	ongoing						
98	struma nodosa retrosternal	01.01.1988	01.01.1992	indapamidum	arterial hypertension	1,5mg	po	01.01.1999	ongoing
	arterial hypertension	01.01.1996	ongoing	bisoprolol	arterial hypertension	10mg	po	18.04.2001	ongoing
	hyperlipidemia	01.09.2007	ongoing	potassium kalipoz kalium	substitution	391mg	po	01.01.1999	ongoing
				amlodypina	arterial hypertension	10mg	po	26.09.2007	ongoing
				atorvastatinum	hyperlipidemia	20mg	po	27.02.2009	ongoing
				losartan	arterial hypertension	50mg	po	01.10.2006	ongoing
99	arterial hypertension	01.01.1999	ongoing	enalapril	arterial hypertension	5mg	po	01.01.1999	ongoing

	spring catarrh	01.01.1999	ongoing	cetirizine	spring catarrh	10mg	po	04.03.2009	ongoing
				estradiol noretysterin	hormona substitution	0,05mg 0,0112g	trans derma us	01.01.2008	ongoing
100	cholelithiasis	01.01.2001	ongoing	tocopherol	prophylaxis	400mg	po	01.01.2007	ongoing
	idiopathic fremitus	01.01.2000	ongoing	allopurinol	podagra hiperuricemia	100mg	po	01.01.2006	ongoing
	podagra hiperurycemia	01.01.2005	ongoing	propranolol	fremitus	40mg	po	26.06.2007	ongoing
	hiperlipidemia	01.01.2000	ongoing						
101				pantoprazole	protection	20mg	po	02.03.2009	15.03.2009
101				pantoprazole	protection	20mg	po	23.03.2009	ongoing
103	lumbar spondilosis	01.01.2005	ongoing	atorvastatin	hypercolesterolemi a	20mg qd	po	22.09.2008	ongoing
	apendicecthomy	01.01.1970	01.01.1970						
	cholecistecthomy	01.01.2005	01.01.2005						
	hypercholesterole mia	22.09.2008	ongoing						
	IInd degree obesity	01.01.2000	ongoing						
	liver steatosis	22.09.2008	ongoing						
104	arterial hypertension	01.01.2004	ongoing	indapamida	arterial hypertension	1,5mg bid	po	19.03.2007	ongoing
	dislipidemia	25.05.2006	ongoing	atorvastatin	dislipidemia	10mg qd	po	25.05.2006	ongoing
	obesity	01.01.1998	ongoing	enalapril	arterial hypertension	10mg bid	po	01.01.2004	ongoing
	lumbar spondilosis	25.05.2006	ongoing						
105	osteoporosis	01.11.2007	ongoing	ibandronat sodic	osteoporosis	150mg/month s	po	01.11.2007	ongoing
105				alpha calcidol	osteoporosis	1000iu qd	po	01.11.2007	ongoing
106	dislipidemia	28.01.2008	ongoing	atorvastatin	dislipidemia	20mg qd	po	28.01.2008	ongoing

	drug controlled arterial hypertension	01.01.2000	ongoing	alpha calcidol	osteoporosis	1000iu qd	po	05.02.2008	ongoing
	ischaemic heart disease	01.01.2004	ongoing	metoprolol	arterial hypertension	50mg qd	po	28.01.2008	ongoing
	left hip osteoarthritis	28.01.2008	ongoing	enalapril	arterial hypertension	5mg bid	po	05.02.2008	ongoing
	osteoporosis type 2	28.01.2008	ongoing	alendromat	osteoporosis	70mg/week	po	05.02.2008	ongoing
	pulmonary tb sequelae	nknknk	ongoing	indapamida	arterial hypertension	1,5mg qd	po	28.01.2008	ongoing
	right bundle branch block	01.01.2004	ongoing	aspirin	ischaemic heart disease	75mg qd	po	28.01.2008	ongoing
107	arterial hypertension	01.01.2004	ongoing	metoprolol	arterial hypertension	50mg bid	po	01.06.2004	ongoing
	hypertrigliceridemia	01.01.2002	ongoing	indapamida	arterial hypertension	1,5mg qd	po	01.06.2004	ongoing
	total hystherecthomy	01.01.2005	ongoing	fenofibrat	dislipidemia	150mg qd	po	01.01.2002	ongoing
108	arterial hypertension	01.01.2002	ongoing	enalapril	arterial hypertension	5mg bid	po	01.01.2002	ongoing
	osteoporosis	01.06.2006	ongoing						
109	drug controlled arterial hypertension	26.09.2008	ongoing	alpha calcidol	osteopenia	1000iu qd	po	15.07.2008	ongoing
	hypercholesterolemia	14.07.2008	ongoing	atorvastatin	hypercholesterolemia	20mg qd	po	14.07.2008	ongoing
	osteopenia	15.07.2008	ongoing	calcium	osteopenia	1000mg qd	po	15.07.2008	ongoing
	right ovarian chyst	14.07.2008	ongoing	aspirin	cardiovascular protection	100mg qd	po	14.07.2008	ongoing
				indapamida	arterial hypertension	0,625mg qd	po	26.09.2008	ongoing
				perindopril	arterial hypertension	2mg qd	po	26.09.2008	ongoing

110	acute conjunctivitis	28.09.2008	30.09.2008	calcium	osteoporosis prophilaxis	1000mg qd	po	28.09.2008	ongoing
	arterial hypertension	01.01.2003	ongoing	indapamida	arterial hypertension	1,5mg qd	po	01.01.2003	ongoing
	hypercholesterolemia	01.01.2005	ongoing	l-tiroxin	hypothyroidia	100ug qd	po	01.01.2005	ongoing
	hypothyroidism	01.01.2005	ongoing	atorvastatin	hypercholesterolemia	20mg qd	po	01.01.2005	ongoing
	lumbar spondilosis	26.09.2008	ongoing	enalapril	arterial hypertension	5mg bid	po	01.01.2003	ongoing
	plurinodular goiter	01.01.2005	ongoing	aspirin	heart protection	75mg qd	po	01.01.2003	ongoing
				alpha calcidol	osteoporosis prophilaxis	1000iu qd	po	28.09.2008	ongoing
111	arterial hypertension	01.01.2005	ongoing	calcium	osteoporosis	1000mg qd	po	26.06.2007	ongoing
	chronic venous insuficiency	20.06.2007	ongoing	alpha calcidol	osteoporosis	1000iu qd	po	26.06.2007	ongoing
	hypercholesterolemia	26.06.2007	ongoing	amlodipin	arterial hypertension	5mg qd	po	01.01.2005	ongoing
	osteoporosis	26.06.2007	ongoing	alendronat	osteoporosis	70mg qs	po	26.06.2007	ongoing
				aspirin	cardiovascular protection	75mg qd	po	19.06.2007	ongoing
				atorvastatin	hypercolesterolemia	20mg qd	po	26.06.2007	ongoing
				diosmin	chronic venous insufiency	50mg bid	po	20.06.2007	ongoing
				indapamida	arterial hypertension	1,5mg qd	po	01.01.2005	ongoing
113	arterial hypertension	01.01.2007	ongoing	enalapril	arterial hypertension	5mg bid	po	01.01.2007	ongoing
	cervical spondilosis	30.09.2008	ongoing	aspirin	heart protection	75mg qd	po	30.09.2008	ongoing

	hypercholesterolemia	30.09.2008	ongoing	indapamida	arterial hypertension	1,5mg bid	po	01.01.2007	ongoing
				atorvastatin	hypercholesterolemia	20mg qd	po	30.09.2008	ongoing
				nicergolinum	cervical spondilosis	30mg bid	po	30.09.2008	ongoing
				tolperison	cervical spondilosis	150mg bid	po	30.09.2008	ongoing
115				isosorbid dinitrat	cardiac prophilaxis	20mg bid	po	01.01.2002	07.10.2002
	cholecystectomy	01.01.1991	01.01.1991	l-tiroxinum	hypothiroidism	125ug qd	po	01.01.2002	ongoing
	arterial hypertension	01.01.2002	ongoing	trimetazidina	cardiovascular protection	35mg bid	po	01.01.2002	ongoing
	chronic venous insufiency	07.10.2008	ongoing	spironolactona	arterial hypertension	25mg qd	po	01.01.2002	ongoing
	hypercholesterolemia	07.10.2008	ongoing	carvedilol	arterial hypertension	12,5mg bid	po	01.01.2002	ongoing
	hypothyroidia	01.01.2002	ongoing	amlodipina	arterial hypertension	10mg qd	po	01.01.2002	ongoing
				aspirin	cardiovascular prophilaxis	100mg qd	po	07.10.2008	ongoing
				atorvastatin	hypercholesterolemia	20mg qd	po	07.10.2008	ongoing
				diosmin	chronic venous insufiency	50mg bid	po	07.10.2008	ongoing
				furantril	arterial hypertension	25mg qd	po	01.01.2002	ongoing
116	thyroidecthomy	01.01.1998	01.01.1998	ibandronat	osteoporosis	150mg qmonth	po	20.10.2008	ongoing
	arterial hypertension	01.01.1996	ongoing	calcium	osteoporosis	1000mg qd	po	16.10.2008	ongoing
	chronic venous insuficiency	16.10.2008	ongoing	aspirin	cardiovascular protection	100mg qd	po	16.10.2008	ongoing
	hypercholesterolemia	16.10.2008	ongoing	atorvastatin	hypercholesterolemia	20mg qd	po	16.10.2008	ongoing

	hypothyroidia	01.01.1998	ongoing	amlodipine	arterial hypertension	5mg qd	po	16.10.2008	ongoing
	osteoporosis	19.10.2008	ongoing	alpha calcidol	osteoporosis	1000iu qd	po	16.10.2008	ongoing
				diosmin	chronic venous insuficiency	50mg bid	po	16.10.2008	ongoing
				l-thyroxin	hypotiroidia	150ug qd	po	01.01.1998	ongoing
117	uterus fibromatosis	01.06.2006	29.06.2006	acid salicilicum	arterial hypertension	75mg/day	po	01.05.2008	ongoing
	umbilical hernia	01.01.2007	01.01.2007	perindoprilum	arterial hypertension	5mg/day	po	01.05.2008	ongoing
	arterial hypertension	01.01.2006	ongoing	simvastatinum	hyperlipemia	20mg/day	po	01.05.2008	ongoing
	cervical spondylosis	01.01.1990	ongoing	omeprazol	gastric protection	20mg/day	po	01.05.2008	ongoing
	diabetus mellitus	01.05.2008	ongoing	l-thyroxine	hypotiroidism	50ug/day	po	01.01.1998	ongoing
	hysterectomie	01.01.2006	01.01.2006						
	biliary lithiasis	01.01.2008	ongoing						
	hyperlipidemia	01.05.2008	ongoing						
	hypotiroidism	01.01.1998	ongoing						
119	cervical spondilosis	21.10.2008	ongoing	nicergolin	cervical spondilosis	30mg bid	po	21.10.2008	ongoing
	chronic lumbar pain	01.01.2004	ongoing	calcium	osteoporosis	1000mg qd	po	22.10.2008	ongoing
	hypercholesterolemia	21.10.2008	ongoing	alpha calcidol	osteoporosis	1000iu qd	po	22.10.2008	ongoing
	macrocitosis	21.10.2008	ongoing	pholic acid	macrocitozis	1mg qd	po	25.10.2008	ongoing
	osteoporosis	21.10.2008	ongoing	risedromat	osteoporosis	35mg qw	po	22.10.2008	ongoing
120	facial zoster	01.06.2008	01.08.2008	perindopril	arterial hypertension	2mg/day	po	01.10.2008	ongoing
	arterial hypertension	15.05.2008	ongoing	indapamid	arterial hypertension	0,625mg/day	po	01.10.2008	ongoing

	cervical spondylosis	01.05.2006	ongoing	simvastatinum	hyperlipemia	20mg/day	po	01.01.2005	ongoing
	mild hyperlipemia	01.01.2005	ongoing	omeprazolum	gastric protector	20mg/prn	po	01.08.2008	ongoing
	peptic ulcer	01.01.2005	ongoing	acid salicilic	arterial hypertension	75mg/day	po	01.10.2008	ongoing
				amlodipina	arterial hypertension	5mg/day	po	01.10.2008	ongoing
				kalium aspartat	arterial hypertension	0,54g/bid	po	01.10.2008	ongoing
				metoprolol	arterial hypertension	50mg/day	po	01.10.2008	ongoing
121	arterial hypertension	01.01.1998	ongoing	enalapril	arterial hypertension	10mg bid	po	01.01.1998	ongoing
	left bundle branch block	01.01.2000	ongoing	furosemide	arterial hypertension	40mg qd	po	01.01.1998	ongoing
				aspirin	cardiovascular prophylaxis	75mg qd	po	01.01.2000	ongoing
				metoprolol	arterial hypertension	50mg qd	po	01.01.1998	ongoing
				spironolactone	arterial hypertension	25mg qd	po	01.01.1998	ongoing
122	arterial hypertension	01.01.2005	ongoing	amlodipina	arterial hypertension	10mg qd	po	01.01.2005	ongoing
	bilateral pes anserinum bursitis	07.07.2008	ongoing	calcium	osteopenia	1,5g qd	po	07.07.2008	ongoing
	cataract	07.07.2008	ongoing	alpha calcidol	osteopenia	1000iu qd	po	07.07.2008	ongoing
	hypercholesterolemy	07.07.2008	ongoing	aspirin	cardiovascular prophylaxis	100mg qd	po	07.07.2008	ongoing
	osteopenia	07.07.2008	ongoing	atorvastatin	hypercholesterolemia	20mg qd	po	07.07.2008	ongoing
123	chronic lumbar pain	01.01.2006	ongoing	simvastatin	hypercholesterolemia	20mg qd	po	01.01.2007	ongoing

	hypercholesterolemia	01.01.2007	ongoing	diosmin	chronic venous insuficiency	50mg bid	po	01.01.2007	ongoing
	chronic venous insuficiency	01.01.2007	ongoing						
124	arterial hypertension	01.01.2006	ongoing	enalapril	arterial hypertension	10mg qd	po	01.01.2006	ongoing
	dislipidemia	01.01.2005	ongoing	aspirin	cardiovascular prophylaxis	100mg qd	po	10.11.2008	ongoing
	type 2 diabetes melitus	01.01.2007	ongoing	indapamida	arterial hypertension	1,5mg qd	po	01.01.2006	ongoing
				rosuvastatin	hypercholesterolemia	10mg qd	po	10.11.2008	ongoing
125	total hysterectomy	01.01.2003	01.01.2003	indapamida	arterial hypertension	1,5mg qd	po	01.01.2005	ongoing
	arterial hypertension	01.01.2005	ongoing	rosuvastatin	hypercholesterolemia	20mg qd	po	27.10.2008	ongoing
	hypercholesterolemia	01.01.2006	ongoing	enalapril	arterial hypertension	10mg qd	po	01.01.2005	ongoing
	ischemic heart disease	01.01.2004	ongoing	metoprolol	arterial hypertension	50mg qd	po	01.01.2005	ongoing
	type 2 diabetes melitus	01.01.2006	ongoing	aspirin	ischemic heart disease	75mg qd	po	01.01.2004	ongoing
	lumbar sciatica l5	25.10.2008	30.10.2008						
	osteopenia	27.10.2008	ongoing						
126	lumbar sciatica	25.10.2008	03.11.2008	tolperison	lumbar sciatica	150mg bid	po	27.10.2008	13.11.2008
	hypercholesterolemia	27.10.2008	ongoing	rosuvastatin	hypercholesterolemia	10mg qd	po	27.10.2008	ongoing
	interstitial pneumopatia	25.10.2008	03.11.2008						
	menopause	01.01.2006	ongoing						
127	arterial hypertension	01.01.2008	ongoing	telmisartan	arterial hypertension	40mg qd	po	01.03.2007	ongoing

				lecarnidipina	arterial hypertension	10mg qd	po	01.03.2007	ongoing
				nebivolol	arterial hypertension	5mg qd	po	01.03.2007	ongoing
				omeprazolum	gastric protection	20mg qd	po	01.01.2006	ongoing
				spironolactona	arterial hypertension	25mg qd	po	01.03.2007	ongoing
128	hypercholesterolemia	26.08.2008	ongoing						
130	left nodular goiter operated	01.01.1998	ongoing	levothyroxinum	left nodular goiter operated	50ug	po	01.01.1996	ongoing
131	dislipidemia	01.01.2004	ongoing	metoprololum	high blood pressure	50mg	po	01.01.2005	ongoing
	high blood pressure	01.01.2002	ongoing	indapamidum	high blood pressure	1,5mg	po	01.01.2005	ongoing
				phenofibratum	dislipidemia	100mg	po	01.01.2006	ongoing
132	biliary dyskinesia	01.01.1985	ongoing	acidum alendronicum	osteoporosis	70mg once a week	po	01.01.2008	ongoing
	high blood pressure	01.01.1993	ongoing	enalaprilum	high blood pressure	10mg	po	01.01.2001	ongoing
	ischemic heart disease	01.01.1993	ongoing	metoprololum	ischemic heart disease	50mg	po	01.01.1993	ongoing
	osteoporosis	01.01.2008	ongoing	indapamidum	high blood pressure	1,5mg	po	01.01.2001	ongoing
133	high blood pressure	01.01.2004	ongoing	captoprilum	high blood pressure	50mg	po	01.01.2004	ongoing
	hypercolesterolemia	01.01.1998	ongoing	trimetazidinum	ischemic heart disease	40mg	po	01.01.1998	ongoing
	ischemic heart disease	01.01.1998	ongoing	diltiazemum	ischemic heart disease	180mg	po	01.01.1998	ongoing
	osteoporosis	01.01.2005	ongoing	acidum alendronicum	osteoporosis	70mg once a week	po	01.01.2008	ongoing
				atorvastatinum	hipercolesterolemia	40mg	po	01.01.1998	ongoing

134	high blood pressure	01.01.1998	ongoing	indapamidum	high blood pressure	1,5mg	po	01.01.2002	ongoing
	histerectomy for uterine fibroma	01.01.1985	ongoing	enalaprilum	high blood pressure	10mg	po	01.01.2002	ongoing
	osteoporosis	01.01.2005	ongoing	risedronatum	osteoporosis	35mg once a week	po	01.01.2007	ongoing
135	dislipidemia	01.01.2000	ongoing	ezetimibum	dislipidemia	5mg	po	01.09.2008	ongoing
	high blood pressure	01.01.1993	ongoing	perindoprilum	high blood pressure	5mg	po	01.01.2005	ongoing
	osteoporosis	01.01.2007	ongoing						
136	dislipidemia	01.01.2005	ongoing	simvastatinum	dislipidemia	20mg qd	po	01.01.2005	ongoing
	osteoporosis	01.01.2000	ongoing	acidum ibandronicum	osteoporosis	150mg once a month	po	01.05.2008	ongoing
137	left internal menislectomy	12.02.2008	12.02.2008						
138	high blood pressure	01.01.1998	ongoing	acidum ibandronicum	osteoporosis	150mg once a month	po	01.01.2005	ongoing
	osteoporosis	01.01.2003	ongoing	metoprololum	high blood pressure	25mg bid	po	01.01.1998	ongoing
				omeprazolum	gastric protection	20mg qd	po	01.01.2007	ongoing
139				famotidina	gastroprotection	10mg at need	po	01.06.2008	ongoing
				movalis	osteoarthritis	7,5mg qd	po	01.06.2008	ongoing
				mydocalm	osteoarthritis	150mg tid	po	01.06.2008	ongoing
				paracetamol	osteoarthritis	1,5g tid	po	01.06.2008	ongoing
140	high blood pressure	01.01.2002	ongoing	indapamidum	high blood pressure	1,5mg qd	po	01.01.2002	ongoing
	osteoporosis	01.01.2004	ongoing	enalaprilum	high blood pressure	10mg tid	po	01.01.2002	ongoing
				paracetamolum	ostheoarthritis of the knees	1000mg prn	po	01.01.2006	ongoing
141	dislipidemia	01.01.2005	ongoing	indapamidum	high blood pressure	0,625mg qd	po	01.01.2004	ongoing
	high blood pressure	01.01.1998	ongoing	perindoprilum	high blood pressure	2mg qd	po	01.01.2004	ongoing

				phenofibratum	dislipidemia	100mg qd	po	01.01.2005	ongoing
				simvastatinum	dislipidemia	20mg qd	po	01.01.2005	ongoing
142	benign prostatic hyperpasia	01.01.2008	ongoing	lercanidipinum	high blood pressure	10mg qd	po	01.01.2007	ongoing
	high blood pressure	01.01.1980	ongoing	zofenoprilum	high blood pressure	30mg qd	po	01.01.2007	ongoing
				indapamidum	high blood pressure	1,5mg qd	po	01.01.2006	ongoing
				nebivololum	high blood pressure	5mg qd	po	01.01.2007	ongoing
143	high blood pressure	01.08.2008	ongoing	indapamidum	high blood pressure	1,5mg qd	po	01.08.2008	ongoing
	osteoporosis	01.06.2008	ongoing	omeprazolum	gastric protection	20mg qd	po	01.02.2008	ongoing
144				tetrazepamum	osteoarthritis	50mg	po	01.01.2007	15.10.2008
145	apendicectomia	01.01.1956	01.01.1956	sopto carpine	glaucoma	2 drops tid	intra ocular	01.01.1999	ongoing
	cholecystectomia	01.01.1998	01.01.1998	omeprazolum	gastritis	20mg qd	oral	01.01.2007	ongoing
	arterial hypertension	01.01.1989	ongoing	captoprilum	arterial hypertension	10mg bid	oral	01.01.2003	ongoing
	dyslipidemia	01.01.2005	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.01.2005	ongoing
	gastritis	01.01.1997	ongoing	trimetazidinum	ischaemic heart disease	20mg qd	oral	01.01.2000	ongoing
	ischemic heart disease	01.01.2000	ongoing	nebivolol	arterial hypertension	5mg qd	oral	01.01.2003	ongoing
	varicose veins of legs	01.01.2004	ongoing	amlodipinum	arterial hypertension	10mg qd	oral	01.01.2006	ongoing
	total hysterectomia with bilateral anexectomia	01.01.1983	01.01.1983						
	bilateral glaucoma	01.01.1999	ongoing						
	obesity	01.01.1995	ongoing						
146	arterial hypertension	01.01.2006	ongoing	metoprololum	arterial hypertension	50mg qd	oral	01.01.2006	ongoing

	ischemic heart disease	01.01.2006	ongoing	trimetazidinum	ischaemic heart disease	10mg qd	oral	01.01.2006	ongoing
	apendicectomia	01.01.1990	01.01.1990						
	total hysterectomia with bilateral anexectomia	01.01.1995	01.01.1995						
	menopause	01.01.1990	ongoing						
147	arterial hypertension	01.01.1988	ongoing	enalaprilum	arterial hypertension	10mg bid	oral	01.01.2005	ongoing
	gastritis	01.01.2005	ongoing	amlodipinum	arterial hypertension	10mg qd	oral	01.01.2006	ongoing
				omeprazolum	gastritis	20mg qd	oral	01.01.2006	ongoing
148	arterial hypertension	01.01.1990	ongoing	captoprilum	arterial hypertension	25mg bid	oral	01.01.1995	ongoing
	dyslipidemia	01.01.2005	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.01.2006	ongoing
	osteoporosis	01.01.2006	ongoing	diosminum	varicose veins of legs	500mg bid	oral	01.01.2007	ongoing
	varicose veins of legs	01.01.2005	ongoing	levotiroxinum	hypothyroidism	100mg qd	oral	01.01.1997	ongoing
	total hysterectomia with bilateral anexectomia	01.01.1988	01.01.1988						
	hypothyroidism	01.01.1997	ongoing						
149	arterial hypertension	01.01.1992	ongoing	metoprololum	arterial hypertension	50mg qd	oral	01.01.2005	ongoing
	diabetus mellitus type II	01.01.1992	ongoing	trimetazidinum	ischaemic heart disease	20mg bid	oral	01.01.2005	ongoing
	dyslipidemia	01.01.2005	ongoing	metforminum	diabetus mellitus type2	1000mg qd	oral	16.04.2006	ongoing
	ischemic heart disease	01.01.1992	ongoing	enalapril	arterial hypertension	20mg qd	oral	01.01.2005	ongoing
	obesity stage I	01.01.2003	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.01.2006	ongoing

	gastro-duodenitis	01.01.1998	ongoing						
	peripherial vascular disease	01.01.1998	ongoing						
150	arterial hypertension	01.01.1984	ongoing	enalaprilum	arterial hypertension	10mg bid	oral	01.01.1984	ongoing
	dyslipidemia	01.08.2008	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.08.2008	ongoing
				indapamidum	arterial hypertension	1,5mg qd	oral	01.01.1984	ongoing
151	arterial hypertension	01.02.2008	ongoing	rosuvastatinum	dyslipidemia	20mg qd	oral	01.02.2008	ongoing
	diabetus mellitus type II	01.01.2001	ongoing	trimetazidinum	ischaemic heart disease	20mg qd	oral	01.02.2008	ongoing
	dyslipidemia	01.02.2008	ongoing	fenofibratum	dyslipidemia	100mg qd	oral	01.04.2008	ongoing
	ischemic heart disease	01.02.2008	ongoing	enalaprilum	arterial hypertension	5mg qd	oral	01.02.2008	ongoing
	stage II obesity	01.01.2003	ongoing	metforminum	diabetus mellitus type2	850mg bid	oral	01.01.2008	ongoing
152	arterial hypertension	01.01.2000	ongoing	telmisartanum	arterial hypertension	40mg qd	oral	01.01.2000	ongoing
	dyslipidemia	09.03.2008	ongoing	trimetazidinum	ischaemic heart disease	20mg tid	oral	01.01.2001	ongoing
	ischemic heart disease	01.01.2001	ongoing	metoprololum	arterial hypertension	50mg qd	oral	01.01.2000	ongoing
				rosuvastatinum	dyslipidemia	10mg qd	oral	15.03.2008	ongoing
153	dyslipidemia	01.01.2007	ongoing	rosuvastatinum	dyslipidemia	20mg qd	oral	01.01.2007	ongoing
154	arterial hypertension	01.01.1998	ongoing	enalaprilum	arterial hypertension	10mg qd	oral	01.01.2000	ongoing
	dyslipidemia	01.01.2000	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.01.2000	ongoing
	ischemic heart disease	01.01.1999	ongoing	trimetazidinum	ischaemic heart disease	20mg bid	oral	01.01.2000	ongoing

	paroxistic supraventricular tachycardia	01.01.2003	ongoing	metoprololum	paroxistic supraventricular tachycardia	50mg bid	oral	01.01.2003	ongoing
155	arterial hypertension	01.01.1993	ongoing	lisinoprilum	arterial hypertension	10mg qd	oral	01.01.1995	ongoing
	ischemic heart disease	01.01.1995	ongoing	trimetazidinum	ischaemic heart disease	20mg bid	oral	01.01.1995	ongoing
	cervical spondilosis	01.01.2000	ongoing						
	renal microlitiasis	01.01.2000	ongoing						
156	dyslipidemia	01.04.2008	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.04.2008	ongoing
157	arterial hypertension	01.01.1992	ongoing	enalaprilum	arterial hypertension	10mg bid	oral	01.01.1995	ongoing
	dyslipidemia	01.01.2000	ongoing	indapamidum	arterial hypertension	1,5mg qd	oral	01.01.1995	ongoing
	ostheoporosis	01.01.2005	ongoing	fenofibratum	dyslipidemia	160mg qd	oral	01.01.2000	ongoing
	apendicectomia	01.01.1958	01.01.1958						
	total hysterectomia with bilateral anexectomia	01.01.1998	01.01.1998						
158	total hysterectomia with bilateral anexectomia	01.01.1972	01.01.1972	acidum ibandronicum	ostheoporosis	150mg once/month	oral	01.01.2006	ongoing
	arterial hypertension	01.01.1995	ongoing	enalaprilum	arterial hypertension	5mg bid	oral	01.01.2000	ongoing
	ischemic heart disease	01.01.2003	ongoing	indapamidum	arterial hypertension	1,5mg qd	oral	01.01.2001	ongoing
	ostheoporosis	01.01.2005	ongoing	isosorbid dinitratum	ischaemic heart disease	20mg bid	oral	01.01.2003	ongoing
159	arterial hypertension	01.01.2000	ongoing	ramiprilum	arterial hypertension	2,5mg qd	oral	01.08.2007	ongoing
	dyslipidemia	01.01.2006	ongoing	betaxololum	arterial hypertension	20mg qd	oral	01.08.2007	ongoing

	obesity	01.01.2000	ongoing	simvastatinum	dyslipidemia	10mg qd	oral	01.01.2006	ongoing
160	arterial hypertension	01.01.2001	ongoing	perindoprilum	arterial hypertension	10mg qd	oral	01.01.2001	ongoing
	dyslipidemia	01.01.2005	ongoing	simvastatinum	dyslipidemia	20mg qd	oral	01.01.2006	ongoing
	ischemic heart disease	01.01.2002	ongoing	trimetazidinum	ischaemic heart disease	20mg bid	oral	01.01.2002	ongoing
161	total hysterectomia with bilateral anexectomia	01.01.2005	01.01.2005	simvastatinum	dyslipidemia	20mg qd	oral	01.01.2005	ongoing
	arterial hypertension	01.01.1990	ongoing	enalaprilum	arterial hypertension	20mg qd	oral	01.01.1992	ongoing
	dyslipidemia	01.01.1990	ongoing	isosorbid dinitratum	ischaemic heart disease	20mg bid	oral	01.01.2000	ongoing
	ischemic heart disease	01.01.1998	ongoing	amlodipinum	arterial hypertension	5mg qd	oral	01.01.2002	ongoing
162	arterial hypertension	01.01.2005	ongoing	indapamidum	arterial hypertension	1,5mg qd	oral	01.01.2005	ongoing
	ischemic heart disease	01.01.2005	ongoing	nifedipinum	arterial hypertension	30mg qd	oral	01.01.2005	ongoing
				isosorbid dinitratum	ischaemic heart disease	20mg bid	oral	01.01.2005	ongoing
163	osteoporosis	01.02.2007	ongoing	ac risedronic	osteoporosis	35mg 1tb/week	po	01.01.2008	ongoing
	histerectomy	01.01.2001	01.01.2001						
164	osteoporosis	19.02.2008	ongoing	ac risedronic	osteoporosis	35mg/week once a week	po	01.02.2008	ongoing
165	osteoporosis	01.01.2007	ongoing	strontium ranelate	osteoporosis	2g od	po	01.01.2008	ongoing
169	patella bipartia	30.11.1960	ongoing	paracetamol	osteoarthrytis of the knee	500mg od	po	01.03.2008	ongoing
170	osteoporosis	01.09.2008	ongoing	ac ibandronic (bonviva)	osteoporosis	150mg	po	01.09.2008	ongoing

171				paracetamol	osteoarthrytis of the knee	500mg	po	01.01.2008	ongoing
172	atrial fibrilation	01.01.2004	ongoing	captopril	blood hypertension	25mg bid	po	01.01.2001	01.01.2004
	blood hypertension	01.01.2004	ongoing	enalapril	blood hypertension	10mg bid	po	01.01.2004	ongoing
				digoxinum	atrial fibrilation	0,25mg od	po	01.01.2004	ongoing
				felodipine	blood hypertension	5mg od	po	01.03.2008	ongoing
				spironolactone	blood hypertension	25mg od	po	01.01.2003	ongoing
				warimrine	atrial fibrilation	2mg od	po	01.01.2004	ongoing
173				enalaprilum	blood hypertension	10mg od	po	01.01.2005	01.01.2008
	blood hypertension	01.01.2005	ongoing	captoprilum	blood hypertension	25mg od	po	01.01.2008	ongoing
				paracetamol	osteoarthrytis of the knee	500mg od	po	01.12.2007	ongoing
174	osteoporosis	11.06.2007	ongoing	ac risedronic	osteoporosis	35mg/week	po	01.06.2007	ongoing
175	osteoporosis	01.07.2008	ongoing	strontium ranelate	osteoporosis	2g	po	01.07.2008	ongoing
				paracetamol	osteoarthrytis of the knee	500mg od	po	01.02.2008	ongoing
176	blood hypertension	01.01.1990	ongoing	captoprilum	blood hypertension	25mg od	po	01.01.1990	ongoing
				paracetamol	osteoarthrytis of the knee	500mg od	po	01.11.2007	ongoing
177				metoprolol	blood hypertension	50mg bid	po	01.01.2004	01.01.2006
	blood hypertension	01.01.2004	ongoing	enalapril	blood hypertension	10mg bid	po	01.01.2004	ongoing
	osteoporosis	23.05.2006	ongoing	ac ribandronic (bonviva)	osteoporosis	150mg	po	01.05.2006	ongoing
178	osteoporosis	28.08.2008	ongoing	alphacalcidol	osteoporosis	0,25ug bid	po	01.08.2008	ongoing
179	osteoporosis	01.03.2007	ongoing	ac ibandronic (bonviva)	osteoporosis	150mg	po	01.03.2007	ongoing
180	apendicectomy	01.01.1980	01.01.1980						
181	high blood pressure	01.01.2000	ongoing	omeprazolum	gastric protection	20mg qd	po	01.04.2008	ongoing

	hyperurilemia	22.07.2008	ongoing	indapamidum	high blood pressure	1,5mg qd	po	01.01.2003	ongoing
	lumbar dicopathy	01.01.2007	ongoing	levothyroxinum	status post thyroidectomy	100ug qd	po	01.01.1979	ongoing
	thyroidectomy for polinodular goiter	01.01.1979	ongoing	trimetazidinum	ischemic heart disease	20mg tid	po	01.01.2000	ongoing
	hysterectomy for uterine fibroma	01.01.1997	ongoing						
	ischemic heart disease	01.01.2000	ongoing						
	urinary lithiasis	01.01.1998	ongoing						
182	dyslipidemia	15.10.2008	ongoing	omeprazolum	gastric protection	40mg qd	po	01.09.2008	ongoing
	ischemic heart disease	01.01.2004	ongoing	diosminum	varicose veins at lower limbs	450mg bid	po	01.01.2003	ongoing
	thyroidectomy for polinodular goiter	01.01.1996	ongoing	levothyroxinum	status post thyroidectomy	100ug qd	po	01.01.1996	ongoing
	varicose veins at lower limbs	01.01.1974	ongoing	verapamilum	ischemic heart disease	40mg tid	po	01.01.2004	ongoing
183	high blood pressure	01.01.1998	ongoing	indapamidum	high blood pressure	1,5mg qd	po	01.01.2005	ongoing
	ischemic heart disease	01.01.1998	ongoing	trimetazidinum	ischemic heart disease	20mg bid	po	01.01.2000	ongoing
	dislipidemia	09.09.2008	ongoing						
	osteoporosis	15.10.2008	ongoing						
184	high blood pressure	01.01.1998	ongoing	trimetazidinum	ischemic heart disease	20mg qd	po	01.01.1998	ongoing
	ischemic heart disease	01.01.1993	ongoing	felodipinum	high blood pressure	5mg qd	po	01.01.2005	ongoing
185				omeprazolum	gastric prophylaxis	40mg qd	po	01.01.2008	ongoing
186	high blood pressure	01.01.1990	ongoing	enalaprilum	high blood pressure	10mg bid	po	01.01.1998	ongoing
	ischemic heart disease	01.01.1988	ongoing	metoprololum	ischemic heart disease	50mg bid	po	01.01.1998	ongoing

	osteoporosis	01.01.2006	ongoing	acidum alendronicum	osteoporosis	70mg once a week	po	01.01.2007	ongoing
	colecistectomy for biliary lithiasis	01.01.2004	ongoing						
	hepatic cyst	23.09.2008	ongoing						
	lumpectomy for fibrocystic mastosis	01.02.1998	ongoing						
187	arterial hypertension	01.01.2005	ongoing	perindoprilum	arterial hypertension	5mg qd	oral	01.01.2005	ongoing
188	hypothyroidism	01.01.2005	ongoing	levothyroxinum	hypothyroidism	100ug qd	oral	01.01.2005	ongoing
	ischemic heart disease	01.01.2005	ongoing	isosorbid dinitratum	ischaemic heart disease	20mg bid	oral	01.01.2005	ongoing
	ostheoporosis	01.01.2006	ongoing	alpha-colcidiolum	ostheoporosis	0,5ug qd	oral	01.01.2006	ongoing
189	arterial hypertension	01.01.1989	ongoing	candesartanum	arterial hypertension	4mg bid	oral	01.01.1990	ongoing
	dyslipidemia	01.01.2000	ongoing	indapamidum	arterial hypertension	1,5mg qd	oral	01.01.1990	ongoing
				simvastatinum	dyslipidemia	20mg qd	oral	01.01.2000	ongoing
190	arterial hypertension	01.01.2003	ongoing	enalaprilum	arterial hypertension	5mg bid	oral	01.01.2003	ongoing
	ischemic heart disease	01.01.2004	ongoing	trimetazidinum	ischaemic heart disease	20mg bid	oral	01.01.2004	ongoing
193	apendicectomy	01.01.1970	01.01.1970	ac ribandronic (bonviva)	osteoporosis	150mg monthly	po	01.12.2007	ongoing
	osteoporosis	01.11.2007	ongoing	ranitidina	gastric protection	150mg	po	01.01.2007	ongoing
				paracetamol	osteoarthrytis of the knee	500mg	po	01.12.2007	ongoing
194	arterial hypertension	01.09.2008	ongoing	enalapril	arterial hypertension	10mg od	po	01.09.2008	ongoing
195	splenectomy (posttraumatic)	01.01.1983	01.01.1983	indapamid	arterial hypertension	1,5mg od	po	01.01.2001	ongoing

	arterial hypertension	01.01.2001	ongoing						
196	arterial hypertension	01.01.1998	ongoing	enalapril	arterial hypertension	10mg bid	po	01.01.1998	ongoing
				paracetamol	osteoarthritis of the knee	500mg od	po	01.01.2007	ongoing
				tertensif	blood hypertension	1,5mg od	po	01.01.1998	ongoing
197	hypercholesterolemy	01.01.2008	ongoing	simvastatin	hypercholesterolemy	20mg od	po	01.01.2008	ongoing
198	blood hypertension	01.01.1990	ongoing	enalapril	blood hypertension	10mg od	po	01.01.1990	ongoing
				omeprazol	gastroprotector	20mg od	po	01.01.2007	ongoing
				tertensif	blood hypertension	1,5mg od	po	01.01.1990	ongoing
199	left hip osteoarthritis	18.11.2008	ongoing	lanzoprazol	gastric protection for nsaids	40mg qd	po	18.11.2008	25.11.2008
	arterial hypertension	01.01.2007	ongoing	indapamida	arterial hypertension	1,5mg qd	po	18.11.2008	ongoing
	hypercholesterolemia	18.11.2008	ongoing	perindopril	arterial hypertension	2,5mg qd	po	18.11.2008	ongoing
	osteoporosis	18.11.2008	ongoing	atorvastatin	arterial hypertension	40mg qd	po	18.11.2008	ongoing
	l4-l5 hernia	18.11.2008	ongoing						
200	cardiac ischemic disease	24.11.2008	ongoing	indapamidum	arterial hypertension	1,5mg qd	po	01.01.2005	20.11.2008
	arterial hypertension	01.01.1992	ongoing	enalaprilum	arterial hypertension	10mg bid	po	01.01.2003	ongoing
	both eyes cataractis	24.11.2008	ongoing	lypanthil supra fenofibrat	dislipidemia	160mg qd	po	01.01.2003	ongoing
	cervical spondilosis	19.11.2008	ongoing	rosuvastatin	hypercholesterolemia	20mg qd	po	01.01.2005	ongoing
	dislipidemia	01.01.1990	ongoing	aspirin	ischemic heart disease	75mg qd	po	01.01.2000	ongoing

	forrestier spondilosis	24.11.2008	ongoing	nicergoline	cervical spondilosis	30mg bid	po	19.11.2008	ongoing
	liver steatosis	24.11.2008	ongoing	pentoxifyllinum	low limbs artheriopathy	400mg qd	po	01.01.1995	ongoing
	type 2 diabetes melitus	01.01.1989	ongoing	glimopiridum	diabetes melitus	2mg qd	po	01.01.2000	ongoing
	both legs arteriopathy	01.01.1995	ongoing						
201	inguinal hernia	01.01.1980	01.01.1980	doxazosinum	prostate's adenoma	4mg/day	po	01.07.2008	ongoing
	ischemic heart disease	01.01.2007	ongoing	simvastatin	ischemic heart disease	20mg	po	01.01.2007	ongoing
	lumbar column's spondylopathy	01.01.1980	ongoing	metoprolol	ischemic heart disease	50mg	po	01.01.2007	ongoing
	prostate's adenoma	01.01.1990	ongoing	perindopril	hypertension	5mg	po	01.01.2007	ongoing
	hypertension	01.01.2007	ongoing						
202	left anterior haemiblock	12.01.2009	ongoing						
	lumbar spondilosis	01.01.2005	ongoing						
203	cervical spondilosis	01.01.2006	ongoing	atorvastatin	hypercholesterolemia	20mg qd	po	01.01.2006	ongoing
	fibromatosus uterus	12.01.2009	ongoing	nicergolin	cervical spondilosis	30mg bid	po	12.01.2009	ongoing
	low urinary tract infection	12.01.2009	ongoing	aspirin	cardiovascular prophylaxis	75mg qd	po	01.01.2006	ongoing
	right ovariari cyst	12.01.2009	ongoing	ciprofloxazin	low urinary tract infection	500mg bid	po	12.01.2009	ongoing
	hypercholesterolemia	01.01.2006	ongoing						
204	inguinal hernia	01.01.1985	01.01.2008	omeprazol	prevention	20mg	po	10.12.2008	27.12.2008
	lumbar column spondylopathy	01.05.2008	ongoing						

205	arterial hypertension	01.01.1995	ongoing	perindopril	arterial hypertension	5mg qd	po	01.01.2004	ongoing
	hypercholesterolemia	13.01.2009	ongoing	indapamida	arterial hypertension	1,5mg qd	po	01.01.2004	ongoing
206	arterial blood's vessels hypertension	01.01.2004	ongoing	amlodipinum	arterial hypertension	5mg/day	po	01.11.2008	ongoing
	uterus fibroma	01.11.2008	ongoing	indapamidum	arterial hypertension	1,5mg/day	po	01.11.2008	ongoing
	varicosity of lower limbs	01.11.2008	ongoing	telmisartanum	arterial hypertension	80mg/day	po	01.11.2008	ongoing
				acid acetylsalicilic	arterial hypertension	75mg/day	po	01.11.2008	ongoing
				detralex	varicosity of lower limbs	500mgx2/day	po	01.11.2008	ongoing
207	gastric hernia	01.01.1995	ongoing	omeprazolum	gastric protection	20mg/day	po	01.08.2008	ongoing
	lumbar vertebral column's osteoarthritis	01.06.2008	ongoing						
208	arterial hypertension	01.01.1996	ongoing	perindoprilum	arterial hypertension	5mg/day	po	01.01.2000	ongoing
	lumbar spondylosis	01.01.2000	ongoing	indapamidum	arterial hypertension	1,5mg/day	po	01.01.2001	ongoing
	media otitis	01.05.2006	01.07.2006						
209	cervical and lumbar spondylosis	01.01.2006	ongoing	loratadinum	chronic faringitis	10mg/day	po	05.12.2008	25.12.2008
	chronic faringitis	01.01.2005	ongoing	omeprazolum	gastric protection	20mg/day	po	01.02.2009	10.02.2009
210				omeprazolum	gastric protection	20mg/day	po	01.02.2009	10.02.2009
	arterial hypertension	01.01.2002	ongoing	perindoprilum	arterial hypertension	10mg/day	po	01.01.2002	ongoing
	chronic gastritis	01.01.1995	ongoing	indapamidum	arterial hypertension	1,5mg/day	po	01.01.2002	ongoing

	ischemic heart disease	01.01.2002	ongoing	metoprololum	arterial hypertension	50mg/day	po	01.01.2002	ongoing
211	aortic and carotidian atheromatosis	01.01.2006	ongoing	perindoprilum	high blood pressure	10mg qd	po	01.01.2006	ongoing
	chronic atrial fibrilation	01.01.2003	ongoing	acenocumarolum	atrial fibrilation	2mg qd	po	01.01.2003	ongoing
	high blood pressure	01.01.1995	ongoing	digoxinum	atrial fibrilation	0,5mg 1/2days	po	01.01.2003	ongoing
	ischemic heart disease	01.01.2006	ongoing	metoprololum	atrial fibrilation	25mg bid	po	01.01.2003	ongoing
	nyha II heart failure	01.01.2006	ongoing						
	pulmonary scleroemphysema	01.01.2006	ongoing						
212	algic sequeles post left artroscopic sinovectomy	27.07.2008	08.08.2008						
213	varicose veins in lower limbs	01.10.2008	ongoing	diosminum	varicose veins in lower limbs	450mg bid	po	02.10.2008	ongoing
214	left knee osteotomy	11.01.2007	11.01.2007						
215	high blood pressure	01.01.2003	ongoing	indapamidum	high blood pressure	1,5mg qd	po	01.10.2008	ongoing
	hysterectomy for uterine fibroma	01.01.1995	ongoing						
216				diosminum	vascular prophylaxis	450mg td	po	01.01.2006	ongoing
220	dyslipidemia	01.01.2006	ongoing						
223	arterial hypertension	01.01.1988	ongoing	indapamidum	arterial hypertension	1,5mg qd	oral	01.01.1988	ongoing
				enalaprilum	arterial hypertension	5mg bid	oral	01.01.1990	ongoing

225	dyslipidemia	01.01.2006	ongoing	metforminum	type II diabetus mellitus	850mg qd	peros	01.08.2007	ongoing
	thypec chronic hepatitis	01.01.2005	ongoing	atorvastatinum	dyslipidemia	20mg qd	peros	01.05.2006	ongoing
	type II diabetus mellitus	01.01.2007	ongoing						
232	arterial hypertension	01.01.2005	ongoing	prestarium	arterial hypertension	5mg od	po	01.01.2006	ongoing
	histerectomy	01.01.1995	01.01.1995						
233	virus A hepatitis	01.01.1967	01.01.1967	prestarium	arterial hypertension	5mg od	po	01.02.2008	ongoing
	arterial hypertension	01.02.2008	ongoing	atorvastatin	dislipidemy	20mg od	po	01.02.2008	ongoing
	diabet mellitus (type 2)	01.01.1999	ongoing	aspenter	arterial hypertension	75mg od	po	01.02.2008	ongoing
233	dislipidemy	01.01.2008	ongoing						
235	apendicectomy	01.01.1981	01.01.1981	enalaprilum	arterial hypertension	10mg od	po	01.01.2000	ongoing
	arterial hypertension	01.01.1987	ongoing						
236	arterial hypertension	01.05.2000	ongoing	siofor	diabetes mellitus	1000mg bid	po	01.01.2004	ongoing
	diabetes mellitus	01.01.2000	ongoing	indapamide	arterial hypertension	1,5mg od	po	01.05.2008	ongoing
				amaryl	diabetes mellitus	2mg od	po	01.01.2004	ongoing
237	apendicectomy	01.01.1970	01.01.1970						
238	osteoporosis	18.11.2008	ongoing	ac ibandronaticum (bonviva)	osteoporosis	150mg	po	18.11.2008	ongoing
239	colecistectomy	01.01.2001	01.01.2001	paracetamol	osteoarthrytis of the knee	500mg od	po	01.01.2006	ongoing
	osteoporosis	21.11.2005	ongoing	ac alendronicum	osteoporosis	70mg o/week	po	21.05.2005	ongoing

240	apendicectomy	01.01.1970	01.01.1970	ac risedronicum	osteoporosis	35mg o/week	po	20.05.2007	ongoing
	osteoporosis	20.05.2007	ongoing						
243	ischemic diseases	01.01.2003	ongoing	miacalcic	osteoporosis	100 IU/ml	nasal spray	01.01.2007	ongoing
	morbus hypertonicus	01.01.1998	ongoing	indapamid	morbus hypertonicus	2,5mg	po	01.02.2008	ongoing
	nephrolitiosis	01.01.2008	ongoing	trimetazidine	ischemic disease	35mg	po	01.01.2003	ongoing
	osteoporosis	01.01.2007	ongoing	corvitol	morbus hypertonicus	50mg	po	01.02.2008	ongoing
	pyelonephritis chronica	01.01.2008	ongoing	enalapril	morbus hypertonicus	20mg	po	01.02.2008	ongoing
	struma nodosum	01.01.2007	ongoing	levothyrox	struma nodosum	50mg	po	01.03.2007	ongoing
	spondylosis	01.01.2007	ongoing						
244	asthma bronchiale	01.01.1973	ongoing	telmisartan	morbus hypertonicus	80ug	po	01.01.2008	ongoing
	morbus hypertonicus	01.01.1990	ongoing	verapamil	morbus hypertonicus	120mg	po	01.01.2008	ongoing
	osteoporosis	01.01.2008	ongoing	salmeterol/fluticason pr.	asthma bronchiale	250/50ug 2x1inh	inh	01.01.2008	ongoing
				alendronic acid	osteoporosis	70mg a week	po	01.01.2008	ongoing
245	hysterectomy	01.01.1976	01.01.1976	losartane	morbus hypertonicus	50mg tb	po	01.01.2008	ongoing
	cholecystectomy	01.06.2004	01.06.2004	indapamide	morbus hypertonicus	2,5mg tb	po	01.01.2008	ongoing
	allergic rhinosinnitis	01.01.2000	ongoing	verapamil	morbus hypertonicus	240mg tb	po	01.01.2008	ongoing
	asthma bronchiale	01.01.2000	ongoing	salmeterol/fluticason	asthma	25/125ug inhaler	inh	01.01.2002	ongoing
	morbus hypertonicus	01.01.1989	ongoing						
	struma nodosum	01.01.2006	ongoing						

	varices cruris	01.01.1983	ongoing						
246	osteoporosis	01.01.2000	ongoing	alendronic acid	osteoporosis	70mg	po	05.02.2009	ongoing
247	morbus hypertonicus	01.01.2001	ongoing	vit D3 et calcium	osteoporosis	0,25mg and 600mg	po	19.12.2008	ongoing
	osteoporosis	01.01.2008	ongoing	enalapril	morbus hypertonicus	10mg	po	01.12.2001	ongoing
				ibandronate	osteoporosis	2,5mg	im	18.12.2008	ongoing
249	chronic pyelonephritis	01.01.1990	ongoing	bisoprolol	hypertonic disease	5mg tbl	po	01.01.1999	ongoing
	hypertonic disease	01.01.1999	ongoing	indapamide	hypertonic disease	2,5mg tbl	po	01.01.1999	ongoing
251	hypertonic disease	01.01.1993	ongoing	lisinopril	hypertonic disease	10mg tbl	po	01.01.2005	ongoing
				indapamide	hypertonic disease	2,5mg tbl	po	01.01.2005	ongoing
				metoprolol	hypertonic disease	25mg tbl	po	01.01.2005	ongoing
252	diabetes mellitus	01.01.2004	ongoing	moxonidine	hypertonic disease	0,2mg 2x1tb	po	01.01.2006	ongoing
	hypertonic disease	01.01.1994	ongoing	bisoprolol	hypertonic disease	5mg 2x1tb	po	01.01.2006	ongoing
				metformine	diabetes mellitus	850mg 3x1tb	po	01.01.2005	ongoing
253	diabetes mellitus	01.01.1982	ongoing	felodipin	morbus hypertonicus	10mg	po	01.02.2009	ongoing
	morbus hypertonicus	01.01.1980	ongoing	telmisartan	morbus hypertonicus	80mg	po	01.02.2009	ongoing
				bisoprolol	morbus hypertonicus	2,5mg	po	01.02.2009	ongoing
				glimepirid	morbus hypertonicus	2mg	po	01.01.2006	ongoing
				metformin	diabetus mellitus	850mg	po	01.01.2001	ongoing
254	morbus hypertonicus	01.01.2000	ongoing	enalapril	morbus hypertonicus	10mg	po	01.01.2000	ongoing
				metoprolol	morbus hypertonicus	30mg	po	01.01.2000	ongoing
255	hypertonic disease	01.01.1999	ongoing	indapamide	hypertonic disease	2,5mg tbl	po	01.02.2009	ongoing

				verapamil	hypertonic disease	120mg tbl	po	01.01.2000	ongoing
256	hypertonic disease	01.01.1985	ongoing	valsartan	hypertonic disease	160mg tbl	po	01.01.2003	ongoing
				enalapril	hypertonic disease	10mg tbl	po	01.01.2003	ongoing
				indapamide	hypertonic disease	2,5mg tbl	po	01.01.2003	ongoing
257	diabetes mellitus	01.01.1990	ongoing	bisoprolol	morbus hypertonicus	5mg	po	01.01.2002	ongoing
	morbus hypertonicus	01.01.1985	ongoing	trandolapril	morbus hypertonicus	2mg	po	01.01.2002	ongoing
				gliclazide mr	diabetus mellitus	30mg	po	01.01.2003	ongoing
				metformin	diabetus mellitus	1000mg	po	01.01.2003	ongoing
259	morbus hypertonicus	01.01.1996	ongoing	indapamid	morbus hypertonicus	1,5mg x1tb	po	01.01.2004	ongoing
				losartan	morbus hypertonicus	50mg x1tb	po	01.01.2004	ongoing
				metoprolol	morbus hypertonicus	50mg x1tb	po	01.01.2004	ongoing
260	morbus hypertonicus	01.01.1998	ongoing	valsartan	morbus hypertonicus	160mg x1tb	po	01.01.2002	ongoing
				bisoprolol	morbus hypertonicus	10mg x1tb	po	01.01.2002	ongoing
				felodipin	morbus hypertonicus	10mg x1tb	po	01.01.2002	ongoing
261	diabetus mellitus	01.01.1994	ongoing	valsartan	morbus hypertonicus	160mg x1	po	06.05.2005	ongoing
	morbus basedow	01.01.1989	ongoing	amlodipin	morbus hypertonicus	5mg x1	po	06.05.2005	ongoing
	morbus hypertonicus	01.01.1990	ongoing	bisoprolol	morbus hypertonicus	10mg x1	po	06.05.2005	ongoing
	obesitas	01.01.1980	ongoing	indipam sr	morbus hypertonicus	1,5mg x1	po	06.05.2005	ongoing
				metformin	diabetus mellitus	1000mg 2x1tb	po	01.01.2008	ongoing

263	hypertonic disease	01.01.1982	ongoing	bisoprolol	hypertonic disease	10mg tbl	po	01.03.2009	ongoing
				enalapril	hypertonic disease	20mg tbl	po	01.01.2004	ongoing
264	hypertonic disease	01.01.2007	ongoing	indapamide	hypertonic disease	2,5mg tbl	po	01.01.2007	ongoing
265	diabetes mellitus	01.01.2003	ongoing	isosorbid dinitrate	ischemic heart illnes	10mg 2x1tbl	po	01.02.2009	ongoing
	ischemic heart illnes	01.01.2005	ongoing	digoxin	ischemic heart illnes	0,25mg 1/2tbl	po	01.02.2009	ongoing
	morbus hypertonicus	01.01.1999	ongoing	corvetilol	morbus hypertonicus	6,25mg 2x1/2tbl	po	01.02.2009	ongoing
				metformin hydrochloride	diabetes	500mg 3x1	po	01.01.2005	ongoing
				perindopril arginine	morbus hypertonicus	5mg	po	01.02.2009	ongoing
267	morbus hypertonicus	01.01.2005	ongoing	metoprolol	morbus hypertonicus	50mg 1tbl	po	01.01.2005	ongoing
				enalapril maleate	morbus hypertonicus	10mg 2x1tbl	po	01.01.2005	ongoing
272				nimesulide	gonartrosis	100mg 1tbl	po	01.03.2009	08.03.2009
273	morbus hypertonicus	01.01.1989	ongoing	enalapril maleate	morbus hypertonicus	20mg 2x1 tbl	po	01.01.1989	ongoing
				hydrochlorothiazide	morbus hypertonicus	25mg 1tbl	po	01.01.2003	ongoing
274	morbus hypertonicus	01.01.1993	ongoing	valsartan	morbus hypertonicus	160mg x1tb	po	01.01.2003	ongoing
				metoprolol	morbus hypertonicus	50mg x1tb	po	01.01.2003	ongoing
276	morbus hypertonicus	01.01.1998	ongoing	losartan	morbus hypertonicus	50mg x1tb	po	01.01.2002	ongoing
				bisoprolol	morbus hypertonicus	50mg x1tb	po	01.01.2002	ongoing
279				glucosamine sulfate	osteoarthrosis	750mg	po	01.12.2008	01.03.2009

281	hypertonic disease	01.01.1985	ongoing	enalapril	hypertonic disease	20mg 2x1tbl	po	01.01.2000	ongoing
				indapamide	hypertonic disease	2,5mg x1tbl	po	01.01.2000	ongoing
282	morbus hypertonicus	01.01.2003	ongoing	bisoprolol	morbus hypertonicus	5mg x1tbl	po	01.01.2003	ongoing
				indapamide	morbus hypertonicus	1,5mg x1tbl	po	01.01.2003	ongoing
285	dislipidemia	01.01.2007	ongoing	carvedilol	morbus hypertonicus	12,5mg x2	po	10.04.2009	ongoing
	ischemic heart illnes	01.01.2000	ongoing	amlodipine	morbus hypertonicus	10mg	po	10.04.2009	ongoing
	morbus hypertonicus	01.01.1985	ongoing	valsartan	morbus hypertonicus	160mg	po	10.04.2009	ongoing
				atorvastatin	dislipidemia	10mg	po	01.02.2009	ongoing
				furosemide	morbus hypertonicus	40mg	po	10.04.2009	ongoing
				isosorbide mononitrate	ischemic heart illnes	40mg	po	01.02.2009	ongoing
287	cholelithiasis	01.01.2009	ongoing	metformin hydrochloride	diabetes mellitus	850mg 3x1/2tbl	po	01.01.2009	ongoing
	diabetes mellitus	01.01.2009	ongoing	indapamide	morbus hypertonicus	1,5mg	po	01.01.2008	ongoing
	morbus hypertonicus	01.01.2000	ongoing	bisoprolol	morbus hypertonicus	5mg	po	01.01.2009	ongoing
288	hypertonic disease	01.01.2009	ongoing	moxonidine	hypertonic disease	0,2mg	po	01.01.2009	ongoing
289	hypertonic disease	01.01.1989	ongoing	losartan	hypertonic disease	50mg	po	01.01.2004	ongoing
				carvedilol	hypertonic disease	12,5mg	po	01.01.2004	ongoing
293	morbus hypertonicus	01.06.2002	ongoing	valsartan		160mg/d	po	01.06.2002	ongoing
				indapamid		1,5mg/d	po	01.06.2002	ongoing
294	morbus hypertonicus	01.01.2000	ongoing	verapamil	morbus hypertonicus	120mg x1tb	po	01.01.2004	ongoing

	osteoporosis	01.01.2005	ongoing	indapamid	morbus hypertonicus	1,5mg x1tb	po	01.01.2004	ongoing
295	morbus hypertonicus	01.01.1998	ongoing	fosinopril	morbus hypertonicus	20mg x1tb	po	01.01.2004	ongoing
				carvedilol	morbus hypertonicus	25mg 2x1tb	po	01.01.2004	ongoing
296	ischemic heart disease	01.01.2003	ongoing	isosorbide dinitrate	ischemic heart illnes	20mg	per os	01.01.2003	ongoing
	morbus hypertonicus	01.01.2003	ongoing	bisoprolol	morbus hypertonicus	5mg	per os	01.01.2003	ongoing
				hydrochlorthiazide	morbus hypertonicus	25mg	per os	01.01.2003	ongoing
				trimetazidine dihydrochloride	ischemic heart illnes	35mg	per os	01.01.2003	ongoing
297	morbus hypertonicus	01.04.2009	ongoing	indapamide	morbus hypertonicus	1,5mg	per os	01.04.2009	ongoing
				amlodipine mesilate	morbus hypertonicus	5mg	per os	01.04.2009	ongoing
				enalapril maleate	morbus hypertonicus	10mg 2x1	per os	01.04.2009	ongoing
298	morbus hypertonicus	01.01.2000	ongoing	trandolapril	morbus hypertonicus	2mg	per os	01.01.2000	ongoing
				bisoprolol	morbus hypertonicus	5mg	per os	01.01.2005	ongoing
				indapamide	morbus hypertonicus	2,5mg	per os	01.01.2000	ongoing
299	diabetus mellitus	01.01.2007	ongoing	nifedipin	morbus hypertonicus	20mg 2x1	per os	01.01.2005	ongoing
	morbus hypertonicus	01.01.1999	ongoing	amlodipine mesilate	morbus hypertonicus	5mg	per os	01.01.2008	ongoing
				glimepiride	diabetes mellitus	1mg 2x1	per os	01.01.2007	ongoing
				metformin hydrochloride	diabetes mellitus	500mg 2x1	per os	01.01.2007	ongoing

300	morbus hypertonicus	01.01.2000	ongoing	enalapril maleate	morbus hypertonicus	20mg 2x1	per os	01.01.2000	ongoing

Table 44: Intake of NSAID (Visit 1)

Rand. Nr	Name of treatment	Dosage and units	Route	Start Date	Stop Date
1	diclofenac	50mg (2)	po	01.01.2005	ongoing
2	voltaren sr	75mg	po bid	01.10.2007	ongoing
3	diclofenac	75mg (2)	po	08.10.2000	ongoing
4	ibuprofen	400mg 3-4x1	po	01.01.2003	ongoing
5	diclofenac	100mg (1)	po	08.10.2008	ongoing
	ibuprofen	400mg (3)	po	01.01.2000	08.10.2008
6	diclofenac	50mg	po bid	03.12.2007	ongoing
7	diclofenac	75mg (2)	po	01.01.2006	ongoing
8	ibalgin	400mg (3)	po	01.01.2006	ongoing
9	voltaren r	50mg (2)	po	11.11.2008	ongoing
	ibalgin	400mg (3)	po	30.09.2008	11.11.2008
10	ibuprofen	400mg (3)	po	01.11.2007	ongoing
11	diclofenac	50mg 2x	po	01.05.2008	ongoing
13	diclofenac	75mg	1x po	14.12.2008	ongoing
14	meloxicam	15mg	1x po	01.01.2009	ongoing
15	diclofenac	75mg	1x po	01.07.2008	ongoing
16	diclofenac	75mg	oral	01.12.2008	ongoing
17	meloxicam	15mg	oral	24.02.2009	ongoing
	ibuprofen	800mg	oral	01.12.2008	24.02.2009
18	aceclofenac	200mg	oral	08.06.2007	ongoing
19	movalis	15mg	qd	01.03.2008	ongoing
20	diclofenac	75mg (2)	po	01.01.2007	ongoing
21	ibalgin	400mg (3)	po	01.09.2008	01.01.2008
2	flurbiprofen	200mg (2)	po	26.03.2008	
22	ibuprofen	400mg 3x	po	01.01.2006	ongoing
23	veral diclofenac	50mg (3)	po	01.01.2008	ongoing
24	diclofenac	50mg (3)	po	22.05.2008	ongoing
25	piroxicamum	20mg	po	14.01.2008	ongoing
26	flugalin	50mg	po	01.06.2008	ongoing
27	aceclofenacum	100mg	po	06.08.2008	ongoing
	piroxicamum	20mg	po	05.05.2008	06.08.2008
28	meloxicam	15mg	po	05.04.2007	ongoing
29	piroxicamum	20mg	po	28.05.2008	ongoing
30	ibuprofen	400mg	po	01.01.2005	ongoing
31	celecoxib	200mg	po	16.07.2008	ongoing
32	meloxicam	15mg	po	21.01.2008	ongoing

33	meloxicam	15mg	po	07.10.2008	ongoing
34	diclofenac	100mg	po	01.06.2008	ongoing
35	aceclofenac	200mg	po	01.07.2008	ongoing
36	diclofenac	150mg	po	23.05.2007	ongoing
37	ibalgin ibuprofen	400mg	po	01.07.2008	ongoing
38	diclofenac	150mg	po	01.10.2007	ongoing
39	meloxicam	15mg	po	05.08.2008	ongoing
40	diclofenac	150mg	po	01.08.2008	ongoing
41	meloxicam	15mg	po	01.05.2008	ongoing
42	diclofenac	100mg	po	01.10.2008	ongoing
43	diclofenac	75mg 1tab	orally	10.01.2008	ongoing
44	dicloberl retard	100mg	po	16.06.2007	ongoing
45	dicloberl	100mg 2x1tb	po	26.05.2008	ongoing
46	diclofenac	75mg 1tab	orally	01.04.2007	ongoing
47	nimesulide	100mg 1x	orally	15.08.2008	ongoing
48	febrofen ketoprofen	200mg	po	08.09.2008	ongoing
49	diclofenac	75mg 1x	orally	29.06.2005	ongoing
50	ketoprofen	100mg	po	10.12.2008	ongoing
51	diclofenac	100mg	orally	30.09.2007	ongoing
52	diclofenac	100mg	orally	10.01.2009	ongoing
53	ketonal (ketoprofen)	150mg 1x1tbl	po	02.12.2008	ongoing
54	acemetacin	90mg	po	01.11.2005	ongoing
55	nimesulid	100mg	po	11.06.2008	ongoing
56	ketoprofen	200mg	po	26.08.2008	ongoing
	meloxicam	15mg	po	01.04.2008	25.08.2008
57	ketoprofen	200mg	po	15.06.2008	30.06.2008
	ketoprofen	200mg	po	15.08.2008	30.08.2008
	nimesulid	200mg	po	01.07.2008	15.07.2008
58	diclofenac	150mg	po	10.08.2008	ongoing
	ketoprofen	100mg	po	01.01.2008	01.08.2008
59	nimesulid	100mg 2x	po	01.09.2008	ongoing
	nimesulid	100mg 2x	po	02.06.2008	15.06.2008
	nimesulid	100mg 2x	po	03.07.2008	17.07.2008
60	meloxicam	15mg	po	11.08.2008	ongoing
	ketoprofen	200mg	po	16.06.2008	13.07.2008
61	nimesulid	200mg	po	15.08.2008	ongoing
	nimesulid	200mg	po	01.07.2008	21.07.2008
62	ketoprofen	150mg	po	10.06.2008	10.07.2008
	ketoprofen	150mg	po	10.08.2008	29.08.2008

63	nimesulid	200mg	po	01.09.2008	ongoing
63	diclofenac	100mg	po	18.07.2008	31.07.2008
	ketoprofen	200mg	po	15.06.2008	05.07.2008
64	nimesulid	200mg	po	14.08.2008	ongoing
	ketoprofen	150mg	po	20.06.2008	10.07.2008
65	meloxicam	15mg	po	15.03.2008	ongoing
66	diclofenac	100mg	po	05.09.2008	ongoing
	ketoprofen	200mg	po	20.07.2008	15.08.2008
67	butapirazol		topical	05.05.2008	ongoing
	diclofenac	75mg	po	06.03.2008	ongoing
68	nimesulid	100mg	po	24.10.2008	ongoing
	ketonal forte	100mg	po	01.03.2008	01.10.2008
69	diclofenac	100mg	po	06.08.2008	ongoing
	ibuprofen	200mg	po	01.01.2008	ongoing
70	nimesulide	100mg	po	30.07.2008	ongoing
	paracetamol	500mg	po	20.11.2008	ongoing
	diclofenac	150mg	po	01.09.2008	01.10.2008
71	ketoprofen	100mg bid	po	25.08.2008	08.09.2008
	ketoprofen	100mg qd	po	15.10.2008	20.11.2008
	nimesulidum	100mg	po	09.09.2008	10.10.2008
72	movalis meloxicam	7,5mg bid	po	01.03.2008	ongoing
73	nimesulide	100mg	po	16.10.2008	ongoing
74	nimesulide	100mg	po	09.09.2008	ongoing
75	diclofenac	100mg	po	01.01.2001	ongoing
76	diclofenac	100mg	rectal	20.01.2009	ongoing
	nimesulid	200mg	po	18.07.2008	15.01.2009
77	diclofenac	150mg	po	01.01.2007	ongoing
78	diclofenac	150mg	po	01.07.2008	ongoing
79	diclofenac	100mg	po	15.07.2008	25.07.2008
	diclofenac	100mg	po	20.08.2008	31.08.2008
	diclofenac	100mg	po	02.10.2008	15.10.2008
80	meloxicam	15mg	po	10.09.2008	ongoing
	ketoprofen	100mg	po	10.07.2008	15.08.2008
81	celecoxyb	100mg	po	16.08.2008	ongoing
	celecoxyb	200mg	po	01.08.2008	15.08.2008
82	diclofenac	100mg	po	01.07.2008	ongoing
83	meloxicam	15mg	po	01.05.2008	ongoing
84	meloxicam	15mg	po	15.08.2008	ongoing
85	diclofenac	100mg	po	10.10.2008	ongoing

	diclofenac	100mg	po	15.08.2008	30.08.2008
	meloxicam	15mg	po	01.09.2008	30.09.2008
86	meloxicam	15mg	po	01.08.2008	ongoing
87	acemetacin	90mg	po	04.07.2008	ongoing
	celecoxyb	100mg	po	15.08.2008	ongoing
	nimesulid	100mg	po	01.06.2008	14.08.2008
89	celecoxyb	100mg	po	10.06.2008	ongoing
90	meloxicam	15mg	po	04.08.2008	ongoing
91	ketoprofenum	200mg	po	01.09.2008	15.09.2008
	meloxicam	15mg	po	01.10.2008	10.10.2008
	meloxicam	15mg	po	03.11.2008	16.11.2008
92	ketoprofenum	100mg	po	15.09.2008	25.09.2008
	nimesulide	100mg	po	10.10.2008	20.10.2008
	nimesulide	100mg	po	17.11.2008	30.11.2008
93	celecoxyb	200mg	po	15.09.2008	30.09.2008
	celecoxyb	200mg	po	13.10.2008	31.10.2008
	celecoxyb	200mg	po	01.11.2008	15.11.2008
94	nimesulid	15mg	po	15.10.2008	ongoing
	ketoprofenum	100mg	po	10.09.2008	25.09.2008
95	nimesulid	100mg	po	03.10.2008	ongoing
96	nimesulid	200mg	po	22.12.2008	ongoing
	ketoprofenum	200mg	po	10.11.2008	23.11.2008
	meloxicam	15mg	po	17.10.2008	31.10.2008
97	nimesulid	100mg	po	08.07.2008	ongoing
98	diclofenac	100mg	po	29.02.2008	ongoing
99	ketoprofen	100mg	po	01.01.2007	ongoing
100	nimesulid	100mg bid	po	01.10.2008	ongoing
101	ketoprofenum	150mg	po	18.05.2009	ongoing
	ketoprofenum	200mg	po	02.03.2009	09.03.2009
	ketoprofenum	200mg	po	23.03.2009	28.03.2009
	ketoprofenum	150mg	po	01.04.2009	12.04.2009
102	nimesulide	200mg	po	04.03.2009	15.03.2009
2	nimesulide	200mg	po	20.04.2009	15.05.2009
103	ketoprofen	200mg qd	po	01.08.2008	31.08.2008
	meloxicam	15mg qd	po	05.07.2008	20.07.2008
	meloxicam	15mg qd	im	22.09.2008	24.09.2008
104	diclofenac	150mg qd	po	01.09.2008	15.09.2008
	ketoprofen	200mg bid	po	05.08.2008	20.08.2008
	nimesulide	200mg bid	po	20.07.2008	04.08.2008

105	aceclofenac	100mg bid	po	18.08.2008	03.09.2008
	meloxicam	15mg qd	po	10.07.2008	30.07.2008
	meloxicam	15mg qd	po	26.06.2008	07.07.2008
106	meloxicam	15mg qd	po	05.07.2008	16.07.2008
	meloxicam	15mg qd	po	05.08.2008	16.08.2008
	meloxicam	15mg qd	po	05.09.2008	16.09.2008
107	piroxicam	20mg qd	po	15.06.2008	ongoing
108	aceclofenac	100mg bid	po	19.09.2008	ongoing
	meloxicam	15mg qd	po	15.08.2008	01.09.2008
	nimesulide	200mg bid	po	15.07.2008	03.08.2008
109	celecoxib	200mg bid	po	14.07.2008	27.07.2008
	celecoxib	200mg bid	po	14.08.2008	24.08.2008
	celecoxib	200mg bid	po	14.09.2008	24.09.2008
110	meloxicam	15mg qd	im	26.09.2008	ongoing
	diclofenac	150mg qd	po	10.08.2008	20.08.2008
	ketoprofen	200mg qd	intrarectal	15.07.2008	25.07.2008
	piroxicam	20mg qd	po	01.09.2008	25.09.2008
111	piroxicam	20mg qd	po	15.07.2008	23.07.2008
	piroxicam	20mg qd	po	03.09.2008	25.09.2008
	piroxicam	20mg qd	po	01.08.2008	20.08.2008
112	piroxicam	20mg qd	po	10.08.2008	ongoing
	diclofenac	150mg qd	po	22.07.2008	30.07.2008
	piroxicam	20mg qd	po	01.08.2008	20.08.2008
113	piroxicam	20mg qd	po	01.09.2008	ongoing
	ketoprofen	200mg qd	po	03.08.2008	15.08.2008
114	piroxicam	20mg qd	po	22.09.2008	ongoing
	ketoprofen	200mg bid	po	10.07.2008	25.07.2008
	ketoprofen	200mg qd	po	15.08.2008	01.09.2008
115	piroxicam	20mg qd	po	10.10.2008	20.10.2008
	piroxicam	20mg qd	po	10.09.2008	20.09.2008
	piroxicam	20mg qd	po	10.08.2008	20.08.2008
116	meloxicam	15mg qd	im	16.10.2008	ongoing
	diclofenac	50mg bid	po	10.09.2008	15.10.2008
	piroxicam	20mg qd	po	20.08.2008	30.08.2008
117	diclofenac	100mg/day	po	01.06.2008	ongoing
118	piroxicam	20mg qd	po	11.09.2008	ongoing
	diclofenac	50mg bid	po	20.08.2008	30.08.2008
119	diclofenac	50mg bid	po	01.09.2008	20.09.2008
	diclofenac	50mg tid	po	15.10.2008	21.10.2008

	diclofenac	50mg qd	im	21.10.2008	27.10.2008
120	aceclofenac	200mg/prn	po	01.08.2008	01.09.2008
	ibuprofen	400mg/prn	po	01.05.2008	01.07.2008
121	ketoprofen	200mg qd	po	01.09.2008	ongoing
	diclofenac	50mg bid	po	30.07.2008	07.08.2008
	ketoprofen	200mg qd	po	10.08.2008	20.08.2008
122	diclofenac	50mg qd	im	27.10.2008	ongoing
	meloxicam	15mg qd	po	11.08.2008	21.08.2008
	meloxicam	10mg qd	po	11.09.2008	21.09.2008
	meloxicam	15mg qd	po	11.10.2008	21.10.2008
123	diclofenac	50mg bid	po	01.11.2008	10.11.2008
	diclofenac	50mg bid	po	01.10.2008	10.10.2008
	diclofenac	50mg bid	po	01.09.2008	10.09.2008
124	diclofenac	50mg bid	po	15.07.2008	10.11.2008
	diclofenac	50mg qd	im	10.11.2008	13.11.2008
125	aceclofenac	100mg bid	po	01.10.2008	10.10.2008
	diclofenac	50mg qd	im	27.10.2008	30.10.2008
	meloxicam	15mg qd	po	12.10.2008	27.10.2008
	piroxicam	20mg qd	po	02.09.2008	17.09.2008
126	diclofenac	50mg bid	po	01.09.2008	26.10.2008
	diclofenac	75mg qd	im	27.10.2008	03.11.2008
127	diclofenac	100mg	po	01.08.2008	15.08.2008
	diclofenac	100mg	po	01.09.2008	15.09.2008
	nimesulidum	200mg	po	01.07.2008	15.07.2008
128	ketoprofen	200mg qd	po	01.08.2008	ongoing
	etoricoxibum	60mg qd	po	01.06.2008	01.07.2008
129	indometacinum	150mg qd	po	10.06.2008	21.09.2008
130	diclofenac	100mg	ir	01.03.2008	ongoing
	paracetamolum	500mg	po	01.01.1996	ongoing
131	diclofenacum	100mg	po	01.06.2008	ongoing
132	etoricoxibum	90mg	po	01.01.2008	23.09.2008
133	nimesulidum	10mg	po	01.05.2008	24.09.2008
134	piroxicamum	20mg	po	01.05.2008	29.09.2008
135	meloxicamum	15mg	po	01.04.2008	29.09.2008
136	naproxenum	220mg bid	po	01.01.2005	06.10.2008
137	meloxicanum	7,5mg qd	po	03.07.2008	ongoing
138	meloxicanum	7,5mg qd	po	01.06.2007	ongoing
139	movalis	7,5mg	po	01.06.2008	ongoing
	mydocalm	150mg	po	01.06.2008	ongoing

	paracetamol	1,5g	po	01.06.2008	ongoing
140	ibuprofenum	1200mg qd	po	07.03.2008	07.10.2008
141	meloxicamum	7,5mg qd	po	07.07.2008	09.10.2008
142	diclofenacum	100mg qd	po	06.06.2008	ongoing
143	piroxicamum	20mg qd	po	14.02.2008	13.10.2008
144	diclofenacum	100mg	po	01.09.2008	15.10.2008
	piroxicamum	20mg	po	01.07.2008	15.10.2008
145	etoricoxibum	120mg qd 10 days/month	oral	01.01.2007	ongoing
	piroxicamum	20mg qd 10days/month	oral	17.06.2008	ongoing
146	etoricoxibum	90mg qd 14days/month	oral	03.08.2007	ongoing
	ibuprofenum	200mg qd 7days/month	oral	14.05.2007	ongoing
147	nimesulidum	100mg bid 15days/month	oral	01.08.2007	ongoing
	piroxicamum	20mg qd 15days/month	oral	01.09.2007	ongoing
148	nimesulidum	100mg bid 10days/month	oral	01.01.2008	ongoing
	tenoxicamum	20mg qd 10days/month	oral	01.05.2008	ongoing
149	ibuprofenum	200mg qd 15days/month	oral	01.02.2008	ongoing
	piroxicamum	20mg qd 10days/month	oral	01.05.2008	ongoing
150	piroxicamum	20mg qd 10days/month	oral	01.05.2008	ongoing
	ketoprofenum	100mg tid 10days/month	oral	01.05.2007	01.08.2007
151	diclofenacum	50mg bid 15days/month	oral	04.01.2008	ongoing
	piroxicamum	20mg qd 10days/month	oral	01.03.2008	ongoing
152	etoricoxibum	90mg qd 10days/month	oral	20.05.2008	ongoing
	ibuprofenum	200mg qd 15days/month	oral	01.06.2008	ongoing
153	ibuprofenum	200mg qd 15days/month	oral	01.02.2008	ongoing
154	nimesulidum	100mg bid 10days/month	oral	01.02.2008	ongoing
	piroxicamum	20mg qd 10days/month	oral	01.05.2008	ongoing
155	nimesulidum	100mg bid 10days/month	oral	01.02.2008	ongoing
156	piroxicamum	20mg qd 15days/month	oral	01.03.2008	ongoing
157	diclofenacum	50mg bid 10days/month	oral	01.01.2008	ongoing
	nimesulidum	100mg bid 10days/month	oral	01.12.2007	ongoing
158	nimesulidum	100mg bid 10days/month	oral	01.05.2008	ongoing
	piroxicamum	20mg qd 10days/month	oral	01.01.2007	ongoing
159	nimesulidum	100mg bid 15days/month	oral	01.04.2008	ongoing
160	piroxicamum	20mg qd 15days/month	oral	01.01.2008	ongoing
161	etoricoxibum	120mg qd 10days/month	oral	01.05.2008	ongoing
	meloxicamum	7,5mg qd 10days/month	oral	01.06.2008	ongoing
162	meloxicamum	15mg qd 15days/month	oral	01.02.2008	ongoing
	nimesulidum	100mg bid 10days/month	oral	01.05.2008	ongoing
163	diclofenac	100mg	po	01.01.2008	ongoing

164	diclofenac	100mg od	po	01.01.2007	ongoing
165	diclofenac	100mg od	po	01.01.2008	ongoing
166	meloxicam	7,5mg bid	po	01.01.2007	01.01.2009
167	diclofenac	100mg od	po	01.01.2008	ongoing
168	diclofenac	50mg bid	po	01.01.2008	ongoing
169	diclofenac	100mg od	po	17.07.2008	ongoing
	meloxicam	7,5mg bid	po	01.03.2008	16.07.2008
170	diclofenac	100mg od	po	01.09.2008	ongoing
	nimesulid	100mg bid	po	01.01.2008	01.09.2008
171	diclofenac	50mg tid	po	01.12.2007	01.09.2008
172	diclofenac	50mg od	po	01.01.2008	ongoing
173	diclofenac	50mg	po	01.11.2007	15.10.2008
174	diclofenacum	100mg od	po	01.05.2008	ongoing
175	diclofenacum	100mg	po	01.02.2008	ongoing
176	diclofenac	100mg	po	01.11.2007	ongoing
177	ketoprofenum	100mg bid	po	01.01.2008	16.10.2008
178	diclofenacum	100mg	po	01.01.2008	ongoing
180	diclofenac	100mg od	po	01.01.2008	ongoing
181	diclofenacum	100mg qd	po	01.04.2008	ongoing
182	etoricoxibum	60mg qd	po	22.07.2008	28.10.2008
183	ketoprofenum	150mg qd	po	17.06.2008	30.10.2008
184	ketoprofenum	150mg qd	po	22.07.2008	30.10.2008
185	ketoprofenum	200mg qd	po	02.07.2008	ongoing
186	etoricoxibum	60mg qd	po	01.04.2008	03.11.2008
187	nimesulidum	100mg bid 15days/month	oral	01.02.2008	ongoing
188	meloxicamum	7,5mg qd 10days/month	oral	01.07.2008	ongoing
188	piroxicamum	20mg qd 15days/month	oral	01.03.2008	ongoing
189	meloxicamum	7,5mg qd 10days/month	oral	01.05.2008	ongoing
	piroxicamum	20mg qd 15days/month	oral	01.02.2008	ongoing
190	meloxicamum	7,5mg qd 10days/month	oral	01.06.2008	ongoing
	nimesulidum	100mg bid 15days/month	oral	01.05.2008	ongoing
191	nimesulidum	100mg bid 15days/month	oral	01.01.2008	ongoing
192	diclofenacum	150mg qd 15days/month	oral	01.01.2008	ongoing
193	diclofenacum	100mg od	po	01.12.2007	ongoing
194	diclofenac	100mg od	po	01.09.2008	ongoing
	ketoprofen	100mg bid	po	01.01.2007	01.09.2008
196	diclofenac	100mg od	po	01.10.2008	ongoing
	diclofenac	50mg bid	po	01.11.2007	01.10.2008
197	diclofenac	100mg od	po	01.01.2008	ongoing

198	diclofenac	50mg bid	po	01.01.2007	ongoing
199	diclofenac	100mg qd	intra rectal	01.05.2008	17.11.2008
	nimesulide	100mg bid	po	18.11.2008	24.11.2008
200	aceclofenac	100mg bid	po	19.11.2008	24.11.2008
	diclofenac	100mg qd	po	01.11.2008	15.11.2008
	diclofenac	100mg qd	po	01.10.2008	15.10.2008
	diclofenac	100mg qd	po	01.09.2008	15.09.2008
201	diclofenac	100mg/day	po	01.09.2008	ongoing
202	piroxicam	20mg	po	01.08.2008	ongoing
203	diclofenac	50mg bid	po	01.01.2007	ongoing
204	piroxicamum	20mg	po	10.09.2008	27.12.2008
205	piroxicam	20mg qd	po	15.09.2008	12.01.2009
206	diclofenac	100mg/day as need	po	21.11.2008	ongoing
207	diclofenacum	100mg/day	po	21.01.2009	31.01.2009
	diclofenacum	100mg/day	po	21.12.2008	31.12.2008
	diclofenacum	100mg/day	po	21.11.2008	30.11.2008
208	ketoprofenum	200mg/day	po	20.01.2009	30.01.2009
	ketoprofenum	200mg/day	po	20.12.2008	30.12.2008
	ketoprofenum	200mg/day	po	20.11.2008	30.11.2008
209	diclofenacum	100mg/day	po	01.02.2009	10.02.2009
	diclofenacum	100mg/day	po	01.01.2009	10.01.2009
	diclofenacum	100mg/day	po	01.12.2008	10.12.2008
210	nimesulide	100mg bid/day	po	01.02.2009	10.02.2009
	nimesulide	100mg bid/day	po	01.01.2009	10.01.2009
	nimesulide	100mg bid/day	po	01.12.2008	10.12.2008
211	piroxicamum	20mg qd	po	11.07.2008	20.11.2008
212	ketoprofenum	150mg bid	po	08.11.2008	ongoing
213	diclofenacum	100mg qd	po	25.09.2008	ongoing
214	nimesulidum	100mg qd	po	17.07.2008	02.12.2008
215	etoricoxibum	90mg qd	po	26.08.2008	04.12.2008
216	piroxicamum	20mg qd	po	01.01.2006	ongoing
217	ketoprofenum	100mg tid 10days/month	oral	01.05.2007	ongoing
	piroxicamum	20mg qd 10days/month	oral	01.01.2008	ongoing
218	meloxicamum	15mg qd 17days/month	oral	01.06.2008	ongoing
	nimesulidum	100mg bid 15days/month	oral	01.02.2008	ongoing
219	etoricoxibum	90mg qd 10days/month	oral	01.06.2008	ongoing
	piroxicamum	20mg qd 15days/month	oral	01.08.2008	ongoing
220	diclofenacum	50mg bid 15days/month	peros	01.01.2008	ongoing
	meloxicamum	7,5mg bid 10days/month	peros	01.05.2008	ongoing

221	diclofenacum	50mg bid 15days/month	peros	01.01.2007	ongoing
	piroxicamum	20mg qd 10days/month	peros	01.01.2008	ongoing
222	diclofenacum	50mg bid 15days/month	oral	01.08.2008	ongoing
	ibuprofenum	200mg qd 15days/month	oral	01.01.2008	ongoing
223	meloxicamum	7,5mg qd 10days/month	oral	01.05.2008	ongoing
	piroxicamum	20mg qd 15days/month	oral	01.02.2008	ongoing
224	diclofenacum	50mg bid 15days/month	peros	01.01.2008	ongoing
	nimesulidum	100mg bid 10days/month	peros	01.09.2008	ongoing
225	diclofenacum	50mg bid 10days/month	peros	01.01.2007	ongoing
	nimesulidum	100mg bid 10days/month	peros	01.02.2008	ongoing
226	diclofenacum	50mg bid 10days/month	peros	01.01.2007	ongoing
	piroxicamum	20mg qd 10days/month	peros	01.03.2008	ongoing
227	meloxicamum	15mg qd 10days/month	peros	01.02.2008	ongoing
	nimesulidum	100mg bid 10days/month	peros	01.08.2008	ongoing
228	diclofenacum	50mg bid 10days/month	oral	01.08.2008	ongoing
	piroxicamum	20mg 10days/month	oral	01.09.2008	ongoing
229	ketoprofen	100mg od	po	01.01.2008	01.11.2008
230	ibuprofen	200mg od	po	01.02.2008	01.09.2008
231	diclofenac	50mg od	po	01.01.2008	01.10.2008
232	diclofenac	75mg od	im	01.10.2008	01.11.2008
233	diclofenac	100mg	po	01.01.2008	ongoing
234	diclofenac	50mg od	po	01.05.2008	25.11.2008
235	diclofenac	100mg od	po	01.02.2008	ongoing
236	diclofenac	100mg od	po	01.02.2008	ongoing
237	diclofenac	50mg bid	po	01.10.2007	01.11.2008
238	diclofenac	100mg	po	01.02.2008	ongoing
239	diclofenac	100mg	po	01.01.2008	ongoing
240	diclofenac	100mg	po	01.01.2008	ongoing
241	diclofenac	75mg	po	15.01.2009	30.01.2009
242	diclofenac	100mg	po	10.01.2009	30.01.2009
243	dexketoprofen	25mg	po	16.02.2009	17.02.2009
	nimesulide	100mg	po	24.12.2008	16.02.2009
244	dexketoprofen	25mg	po	14.01.2008	ongoing
245	nimesulide	100mg	po	10.01.2009	25.01.2009
246	nimesulide	100mg	po	01.09.2008	05.03.2009
247	nimesulide	100mg	po	01.12.2008	04.03.2009
248	meloxicam	15mg	im	12.02.2009	16.02.2009
	paracetamol	500mg	po	17.02.2009	28.02.2009
249	indometacin	2x25mg	po	13.02.2009	28.02.2009

250	diclofenac	75mg	po	16.02.2009	26.02.2009
251	nimesulide	100mg	po	10.02.2009	17.02.2009
	piroxicam	20mg	po	04.01.2009	30.01.2009
252	meloxicam	15mg	po	10.02.2009	20.02.2009
253	nimesulide	100mg	po	01.11.2008	09.03.2009
254	nimesulide	100mg	po	12.11.2008	12.03.2009
255	diclofenac	2x50mg	po	10.02.2009	20.02.2009
256	meloxicam	15mg	po	15.02.2009	01.03.2009
257	meloxicam	7,5mg	po	14.07.2008	12.03.2009
258	diclofenac	75mg amp	im	15.02.2009	17.02.2009
	diclofenac	75mg tbl	po	18.02.2009	25.02.2009
259	diclofenac	100mg x1tb	po	01.01.2005	ongoing
260	diclofenac	75mg x1tb	po	09.09.2008	ongoing
261	meloxicam	7,5mg x1tb	po	05.05.2008	18.03.2009
262	diclofenac	100mg x1tb	po	04.05.2008	ongoing
263	indometacin	25mg 3x1tbl	po	25.02.2009	10.03.2009
264	meloxicam	15mg tbl	po	22.02.2009	03.03.2009
265	nimesulide	100mg	per os	02.01.2009	10.01.2009
266	meloxicam	15mg	po	01.02.2009	25.02.2009
267	nimesulide	100mg	po	01.01.2009	01.02.2009
268	diclofenac	75mg x1tb	po	01.12.2008	27.03.2009
268	acetylsalicylic acid	500mg x1tbl	po	01.12.2008	27.03.2009
269	profenid	50mg	po	20.02.2009	15.03.2009
270	dexketoprofen	25mg 2x1	po	01.03.2009	20.03.2009
271	piroxicam	20mg	po	01.12.2008	10.12.2008
272	nimesulide	100mg	po	01.03.2009	08.03.2009
	nimesulide	100mg	po	01.01.2009	27.03.2009
274	diclofenac	75mg x1tb	po	01.10.2008	ongoing
275	coxib	60mg tbl	po	05.03.2009	18.03.2009
276	nimesulide	100mg x1tb	po	01.09.2007	31.03.2009
277	meloxicam	15mg tbl	po	10.03.2009	24.03.2009
278	nimesulide	100mg	per os	03.02.2009	06.02.2009
279	nimesulide	100mg	po	03.03.2009	10.03.2009
280	diclofenac	75mg	po	01.03.2009	20.03.2009
281	meloxicam	15mg x1tbl	po	15.03.2009	30.03.2009
282	nimesulide	100mg	per os	02.03.2009	03.03.2009
283	nimesulide	100mg	po	04.03.2009	09.03.2009
284	meloxicam	15mg	po	20.03.2009	30.03.2009
285	nimesulide	100mg	per os	01.03.2009	09.04.2009

286	nimesulide	100mg	per os	05.02.2009	20.02.2009
287	nimesulide	100mg	per os	03.01.2009	13.01.2009
288	indometacin	25mg 3x1	po	15.03.2009	30.03.2009
289	nimesulide	100mg	po	25.03.2009	15.04.2009
290	nimesulide	100mg	po	01.01.2008	14.04.2009
291	meloxicam	15mg	po	01.02.2009	20.02.2009
292	nimesulide	100mg tbl	po	01.04.2009	10.04.2009
293	meloxicam	15mg	im	15.03.2009	20.03.2009
	meloxicam	15mg	po	21.03.2009	29.03.2009
294	meloxicam	15mg x1tb	po	06.04.2008	21.04.2009
295	diclofenac	150mg x1tb	po	06.09.2008	21.04.2009
296	nimesulide	100mg	per os	05.03.2009	15.03.2009
297	nimesulide	100mg	per os	21.04.2009	22.04.2009
298	nimesulide	100mg	per os	03.02.2009	07.02.2009
299	nimesulide	100mg	per os	03.03.2009	06.04.2009
300	nimesulide	100mg	per os	04.04.2009	07.04.2009

Table 45: Prescribed NSAIDs during the trial

Rand. Nr	V1	V2	V3	V4
1	diclofenac 50mg 2x1;	diclofenac 50mg 2x1;	ibalgin 1200mg po /day;	ibalgin 400mg 3
2	voltaren sr 75mg bid;	voltaren sr 75mg bid;	voltaren 75mg po bid;	voltaren 75mg 2
3	diclofenac 75mg 2x;	arthrotec forte 75mg 1-2x1;	diclofenac 75mg po 2;	diclofenac 75mg po 2
4	ibalgin 400mg 3-4x;	ibalgin 400mg 3-4x;	ibalgin 1200mg po;	ibalgin 1200mg po
5	diclofenac 100mg 1;	diclobene ret 150mg 1x;	diclobene ret 150mg qd;	diclobene ret 150mg qd
6	diclofenac 50mg 2x/day;	diclofenac 50mg 2xd;	diclofenac 50mg 2;	diclofenac 50mg 2
7	diclofenac 75mg 2;	arthrotec forte diclofenac 75mg 2x1;	diclofenac 75mg 2;	diclofenac 75mg 2
8	ibalgin 400mg po tid;	ibalgin 400mg 3x1;	voltaren 75mg po bid;	voltaren 75mg po 2
9	voltaren r 50mg 2x1;	voltaren rapid 50mg 2;	voltaren rapid 50mg 2;	voltaren rapid 50mg 2
10	ibuprofen 400mg 3;	ibalgin 1200mg po;	ibalgin 400mg po 3;	ibalgin 400mg 3
11	diclofenac 50mg 2;	;	diclofenac 50mg 2;	diclofenac 50mg 2
12	voltaren rapid 50mg 2x1;	voltaren rapid 50mg 1-2x;	voltaren rapid 50mg po 2;	diclofenac 50mg 2
13	diclofenac 75mg 1x;	diclofenac 75mg 1x/day;	diclofenac 75mg 1x/day;	diclofenac 75mg 1x/day
14	meloxicam 15mg 1x;	meloxicam 15mg 1x/day;	meloxicam 15mg 1x/day;	meloxicam 15mg 1x/day
15	diclofenac 75mg 1x;	diclofenac 75mg 1x/day;	diclofenac 75mg 1x/day;	diclofenac 75mg 1x/day
16	diclofenac 75mg /day 1x;	diclofenac 75mg /day 1x;	diclofenac 75mg /day 1x;	diclofenac 75mg 1x/day
17	meloxicam 15mg 1/day;	meloxicam 15mg 1/day;	meloxicam 15mg 1x/day;	meloxicam 15mg 1x/day
18	aceclofenac 200mg 2/day;	aceclofenac 200mg 2/day;	aflamil aceclofenac 100mg 2x/day;	aceclofenac aflamil 100mg 2x/day
19	voltaren rapid 50mg po bid;	voltaren rapid 50mg 2;	diclofenac 50mg 2;	diclofenac 50mg 2
20	diclobene ret. 150mg 1;	diclofenac 50mg 2;	diclofenac 50mg 2;	diclofenac 50mg 2
21	diclofenac 50mg 2;	diclofenac 50mg 2;	diclofenac 50mg 2;	diclofenac 50mg 2
22	ibuprofen 400mg 3;	;	;	
23	diclofenac 50mg bid;	diclofenac 100mg 2;	diclofenac 100mg 2;	diclofenac 50mg 2
24	diclofenac 50mg 3;	diclofenac 50mg 3;	diclofenac 50mg 3;	diclofenac 50mg 3
25	flamexin 20mg /day;	flamexin 20mg 1x;	flamexin 20mg 1/day;	flamexin 20mg 1/day

26	flugalin 50mg 2x;	flugalin 50mg 1-2x;	flugalin 50mg 1-2x;	flugalin 50mg 1-2x
27	aflamil 100mg 1-2x;	aflamil 100mg 1x;	aceclofenac 100mg 1x;	aceclofenac 100mg 1x
28	movalis 15mg 1x;	movalis 15mg 1x/day;	movalis 15mg 1x/day;	movalis 15mg 1x/day
29	flamexin 20mg 1x/day;	flamexin 20mg 1x/day;	flamexin 20mg 1x/day;	flamexin 20mg 1x/day
30	ibalgin 400mg 3x;	ibalgin 400mg 2-3x;	ibalgin 400mg 3x;	ibalgin 400mg 3x
31	celebrex 200mg 1-2x/day;	celebrex 200mg /day;	celecoxib 200mg 1x;	celecoxib 200mg 1x
32	movalis 15mg 1x/day;	movalis 15mg 1x/day;	movalis 15mg 1x/day;	movalis 15mg 1x/day
33	movalis 15mg 1x/day;	movalis 15mg 1x/day;	meloxicam 15mg 1x;	meloxicam 15mg 1x
34	diclac ret. 100mg 1x;	diclac 100mg /day;	diclofenac 100mg 1x/day;	diclofenac 100mg 1x/day
35	aflamil 100mg 2x;	aflamil 100mg 2x;	aceclofenac 100mg 2x/day;	aceclofenac 100mg 1-2x/day
36	arthrotec forte 75mg 2x;	arthrotec forte 75mg 2x;	diclofenac 75mg 2x/day;	diclofenac 75mg 2x/day
37	ibalgin 400mg 3x;	ibuprofen 400mg 2x/day;	ibuprofen 400mg 2x/day;	ibuprofen 400mg 2x/day
38	arthrotec forte 75mg 2x;	diclofenac 75mg 2x;	diclofenac 75mg 1-2x/day;	diclofenac 75mg 1-2x/day
39	movalis 15mg /day;	meloxicam 15mg 1x/day;	meloxicam 15mg 1x/day;	meloxicam 15mg 1x/day
40	diclobene ret. 150mg /day;	diclofenac 150mg 1x/day;	diclofenac 150mg 1x/day;	diclofenac 150mg 1x/day
41	movalis 15mg /day;	NA ;	;	
42	diclofenac 100mg 1x;	diclofenac 100mg 1x/day;	diclofenac 100mg 1x/day;	diclofenac 100mg 1x/day
43	diclofenac 100mg ;	diclofenac 75mg 1x;	diclofenac 75mg 1x;	diclofenac 75mg 1x
44	dicloberl retard 100mg ;	aulin 100mg 2x1;	diclofenac 100mg 1x1;	diclofenac 100mg 1x1
45	diclofenac 100mg 1x1;	diclofenac 100mg 1x1;	diclofenac 100mg 1x1;	diclofenac 100mg 1
46	diclofenac 75mg /day;	diclofenac 75mg /day;	diclofenac 75mg /day;	diclofenac 75mg 1
47	meloxicam 7,5mg 1x1;	meloxicam 7,5mg 1x;	meloxicam 7,5mg 1x;	meloxicam 7,5mg
48	ketoprofen 200mg 1x1;	diclofenac 100mg 1;	diclofenac 100mg 1;	diclofenac 150mg 1
49	diclofenac 75mg 1x;	diclofenac 75mg 1;	diclofenac 75mg 1;	diclofenac 75mg 1
50	nimesulide 100mg 1;	acemetacin 90mg 1;	rantudil retard 90mg 1;	acemetacin 90mg 1
51	diclofenac 100mg 1;	NA ;	;	
52	diclofenac 100mg 1;	diclofenac 100mg 1;	diclofenac 100mg 1;	diclofenac 100mg 1
53	ketoprofen 100mg 1;	;	;	
54	rantudil retard acemetacin 90mg 1;	rantudil forte (acemetacin) 60mg 1x1;	acemetacin 60mg 1;	acemetacin 60mg 1
55	nimesulide 100mg 2xdd;	nimesulid 100mg dd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
56	ketoprofenum 150mg dd;	nimesulid 100mg dd;	nimesulid 100mg dd;	ketoprofenum 200mg dd
57	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd

58	diclofenac 150mg dd;	diclofenac 50mg 3xdd;	diclofenac 50mg 3xdd;	diclofenac 50mg 3xdd
59	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
60	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
61	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
62	nimesulid 200mg dd;	nimesulid 100mg 2x;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
63	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
64	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
65	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
66	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg dd;	nimesulid 100mg dd
67	diclac 75mg bid;	diclofenac 75mg ;	diclac 75mg ;	diclofenac 100mg
68	nimesil 100mg bid;	nimesulide 100mg bid;	nimesil 100mg bid;	nimesulid 100mg
69	diclofenac 100mg ;	ibuprofen 250mg 1;	ibuprofen 200mg 1;	ibuprofen 200mg
70	nimesulid 100mg bid;	nimesulid 100mg ;	nimesulid 100mg ;	nimesulid 100mg
71	nimesulidum 100mg 2x1 po bid;	diclofenac 100mg 1x1 po qd;	diclofenac 100mg 1x1 po qd;	diclofenac 75mg 1x1 po qd
72	meloxicam 7,5mg bid;	meloxicam 7,5mg ;	meloxicam 7,5mg ;	movalis meloxicam 7,5mg bid
73	nimesulide 100mg bid;	aulin nimesulide 100mg bid;	nimesulide 100mg ;	nimesulide 100mg 1
74	diclofenac 100mg bid;	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg 1
75	diclofenac 100mg 1x1;	diclofenac 100mg 1;	diclofenac 100mg 1;	diclofenac 100mg 1
76	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg 1;	diclofenac 100mg 1
77	diclofenac 150mg ;	diclofenac 100mg ;	diclofenac 100mg 1;	diclofenac 100mg 1
78	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg 1
79	celecoxyb 100mg dd;	celecoxyb 100mg dd;	celecoxyb 100mg dd;	celebrex celecoxyb 100mg 2xdd
80	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
81	celecoxyb 100mg dd;	celecoxyb 100mg dd;	celecoxyb 100mg dd;	
82	ketoprofenum 100mg 2xdd;	ketoprofenum 100mg 2xdd;	ketoprofenum 100mg 2xdd;	ketoprofenum 100mg 2xdd
83	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
84	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
85	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
86	ketoprofenum 100mg 2xdd;	ketoprofenum 100mg 2xdd;	ketoprofenum 100mg 2xdd;	ketoprofenum 100mg 2xdd
87	acemetacin 90mg dd;	acemetacin 90mg dd;	acemetacin 90mg dd;	acemetacin 90mg dd
88	celecoxyb 100mg dd;	celecoxyb 100mg dd;	celecoxyb 200mg dd;	celecoxyb 100mg dd

89	celecoxyb 100mg dd;	celecoxyb 100mg dd;	celebrex/celecoxyb 100mg dd;	celecoxyb 100mg dd
90	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
91	nimesulide 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulide 100mg 2xdd;	nimesulide 100mg 2xdd
92	nimesulide 100mg 2xdd;	nimesulide 100mg 2xdd;	nimesulide 100mg 2xdd;	nimesulide 100mg 2xdd
93	celecoxyb 200mg dd;	celecoxyb 200mg dd;	celecoxyb 200mg dd;	celecoxyb 200mg
94	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
95	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd;	nimesulid 100mg 2xdd
96	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd
97	nimesulid 100mg bid 2;	nimesulid 100mg bid 2;	nimesulid 100mg 2;	nimesulid 100mg 2
98	diclofenac 50mg bid 2;	diclofenac 50mg bid 2;	diclofenac 50mg 2;	diclofenac 50mg 2
99	ketoprofen 100mg bid;	ketoprofen 100mg bid 2;	;	
100	nimesulide 100mg bid 2;	nimesulid 100mg bid 2;	nimesulid 100mg bid 2;	nimesulide 100mg bid 2
101	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicam 15mg dd;	meloxicamum 15mg dd
102	ketoprofenum ;	ketoprofenum 150mg dd;	ketoprofenum 150mg dd;	febrofenum 150mg dd
103	diclofenac 150mg qd;	diclofenac 50mg bid;	diclofenac 150mg qd;	diclofenac 150mg qd
104	aceclofenac 100mg bid;	diclofenac duo 150mg qd;	aceclofenac 100mg qd;	aceclofenac 100mg bid/qd
105	aceclofenac 100mg bid;	diclofenac 150mg qd;	diclofenac 75mg qd/bid;	diclofenac 75mg qd
106	diclofenac 150mg qd;	diclofenac 50mg bid;	diclofenac 50mg qd;	diclofenac 75mg qd
107	piroxicam 20mg cp 1 qd;	piroxicam 20mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd
108	aceclofenac 100mg bid;	diclofenac 50mg qd;	diclofenac 75mg qd;	diclofenac 50mg qd
109	diclofenac 150mg qd;	diclofenac 50mg po bid;	diclofenac 50mg qd;	diclofenac 75mg qd
110	nimesulide 100mg bid;	diclofenac 150mg qd;	diclofenac 150mg qd;	diclofenac 75mg qd
111	diclofenac 100mg qd;	aceclofenac 100mg bid;	aceclofenac 100mg qd/bid;	aceclofenac 100mg qd
112	diclofenac 150mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd
113	piroxicam 20mg qd;	diclofenac 150mg qd;	diclofenac 75mg qd;	diclofenac 150mg qd
114	diclofenac 150mg qd;	diclofenac 50mg qd;	aceclofenac 100mg qd;	diclofenac 50mg qd/bid
115	diclofenac 150mg qd;	diclofenac 150mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd
116	diclofenac 50mg bid;	diclofenac 50mg as needed;	diclofenac 50mg qd;	diclofenac 50mg qd
117	diclofenac 150mg /day po;	diclofenac 150mg /day po;	diclofenacum 150mg /day po 10day/month;	diclofenac 150mg 1cp/day po 10days/month
118	diclofenac duo 150mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd
119	diclofenac 50mg bid;	diclofenac 50mg qd;	diclofenac 75mg qd/bid;	diclofenac 50mg qd
120	diclofenac 100mg /day	diclofenac 100-150mg /day	diclofenac 150mg /day	diclofenac 150mg 1cp/day

	10days/month;	10days/month;	10days/month;	10days/month
121	diclofenac 50mg qd;	diclofenac 50mg cp qd;	diclofenac 75mg qd;	diclofenac 50mg qd
122	diclofenac 50mg qd/bid;	diclofenac 50mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd
123	aceclofenac 100mg bid;	aceclofenac 100mg bid;	diclofenac 75mg qd;	diclofenac 50mg bid/qd
124	aceclofenac 100mg bid 40cp;	aceclofenac 100mg bid;	diclofenac 150mg qd;	diclofenac 150mg qd
125	diclofenac 50mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd/bid;	diclofenac 50mg qd
126	aceclofenac 100mg cp bid;	aceclofenac 100mg bid;	aceclofenac 100mg qd/bid;	aceclofenac 100mg qd/bid
127	diclofenac 100mg qd at need;	diclofenacum 100mg /day at need;	diclofenac 100mg /day at need;	diclofenacum 100mg /day at need
128	ketoprofenum 200mg /day at need;	ketoprofenum 200mg /day at need;	ketoprofenum 200mg /day at need;	
129	diclofenac 100mg at need /day;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
130	diclofenac 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
131	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
132	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
133	diclofenac 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
134	diclofenacum 100mg at need /day;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
135	diclofenacum 100mg at need /day;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
136	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
137	meloxicanum 7,5mg /day at need;	meloxicanum 7,5mg /day at need;	meloxicanum 7,5mg /day at need;	meloxicamum 7,5mg /day at need
138	meloxicanum 7,5mg /day at need;	meloxicanum 7,5mg /day at need;	meloxicanum 7,5mg /day at need;	meloxicamum 7,5mg /day at need
139	diclofenac 100mg qd;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need

140	diclofenacum 100mg /day at need;	diclofenac 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
141	diclofenacum 100mg /day at need;	diclofenac 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
142	diclofenacum 100mg /day at need;	diclofenac 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
143	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
144	diclofenac 100mg bid;	diclotard 100mg qd;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
145	piroxicamum 20mg qd 10days/month;etoricoxibum 120mg qd 10days/month	piroxicamum 20mg qd 10days/month;etoricoxibum 120mg qd 10days/month	etoricoxibum 120mg qd 10days/month;paracetamolum 500mg qd 10days/month	diclofenacum 50mg qd 15days/month
146	etoricoxibum 90mg 1tb/day 14days/month;ibuprofenum 200mg 1tb/day 7days/month	ibuprofenum 200mg qd 7days/month;	ibuprofenum 200mg qd 7days/month;	ibuprofenum 200mg qd prn
147	piroxicamum 20mg qd 15days/month;nimesulidum 100mg bid 15days/month	nimesulidum 100mg qd 15days/month;	nimesulidum 100mg bid 15days/month;	piroxicamum 20mg qd 10days/month
148	nimesulidum 100mg bid 10days/month;tenoxicamum 20mg qd 10days/month	nimesulidum 100mg bid 10days/month;tilcotilum 20mg qd 10days/month	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg qd 10days/month
149	ibuprofenum 200mg qd 15days/month;piroxicamum 20mg qd 10days/month	ibuprofenum 200mg qd 10days/month;	ibuprofenum 200mg qd 10days/month;	ibuprofenum 200mg prn
150	piroxicamum 20mg qd 10days/month;	piroxicamum 20mg qd 5days/month;	piroxicamum 20mg qd 5days/month;	piroxicamum 20mg prn
151	diclofenacum 50mg bid 15days/month;piroxicamum 20mg qd 10days/month	diclofenacum 50mg bid 15days/month;piroxicamum 20mg qd 10days/month	diclofenacum 50mg bid 15days/month;	diclofenacum 50mg prn
152	etoricoxibum 90mg qd 10days/month;ibuprofenum 200mg qd 15days/month	etoricoxibum 90mg qd 10days/month;ibuprofenum 200mg 15days/month	ibuprofenum 200mg qd 15days/month;	diclofenacum 50mg qd 15days/month
153	ibuprofenum 200mg qd	ibuprofenum 200mg qd	ibuprofenum 200mg qd	ibuprofenum 200mg qd

	15days/month;	15days/month;	15days/month;	7days/month
154	nimesulidum 100mg bid 10days/month;piroxicamum 20mg qd 10days/month	piroxicamum 20mg qd 10days/month;	piroxicamum 20mg qd 10days/month;	nimesulidum 100mg prn
155	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg bid prn;	nimesulidum 100mg bid prn;	nimesulidum 100mg bid prn
156	piroxicamum 20mg qd 15days/month;	piroxicamum 20mg qd 15days/month;	piroxicam 20mg qd 15days/month;paracetamolum 500mg qd 10days/month	nimesulidum 100mg qd 10days/month
157	nimesulidum 100mg bid 10days/month;diclofenacum 50mg bid 10days/month	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg qd prn
158	nimesulidum 100mg bid 10days/month;piroxicamum 20mg qd 10days/month	nimesulidum 100mg 2cp/day 10days/month;	nimesulidum 100mg bid 10days/month;	meloxicamum 7,5mg qd 10days/month
159	nimesulidum 100mg bid 15days/month;	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg qd prn
160	piroxicamum 20mg qd 15days/month;	flamexin 20mg qd 15days/month;paracetamol 500mg 15days/month	piroxicam 20mg qd 15days/month;paracetamolum 500mg qd 10days/month	nimesulidum 100mg bid 10days/month
161	etoricoxibum 120mg qd 10days/month;meloxicamum 7,5mg qd 10days/month	etoricoxibum 120mg qd 10days/month;	meloxicanum 7,5mg qd 10days/month;	nimesulidum 100mg bid 10days/month
162	meloxicamum 15mg qd oral 15days/month;nimesulidum 100mg bid oral 10days/month	nimesulidum 100mg bid 10days/month;	diclofenacum 50mg qd 10days/month;	diclofenacum 50mg qd prn
163	diclofenac 100mg od;	NA ;	diclofenac 100mg od po;	NA
164	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
165	diclofenac 100mg od;	diclofenac 100mg od po;	NA ;	NA
166	diclofenac 100mg od;	diclotard 100mg 1cp od;	diclofenac 100mg po od;	diclofenac 100mg od po
167	diclofenac 100mg od po;	diclofenac (diclotard) 100mg 1cp od;	diclofenac 100mg od po;	diclofenac 100mg od po
168	diclofenac 100mg od;	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po

169	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
170	diclofenac 100mg od;	diclotard 100mg po od;	diclofenac 100mg od po;	diclofenac 100mg od po
171	diclofenac 100mg od;	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po
172	diclofenac 50mg od;	diclofenac 50mg od;	diclofenac 100mg od po;	diclofenac 100mg od po
173	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
174	diclofenac 100mg od;	diclotard 100mg 1cp od po;	diclofenac 100mg od po;	diclofenac 100mg od po
175	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
176	diclotard 100mg 1cp/d od;	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po
177	diclofenac 100mg od;	diclofenacum 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po
178	diclofenac 100mg od po;	diclofenac 100mg 1cp od;	diclofenac 100mg od po;	diclofenac 100mg od po
179	diclofenac 100mg od po;	diclotard 100mg od po;	diclofenac 100mg 1cp/od po;	diclofenac 100mg od po
180	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
181	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
182	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
183	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
184	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
185	ketoprofenum 200mg /day at need;	ketoprofenum 200mg /day at need;	ketoprofenum 200mg /day at need;	diclofenacum 100mg /day at need
186	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
187	nimesulidum 100mg bid 15days/month;	nimesulidum 100mg bid 10days/month;piroxicamum 20mg qd 10days/month	nimesulidum 100mg qd 15days/month;	nimesulidum 100mg qd prn
188	piroxicamum 20mg qd 15days/month;meloxicamum 7,5mg qd 10days/month	piroxicamum 20mg qd 15days/month;	meloxicamum 7,5mg qd 10days/month;	meloxicamum 7,5mg qd prn
189	piroxicamum 20mg qd 15days/month;meloxicamum 7,5mg qd 10days/month	piroxicamum 20mg qd 15days/month;	meloxicamum 7,5mg 1cp/d qd 10days/month;	piroxicamum 20mg qd 15days/month

190	nimesulidum 100mg bid 15days/month;meloxicamum 7,5mg qd 10days/month	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg qd 10days/month;	nimesulidum 100mg qd prn
191	nimesulidum 100mg bid 15days/month;	nimesulidum 100mg bid 15days/month;	nimesulidum 100mg prn;	nimesulidum 100mg qd prn
192	diclofenacum 150mg qd 15days/month;	nimesulidum 100mg bid 15days/month;	nimesulidum 100mg prn;	nimesulidum 100mg qd prn
193	diclofenac 100mg 1cp od;	diclofenac 100mg 1cp od po;	diclofenac 100mg od po;	diclofenac 100mg od po
194	diclofenac 100mg od;	diclotard 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
195	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
196	diclofenac 100mg 1 cp/d;	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po
197	diclofenac 100mg od;	diclofenac 100mg od;	diclofenac 100mg od po;	diclotard 100mg od po
198	diclofenac 100mg od;	diclofenac 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po
199	aceclofenac 100mg bid;	aceclofenac 100mg qd;	diclofenac 100mg qd;	diclofenac 50mg qd
200	aceclofenac 100mg bid;	aceclofenac 100mg bid;	aceclofenac 100mg qd;	aceclofenac 100mg qd/bid
201	diclofenac 100mg /day 10days/month;	diclofenac 100mg /day 10days/month;	;	
202	diclofenac 150mg qd;	diclofenac 150mg qd;	diclofenac 150mg qd;	diclofenac 50mg qd
203	diclofenac 150mg qd;	diclofenac 50mg bid;	diclofenac 50mg qd/bid;	diclofenac 50mg qd
204	ketoprofen 200mg /day;piroxicam 20mg /day 10days/month	diclofenac 100mg /day 10days/month;	diclofenac 150mg 1cp/day po 10days/month;	diclofenac 150mg 1cp/day po 10days/month
205	diclofenac 75mg qd;	diclofenac 50mg qd;	diclofenac 50mg qd;	aceclofenac 100mg qd/bid
206	diclofenac 150mg /day po 10days/month;	diclofenac 150mg 1cp/day 10days/month;	diclofenac 150mg 1cp/day 10days/month;	diclofenac 150mg 1cp/day 10days/month
207	diclofenac 150mg /day po 10days/month;	diclofenac 150mg 1cp/day 10days/month;	diclofenac 150mg /day 10days/month;	diclofenac 150mg 1cp/day 10days/month
208	diclofenac 150mg /day 10days/month;	diclofenac 150mg /day 10days/month;	diclofenac 150mg 1cp/day 10days/month;	diclofenac 150mg 1cp/day 10days/month
209	diclofenac 150mg /day 10days/month;	diclofenac 150mg 1cp/day 10days/month;	diclofenac 150mg 1cp/day 10days/month;	diclofenac 150mg 1cp/day 10days/month
210	diclofenac 100mg /day 10days/month;	diclofenac 150mg 1/day 10days/month;	;	

211	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
212	ketoprofenum 150mg twice a day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
213	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
214	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need
215	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	diclofenacum 100mg /day at need;	
216	piroxicamum 20mg /day at need;	piroxicamum 20mg /day at need;	piroxicamum 20mg /day at need;	piroxicamum 20mg /day at need
217	piroxicamum 20mg qd 15days/month;	piroxicamum 20mg qd 10days/month;	piroxicamum 20mg qd prn;	piroxicamum 20mg qd prn
218	nimesulidum 100mg bid 15days/month;	nimesulidum 100mg bid 10days/month;	nimesulidum 100mg qd 10days/month;	nimesulidum 100mg qd prn
219	etoricoxibum 90mg qd 10days/month;piroxicamum 20mg qd 15days/month	piroxicamum 20mg qd 15days/month;	piroxicamum 20mg qd 7days/month;	piroxicamum 20mg qd 10days/month
220	movalis 7,5mg bid 10days/month;diclofenacum 50mg bid 15days/month	meloxicamum 7,5mg qd 10days/month;diclofenacum 50mg qd 10days/month	diclofenacum 50mg bid 10days/month;	meloxicamum 7,5mg qd 10days/month
221	piroxicamum 20mg qd 10days/month;diclofenacum 50mg bid 15days/month	diclofenacum 50mg bid 15days/month;	diclofenacum 50mg bid 15days/month;	diclofenacum 50mg bid prn
222	ibuprofenum 200mg qd 15days/month;	ibuprofenum 200mg qd 10days/month;	ibuprofenum 200mg qd 10days/month;	ibuprofenum 200mg qd prn
223	piroxicamum 20mg qd 15days/month;meloxicamum 7,5mg qd 10days/month	piroxicamum 20mg qd 10days/month;meloxicamum 7,5mg qd 10days/month	piroxicamum 20mg qd 10days/month;	meloxicamum 7,5mg qd 10days/month
224	diclofenacum 50mg bid 15days/month;nimesulidum 100mg bid 10days/month	diclofenacum 50mg bid 15days/month;	diclofenacum 50mg bid 15days/month;	nimesulidum 100mg bid 10days/month
225	nimesulidum 100mg bid	diclofenacum 50mg bid	nimesulidum 100mg qd	nimesulidum 100mg qd prn

	10days/month;diclofenacum 50mg bid 10days/month	10days/month;	10days/month;	
226	piroxicamum 20mg qd 10days/month;diclofenacum 50mg bid 10days/month	piroxicamum 20mg qd 10days/month;	diclofenacum 50mg bid 10days/month;	diclofenacum 50mg qd prn
227	meloxicamum 15mg qd 10days/month;nimesulidum 100mg qd 10days/month	meloxicamum 15mg qd 10days/month;	nimesulidum 100mg qd 10days/month;	nimesulidum 100mg qd prn
228	diclofenacum 50mg bid oral 10days/month;	diclofenacum 50mg bid 10days/month;	diclofenacum 50mg qd 10days/month;	diclofenacum 50mg qd prn
229	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
230	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	NA
231	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	NA
232	diclotard 100mg od;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
233	diclotard 100mg po od;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenacum 100mg od po
234	diclotard 100mg od po;	diclotard (diclofenac) 100mg od po;	diclofenac 100mg od po;	NA
235	diclotard 100mg po od;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenacum 100mg od po
236	diclotard 100mg po od;	diclofenac 100mg od po;	diclofenac 100mg po od;	diclofenacum 100mg od po
237	diclotard 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po
238	diclotard 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	diclofenacum 100mg od po
239	diclotard 100mg od po;	diclofenac 100mg od po;	diclofenac 100mg od po;	NA
240	diclotard 100mg po od;	diclofenac 100mg od po;	diclofenac 100mg od po;	NA
241	voltaren r 100mg ;	voltaren r 100mg ;	voltaren r 100mg /day;	voltaren r 100mg /day
242	voltaren r 100mg /day;	meloxicam 15mg /day;	meloxicam 15mg /day;	meloxicam 15mg /day
243	diclofenac 75mg ;	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg
244	voltaren sr 100mg once a day;	voltaren sr 100mg ;	voltaren sr 100mg ;	voltaren sr 100mg
245	voltaren sr 100mg 1tbl;	voltaren sr 100mg 1tbl /day;	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day
246	voltaren sr 100mg x1t;	voltaren sr 100mg x1t;	voltaren sr 100mg ;	voltaren sr 100mg
247	voltaren sr 100mg once a day;	voltaren sr 100mg once a day;	voltaren sr 100mg ;	voltaren sr 100mg
248	voltaren r 100mg /day;	voltaren r 100mg ;	voltaren r 100mg /day;	voltaren r 100mg /day
249	voltaren sr 100mg 1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
250	voltaren r 100mg /day;	meloxicam 15mg /day;	meloxicam 15mg /day;	meloxicam 15mg /day

251	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg /day
252	voltaren sr 100mg 1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
253	voltaren sr 100mg x1;	voltaren sr 100mg ;	voltaren sr 100mg dd;	voltaren sr 100mg dd
254	voltaren sr 100mg once a day;	voltaren 100mg ;	voltaren 100mg ;	voltaren 100mg
255	voltaren sr 100mg 1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
256	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl ;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
257	voltaren sr 100mg once a day;	voltaren sr 100mg x1;	voltaren sr 100mg ;	voltaren sr 100mg
258	voltaren r 100mg ;	meloxicam 15mg /day;	meloxicam 15mg /day;	meloxicam 15mg /day
259	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg
260	voltaren sr 100mg ;	voltaren sr 100mg dd;	voltaren sr 100mg ;	voltaren sr 100mg
261	diclofenac 75mg once a day;	diclofenac 75mg once a day;	diclofenac 75mg ;	diclofenac 75mg
262	diclofenac 100mg once a day;	diclofenac 100mg ;	diclofenac 100mg ;	diclofenac 100mg
263	voltaren sr 100mg 1tbl po;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
264	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
265	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
266	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day
267	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
268	voltaren sr 100mg ;	voltaren sr 100mg ;	voltaren sr 100mg ;	voltaren sr 100mg
269	voltaren r 100mg ;	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
270	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
271	diclofenac duo 75mg /day;	meloxicam 15mg /day;	diclofenac duo 75mg /day;	diclofenac duo 75mg /day
272	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
273	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
274	diclofenac 75mg one a day;	diclofenac 75mg once a day;	diclofenac 75mg ;	diclofenac 75mg
275	voltaren sr 100mg x1tbl d.;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl;	voltaren 100mg x1tbl /day
276	diclofenac 75mg ;	diclofenac 75mg once a day;	diclofenac 75mg ;	diclofenac 75mg
277	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren 100mg x1tbl /day
278	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
279	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
280	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day
281	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day
282	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
283	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg

284	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
285	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
286	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
287	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
288	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
289	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day
290	diclofenac 75mg tb;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
291	voltaren r 100mg ;	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day
292	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl /day;	voltaren sr 100mg x1tbl;	voltaren sr 100mg x1tbl /day
293	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day;	voltaren r 100mg /day
294	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
295	voltaren sr 100mg ;	voltaren sr 100mg ;	voltaren sr 100mg ;	voltaren sr 100mg
296	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
297	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
298	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
299	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg
300	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg ;	diclofenac 75mg

Table 46: Changes in concomitant medication (not NSAID) during the trial

Random Nr	Concomitant Treatment
1	actonel 35
	calcium eff.
	accuzide
3	diclofenac
	plaquenil
5	nitropelet
	chondrosulf
	calcium
7	lozap h
	tevalen
8	tonocalcin 200
9	atenobene
11	sylimarinum
1	xanax
1	condrosulf
15	levothyroxin
17	varfarinum natrium
18	calcii carbonas
	cholecalciferol
19	euthyrox
	condrosulf
20	tritazide
22	osteocenon
23	euthyrox
	novalgin
25	perindopril
26	amlodipin
	trandolapril
	dutasterid
	hyaluronic acid
27	caltrate plus ca+vitamin d
28	bisoprolol
29	nitrendipin
30	perindopril
32	perindopril
34	levothyroxinum
	calcium+dvit.
35	bisoprolol
36	ibandronat
	calcium
	isosorbit dinitrat
38	diltiazem
40	taloxifen

	calcium+dvit
41	trimetazidin
	acid acetylosalicylic
	ramipril
43	losartanum kalicum
	ezetimibum
	magnesii lactas
	aspirin
	latanoprostum brimoniti tartas+timololum
44	accurenal quinapril
	diuresin indapamide
	kalipoz potassium K+10meq
	bisocard bisoprolol
	atoris atorvastatinum
	lacipil lacidypina
	acard acetylsalicilic acid
	helicid omeprazol
45	losartan loristia
	lacidipin lacipil 4mg
	indapamide ipres long
	ramipril axtil 5mg
	metoprolol metocard
	potassium kali poz
	metformin metformax
	simvastatin simvacard
	omeprazole helicid
	oxybutinin driptane
46	alendronate sodium
	lovastatin
	betahistin
	amilorid
	hydrochlorotiazyd
	aspirin
47	metoprolol succinate
	perindopril
	simvastatin
	pentoxifylline
	aspirin
48	metoprolol
	indapamid
	simvastatin
	kalipoz
	acard
	ranitydinum ranigast
	omeprazol
	helicid
49	bisoprolol

	simvastatin
	levothyroxine sodium
	vinpocetine
	omeprazole
	diosmina
50	metoprolol
	sorbonit isosorbid dinitrate
	amlodipine
	chlortalidone
	simvastatin
	aspirin
	potassium
	omeprazol
51	paroxetine
	lorazepam
	omeprazole
52	triderm
53	simvastatin vasilip
	bisoprolol bisocard
	aspirin acard
54	bisoprolol
	aspirin
	simvastatin
	trimetazidyne
	propafenone
	indapamide
55	perindopril
	indapamide
	acetylosalicylic acid
56	lisinopril
	omeprazol
	paracetamol
60	detralex
	enalapril
	hydrochlorothiazid
	paracetamol
61	paracetamol
62	tolperison
	tetrazepam
	talvosilen forte
63	pantoprazol
64	perindopril
	indapamid
65	glimepiride
	carvediol
	indapamid
	paracetamol

67	otrex 600
	heparinum lioton 1000
	simvastatinum simvahexal
	betaloc zok
	losartanum lorista
	furosemidum
	potassium kaldyum
68	hesperidinum detralex diosminum
69	potassium kalipoz
	indapamidum tertensif sr
	propafenon polfenon
	doxazosinum doxanorm
	bisoprolol bisocard
	opipramolum pramolan
	estazolam
	atorvastatinum sortis
	fenofibratum lipanthyl 267 M
	pantoprazolum anesteloc
70	gliklazyd
	fenofibrate
	bisoprolol
	phospholipids
	pantoprazol
	allopurinol
72	piracetam
	potassium kaldyum
	indapamide
	levothyroxine
	betahistine
	nicergoline
73	glimepiride
	metformin
	lisinopril
	nitrendypine
	betozk/metoprolol
	furosemid
	spironol
	losartan
	fenofibrate
	salmeterol
	ciclesonide
74	bisoprolol
	trimetazidine
	molsidomine
	simvastatine
	acetylsalicylic acid
	kalium potassium

	magnezium
75	tritace ramipril
	betaloc zoc metoprolol
	acenocumarol
	ranigast ranitydyna
	milurit allopurinol
	kalipoz potassium
	tialorid amilorid hydrochlorothiazid
76	ambroxol
	cetirizine+pseudoephedrine
77	metildigoxin
	nicergoline
	amilorid hydrochlorothiazid
	glyceryl trinitrate
	vitaminum pp
	enalapril
78	gliclazyde
	fenofibrat
	azopt
	metformina
79	paracetamol
80	rampiril
	paracetamol
81	tolperisone
	paracetamol
82	paracetamol
83	lanzoprazolum
84	bisoprolol fumarate
	indapamidum
	acetylosalicylic acid
85	perindopril
	indapamide
	acetylosalicylic acid
87	omeprazole
88	pantoprazole
	tibolone
89	pantoprazole
90	glipiride
	rampiril
	acetylosalicylic acid
91	omeprazole
93	pantoprazole
95	omeprazole
96	lansoprazol
97	atorvastatinum
	perindopril
	indapamidum

	lacidipine
	bisoprolol
	tamsulosin
98	bisoprolol
	indapamidum
	potassium kalipoz kalium
	losartan
	amlodypina
	atorvastatinum
99	enalapril
	cetirizine
	estradiol noretysterin
100	propranolol
	tocopherol
	allopurinol
101	pantoprazole
103	atorvastatin
104	enalapril
	indapamida
	atorvastatin
105	ibandronat sodic
	alpha calcidol
106	aspirin
	atorvastatin
	alendromat
	alpha calcidol
	enalapril
	indapamida
	metoprolol
107	metoprolol
	indapamida
	fenofibrat
108	enalapril
109	atorvastatin
	aspirin
	calcium
	alpha calcidol
	perindopril
	indapamida
110	enalapril
	indapamida
	aspirin
	atorvastatin
	l-tiroxin
	calcium
	alpha calcidol
111	alendronat

	calcium
	alpha calcidol
	amlodipin
	indapamida
	diosmin
	atorvastatin
113	enalapril
	indapamida
	aspirin
	atorvastatin
	nicergolinum
	tolperison
115	l-tiroxinum
	trimetazidina
	amlodipina
	carvedilol
	spironolactona
	furantril
	aspirin
	atorvastatin
	isosorbid dinitrat
	diosmin
116	ibandronat
	alpha calcidol
	calcium
	atorvastatin
	amlodipine
	aspirin
	l-thyroxin
	diosmin
117	l-thyroxine
	simvastatinum
	acid salicilicum
	omeprazol
	perindoprilum
119	risedromat
	calcium
	alpha calcidol
	pholic acid
	nicergolin
120	simvastatinum
	omeprazolum
	perindopril
	indapamid
	acid salicilic
	metoprolol
	amlodipina

	kalium aspartat
121	enalapril
	furosemide
	spironolactone
	metoprolol
	aspirin
122	amlodipina
	aspirin
	atorvastatin
	alpha calcidol
	calcium
123	simvastatin
	diosmin
124	indapamida
	enalapril
	aspirin
	rosuvastatin
125	aspirin
	rosuvastatin
	enalapril
	metoprolol
	indapamida
126	rosuvastatin
	tolperison
127	telmisartan
	nebivolol
	lecarnidipina
	spironolactona
	omeprazolum
130	levothyroxinum
131	indapamidum
	metoprololum
	phenofibratum
132	indapamidum
	enalaprilum
	metoprololum
	acidum alendronicum
133	acidum alendronicum
	captoprilum
	diltiazemum
	trimetazidinum
	atorvastatinum
134	risedronatum
	indapamidum
	enalaprilum
135	perindoprilum
	ezetimibum

136	acidum ibandronicum
	simvastatinum
138	acidum ibandronicum
	metoprololum
	omeprazolum
139	mydocalm
	movalis
	paracetamol
	famotidina
140	indapamidum
	enalaprilum
	paracetamolum
141	perindoprilum
	indapamidum
	simvastatinum
	phenofibratum
142	zofenoprilum
	lercanidipinum
	indapamidum
	nebivololum
143	indapamidum
	omeprazolum
144	tetrazepamum
145	captoprilum
	nebivolol
	amlodipinum
	trimetazidinum
	simvastatinum
	omeprazolum
	sopto carpine
146	metoprololum
	trimetazidinum
147	enalaprilum
	amlodipinum
	omeprazolum
148	simvastatinum
	captoprilum
	levotiroxinum
	diosminum
149	metoprololum
	enalapril
	trimetazidinum
	metforminum
	simvastatinum
150	simvastatinum
	enalaprilum
	indapamidum

151	fenofibratum
	rosuvastatinum
	enalaprilum
	trimetazidinum
	metforminum
152	telmisartanum
	metoprololum
	trimetazidinum
	rosuvastatinum
153	rosuvastatinum
154	enalaprilum
	trimetazidinum
	simvastatinum
	metoprololum
155	lisinoprilum
	trimetazidinum
156	simvastatinum
157	enalaprilum
	indapamidum
	fenofibratum
158	enalaprilum
	indapamidum
	isosorbid dinitratum
	acidum ibandronicum
159	ramiprilum
	betaxololum
	simvastatinum
160	perindoprilum
	trimetazidinum
	simvastatinum
161	enalaprilum
	amlodipinum
	isosorbid dinitratum
	simvastatinum
162	indapamidum
	nifedipinum
	isosorbid dinitratum
163	ac risedronic
164	ac risedronic
165	strontium ranelate
169	paracetamol
170	ac ibandronic
171	paracetamol
172	captopril
	enalapril
	warimrine
	digoxinum

	felodipine
	spironolactone
173	captoprilum
	enalaprilum
	paracetamol
174	ac risedronic
175	strontium ranelate
	paracetamol
176	captoprilum
	paracetamol
177	ac ribandronic
	enalapril
	metoprolol
178	alphacalcidol
179	ac ibandronic
181	levothyroxinum
	indapamidum
	trimetazidinum
	omeprazolum
182	diosminum
	verapamilum
	levothyroxinum
	omeprazolum
183	indapamidum
	trimetazidinum
184	felodipinum
	trimetazidinum
185	omeprazolum
186	enalaprilum
	metoprololum
	acidum alendronicum
187	perindoprilum
188	levothyroxinum
	alpha-colcidiolum
	isosorbid dinitratum
189	candesartanum
	indapamidum
	simvastatinum
190	enalaprilum
	trimetazidinum
193	ac ribandronic
	ranitidina
	paracetamol
194	enalapril
195	indapamid
196	enalapril
	tertensif

	paracetamol
197	simvastatin
198	enalapril
	tertensif
	omeprazol
199	indapamida
	perindopril
	atorvastatin
	lanzoprazol
200	glimopiridum
	enalaprilum
	indapamidum
	aspirin
	rosuvastatin
	lypanthil supra fenofibrat
	pentoxifyllinum
	nicergoline
201	metoprolol
	simvastatin
	perindopril
	doxazosinum
203	atorvastatin
	ciprofloxazin
	aspirin
	nicergolin
204	omeprazol
205	perindopril
	indapamida
206	amlodipinum
	indapamidum
	telmisartanum
	acid acetylsalicilic
	detralex
207	omeprazolum
208	perindoprilum
	indapamidum
209	omeprazolum
	loratadinum
210	metoprololum
	perindoprilum
	indapamidum
	omeprazolum
211	digoxinum
	metoprololum
	acenocumarolum
	perindoprilum
213	diosminum

215	indapamidum
216	diosminum
223	indapamidum
	enalaprilum
225	atorvastatinum
	metforminum
232	prestarium
233	prestarium
	atorvastatin
	aspenter
235	enalaprilum
236	indapamide
	siofor
	amaryl
238	ac ibandronaticum (bonviva)
239	paracetamol
	ac alendronicum
240	ac risedronicum
243	indapamid
	corvitol
	enalapril
	trimetazidine
	levothyrox
	miacalcic
244	verapamil
	telmisartan
	salmeterol/fluticason pr.
	alendronic acid
245	indapamide
	losartane
	verapamil
	salmeterol/fluticason
246	alendronic acid
247	enalapril
	vit D3 et calcium
	ibandronate
248	indapamide
	bisoprolol
251	lisinopril
	indapamide
	metoprolol
252	bisoprolol
	moxonidine
	metformine
253	telmisartan
	felodipin
	bisoprolol

	metformin
	glimepirid
254	enalapril
	metoprolol
255	indapamide
	verapamil
256	valsartan
	indapamide
	enalapril
257	trandolapril
	bisoprolol
	gliclazide mr
	metformin
259	indapamid
	metoprolol
	losartan
260	valsartan
	felodipin
	bisoprolol
261	bisoprolol
	valsartan
	amlodipin
	indipam sr
	metformin
263	bisoprolol
	enalapril
264	indapamide
265	corvetilol
	digoxin
	isosorbid dinitrate
	perindopril arginine
	metformin hydrochloride
267	metoprolol
	enalapril maleate
272	nimesulide
273	enalapril maleate
	hydrochlorothiazide
274	valsartan
	metoprolol
276	losartan
	bisoprolol
279	glucosamine sulfate
281	enalapril
	indapamide
282	bisoprolol
	indapamide
285	valsartan

	amlodipine
	carvedilol
	furosemide
	isosorbide mononitrate
	atorvastatin
287	bisoprolol
	indapamide
	metformin hydrochloride
288	moxonidine
289	losartan
	carvedilol
293	valsartan
	indapamid
294	verapamil
	indapamid
295	fosinopril
	carvedilol
296	bisoprolol
	isosorbide dinitrate
	trimetazidine dihydrochloride
	hydrochlorthiazide
297	indapamide
	amlodipine mesilate
	enalapril maleate
298	trandolapril
	indapamide
	bisoprolol
299	amlodipine mesilate
	nifedipin
	metformin hydrochloride
	glimepiride
300	enalapril maleate

Table 47: Baseline values – test for normality

Tests of Normality[b]

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig	Statistic	df	Sig
Age	,074	150	,043	,972	150	,003
Height	,133	150	,000	,930	150	,000

Tests of Normality[b]

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
Weight	,088	150	,006	,949	150	,000
BMI	,089	150	,006	,929	150	,000
Systolic Blood Pressure	,179	150	,000	,918	150	,000
Diastolic Blood Pressure	,221	150	,000	,897	150	,000
Heart rate	,095	150	,002	,979	150	,022
Kellgren-Lawrence score	,296	150	,000	,790	150	,000

a. Lilliefors Significance Correction

b. was assigned to the following treatment group = PAST

Tests of Normality[b]

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig	Statistic	df	Sig
Age	,059	150	,200*	,983	150	,069
Height	,077	150	,030	,986	150	,124
Weight	,092	150	,003	,960	150	,000
BMI	,081	150	,019	,956	150	,000
Diastolic Blood Pressure	,236	150	,000	,853	150	,000
Heart rate	,104	150	,000	,975	150	,008

Tests of Normality[b]

	Kolmogorov-Smirnov[a]	Shapiro-Wilk

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.

b. was assigned to the following treatment group = STO

Table 48: Homogeneity of age according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Age	300	61.83	9,095	45	86
treatment group	300	1.50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Age	PAST	150	145.69	21854,00
	STO	150	155.31	23296,00
	Total	300		

Test Statistics[a]

	Age
Mann-Whitney U	10529,000
Wilcoxon W	21854,000
Z	-,960
Asymp. Sig. (2-tailed)	,337

a. Grouping Variable: was assigned to the following treatment group

Table 49: Homogeneity of height according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Height	300	163,21	8,013	140	202
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Height	PAST	150	145,86	21879,50
	STO	150	155,14	23270,50
	Total	300		

Test Statistics[a]

	Height
Mann-Whitney U	10554,500
Wilcoxon W	21879,500
Z	-,928
Asymp. Sig. (2-tailed)	,354

a. Grouping Variable: was assigned to the following treatment group

Table 50: Homogeneity of weight according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Weight	300	77,78	14,676	45	147
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Weight	PAST	150	145,64	21845,50
	STO	150	155,36	23304,50
	Total	300		

Test Statistics[a]

	Weight
Mann-Whitney U	10520,500
Wilcoxon W	21845,500
Z	-,972
Asymp. Sig. (2-tailed)	,331

a. Grouping Variable: was assigned to the following treatment group

Table 51: Homogeneity of BMI according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
BMI	300	29,2079	5,21985	19,81	56,01
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
BMI	PAST	150	145,91	21887,00
	STO	150	155,09	23263,00
	Total	300		

Test Statistics[a]

	BMI
Mann-Whitney U	10562,000
Wilcoxon W	21887,000
Z	-,916
Asymp. Sig. (2-tailed)	,360

a. Grouping Variable: was assigned to the following treatment group

Table 52: Homogeneity of systolic blood pressure according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Systolic Blood Pressure	300	129,58	12,648	100	180
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Systolic Blood Pressure	PAST	150	142,94	21441,00
	STO	150	158,06	23709,00
	Total	300		

Test Statistics[a]

	Systolic Blood Pressure
Mann-Whitney U	10116,000
Wilcoxon W	21441,000
Z	-1,539
Asymp. Sig. (2-tailed)	,124

a. Grouping Variable: was assigned to the following treatment group

Table 53: Homogeneity of diastolic blood pressure according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Diastolic Blood Pressure	300	76,65	7,542	60	120
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Diastolic Blood Pressure	PAST	150	148,56	22284,50
	STO	150	152,44	22865,50
	Total	300		

Test Statistics[a]

	Diastolic Blood Pressure
Mann-Whitney U	10959,500
Wilcoxon W	22284,500
Z	-,409
Asymp. Sig. (2-tailed)	,682

a. Grouping Variable: was assigned to the following treatment group

Table 54: Homogeneity of heart rate according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Heart rate	300	73,71	6,575	54	95
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Heart rate	PAST	150	150,67	22600,50
	STO	150	150,33	22549,50
	Total	300		

Test Statistics[a]

	Heart rate
Mann-Whitney U	11224,500
Wilcoxon W	22549,500
Z	-,034
Asymp. Sig. (2-tailed)	,973

a. Grouping Variable: was assigned to the following treatment group

Table 55: Homogeneity of breath rate according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Breath rate	300	16,83	2,706	12	28
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Breath rate	PAST	150	148,99	22348,50
	STO	150	152,01	22801,50
	Total	300		

Test Statistics[a]

	Breath rate
Mann-Whitney U	11023,500
Wilcoxon W	22348,500
Z	-,306
Asymp. Sig. (2-tailed)	,760

a. Grouping Variable: was assigned to the following treatment group

Table 56: Homogeneity of Kellgren-Lawrence score according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Kellgren-Lawrence score	300	1,96	,632	1	3
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Kellgren-Lawrence score	PAST	150	145,62	21843,00
	STO	150	155,38	23307,00
	Total	300		

Test Statistics[a]

	Kellgren-Lawrence score
Mann-Whitney U	10518,000
Wilcoxon W	21843,000
Z	-1,112
Asymp. Sig. (2-tailed)	,266

a. Grouping Variable: was assigned to the following treatment group

Table 57: Efficacy parameters: test for normality

Tests of Normality

	treatment group	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Total index	PAST	,073	143	,056	,965	143	,001
	STO	,097	148	,002	,954	148	,000
Total index2	PAST	,100	143	,001	,971	143	,004
	STO	,062	148	,200*	,980	148	,033
Total index3	PAST	,097	143	,002	,973	143	,006
	STO	,069	148	,080	,986	148	,126
Total index4	PAST	,090	143	,006	,979	143	,028
	STO	,087	148	,008	,982	148	,045
Total index5	PAST	,099	143	,002	,961	143	,000
	STO	,052	148	,200*	,989	148	,307
quality_of_life1	PAST	,117	143	,000	,972	143	,005
	STO	,106	148	,000	,979	148	,026
quality_of_life2	PAST	,085	143	,014	,978	143	,021
	STO	,101	148	,001	,975	148	,009
quality_of_life3	PAST	,145	143	,000	,908	143	,000
	STO	,094	148	,003	,971	148	,003
quality_of_life4	PAST	,135	143	,000	,935	143	,000
	STO	,117	148	,000	,976	148	,010
quality_of_life5	PAST	,125	143	,000	,976	143	,013
	STO	,111	148	,000	,960	148	,000
VAS	PAST	,147	143	,000	,926	143	,000
	STO	,126	148	,000	,942	148	,000
VAS2	PAST	,064	143	,200*	,982	143	,054
	STO	,065	148	,200*	,990	148	,339
VAS3	PAST	,091	143	,005	,968	143	,002

	STO	,069	148	,080	,984	148	,083
VAS4	PAST	,099	143	,002	,947	143	,000
	STO	,082	148	,017	,987	148	,197
VAS5	PAST	,127	143	,000	,916	143	,000
	STO	,062	148	,200*	,986	148	,144

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.

Table 58: Homogeneity of Lequesne-index according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Total index	300	12,603	4,1076	5,0	22,0
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Total index	PAST	150	147,49	22123,00
	STO	150	153,51	23027,00
	Total	300		

Test Statistics[a]

	Total index
Mann-Whitney U	10798,000
Wilcoxon W	22123,000
Z	-,602
Asymp. Sig. (2-tailed)	,547

a. Grouping Variable: was assigned to the following treatment group

Table 59: Homogeneity of VAS according to randomization at baseline (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
VAS	300	39,93	7,074	23	50
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
VAS	PAST	150	155,14	23270,50
	STO	150	145,86	21879,50
	Total	300		

Test Statistics[a]

	VAS
Mann-Whitney U	10554,500
Wilcoxon W	21879,500
Z	-,928
Asymp. Sig. (2-tailed)	,354

a. Grouping Variable: was assigned to the following treatment group

Table 60: Homogeneity of Lequesne-index according to randomization at visit 5 (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
Lequesne-index 5	294	8,090	4,5560	,0	21,5
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
Lequesne-index 5	PAST	146	109,08	15925,00
	STO	148	185,41	27440,00
	Total	294		

Test Statistics[a]

	Total index5
Mann-Whitney U	5194,000
Wilcoxon W	15925,000
Z	-7,705
Asymp. Sig. (2-tailed)	,000

a. Grouping Variable: was assigned to the following treatment group

Table 61: Homogeneity of VAS according to randomization at visit 5 (Mann-Whitney test)

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
VAS 5	294	26,15	17,120	0	75
treatment group	300	1,50	,501	1	2

Ranks

	treatment group	N	Mean Rank	Sum of Ranks
VAS5	PAST	146	111,62	16297,00
	STO	148	182,89	27068,00
	Total	294		

Test Statistics[a]

	VAS5
Mann-Whitney U	5566,000
Wilcoxon W	16297,000
Z	-7,191
Asymp. Sig. (2-tailed)	,000

a. Grouping Variable: **was assigned to** the following treatment group

Table 62: Repeated between groups comparison of number of patients weaning off from NSAID (chi-square test)

Visit 2

$\chi^2(1) = 20{,}55$; $p<0{,}001$ – highly significant difference

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	20,550[a]	1	,000		
Continuity Correction[b]	18,731	1	,000		
Likelihood Ratio	23,878	1	,000		
Fisher's Exact Test				,000	,000
Linear-by-Linear Association	20,481	1	,000		
N of Valid Cases	299				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 12,96.

b. Computed only for a 2x2 table

Visit 3 $\chi^2(1) = 12{,}39$; $p<0{,}001$ – highly significant difference

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	12,359[a]	1	,000		
Continuity Correction[b]	11,077	1	,001		
Likelihood Ratio	12,972	1	,000		
Fisher's Exact Test				,001	,000
Linear-by-Linear Association	12,317	1	,000		
N of Valid Cases	293				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 15,62.

b. Computed only for a 2x2 table

Visit 4

$\chi^2(1) = 31,53$; $p<0,001$ – highly significant difference

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	31,535[a]	1	,000		
Continuity Correction[b]	29,800	1	,000		
Likelihood Ratio	34,293	1	,000		
Fisher's Exact Test				,000	,000
Linear-by-Linear Association	31,427	1	,000		
N of Valid Cases	291				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 24,08.

b. Computed only for a 2x2 table

Visit 5

$\chi^2(1) = 34,28$; $p<0,001$ – highly significant difference

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	34,283[a]	1	,000		
Continuity Correction[b]	32,640	1	,000		
Likelihood Ratio	36,627	1	,000		
Fisher's Exact Test				,000	,000
Linear-by-Linear Association	34,167	1	,000		
N of Valid Cases	295				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 31,39.

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	34,283[a]	1	,000		
Continuity Correction[b]	32,640	1	,000		
Likelihood Ratio	36,627	1	,000		
Fisher's Exact Test				,000	,000
Linear-by-Linear Association	34,167	1	,000		
N of Valid Cases	295				

a. 0 cells (,0%) have expected count less than 5. The minimum expected count is 31,39.

b. Computed only for a 2x2 table

Table 63: Repeated measures ANOVA for Lequesne-index

Within-Subjects Factors

Measure:MEASURE_1

time	Dependent Variable
1	Totalindex
2	Lequesne2
3	Lequesne3
4	Lequesne4
5	Lequesne5

Between-Subjects Factors

		Value Label	N
was assigned to the following treatment group	1	PAST	143
	2	STO	148

Box's Test of Equality of Covariance Matrices[a]

Box's M	31,501
F	2,061
df1	15
df2	335421,923
Sig.	,009

Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal across groups.

a. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Multivariate Tests[b]

Effect		Value	F	Hypothesis df	Error df	Sig.	Partial Eta Squared
time	Pillai's Trace	,592	103,582[a]	4,000	286,000	,000	,592
	Wilks' Lambda	,408	103,582[a]	4,000	286,000	,000	,592
	Hotelling's Trace	1,449	103,582[a]	4,000	286,000	,000	,592
	Roy's Largest Root	1,449	103,582[a]	4,000	286,000	,000	,592
time *	Pillai's Trace	,195	17,276[a]	4,000	286,000	,000	,195

	Wilks' Lambda	,805	17,276[a]	4,000	286,000	,000	,195
	Hotelling's Trace	,242	17,276[a]	4,000	286,000	,000	,195
	Roy's Largest Root	,242	17,276[a]	4,000	286,000	,000	,195

a. Exact statistic

b. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[a]		
					Greenhouse-Geisser	Huynh-Feldt	Lower-bound
time	,174	501,971	9	,000	,512	,518	,250

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
time	Sphericity Assumed	3853,577	4	963,394	268,281	,000	,481
	Greenhouse-Geisser	3853,577	2,048	1881,231	268,281	,000	,481
	Huynh-Feldt	3853,577	2,070	1861,304	268,281	,000	,481
	Lower-bound	3853,577	1,000	3853,577	268,281	,000	,481
time * wasassignedtothefollowingtreatmentgroup	Sphericity Assumed	635,426	4	158,857	44,238	,000	,133
	Greenhouse-Geisser	635,426	2,048	310,201	44,238	,000	,133
	Huynh-Feldt	635,426	2,070	306,915	44,238	,000	,133
	Lower-bound	635,426	1,000	635,426	44,238	,000	,133
Error(time)	Sphericity Assumed	4151,183	1156	3,591			
	Greenhouse-Geisser	4151,183	591,997	7,012			
	Huynh-Feldt	4151,183	598,335	6,938			
	Lower-bound	4151,183	289,000	14,364			

Tests of Within-Subjects Contrasts

Measure:MEASURE_1

Source	time	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
time	Level 1 vs. Level 2	1338,619	1	1338,619	208,876	,000	,420
	Level 2 vs. Level 3	282,698	1	282,698	108,037	,000	,272
	Level 3 vs. Level 4	248,330	1	248,330	81,614	,000	,220
	Level 4 vs. Level 5	91,295	1	91,295	30,578	,000	,096
time * wasassignedtothefollowingtreatmentgroup	Level 1 vs. Level 2	207,434	1	207,434	32,368	,000	,101
	Level 2 vs. Level 3	64,884	1	64,884	24,796	,000	,079
	Level 3 vs. Level 4	21,505	1	21,505	7,068	,008	,024
	Level 4 vs. Level 5	26,786	1	26,786	8,972	,003	,030
Error(time)	Level 1 vs. Level 2	1852,104	289	6,409			
	Level 2 vs. Level 3	756,221	289	2,617			
	Level 3 vs. Level 4	879,347	289	3,043			
	Level 4 vs. Level 5	862,834	289	2,986			

Levene's Test of Equality of Error Variances[a]

	F	df1	df2	Sig.
Total index	1,423	1	289	,234
Total index2	1,168	1	289	,281
Total index3	3,339	1	289	,069
Total index4	9,614	1	289	,002
Total index5	9,647	1	289	,002

Tests the null hypothesis that the error variance of the dependent variable is equal across groups.

a. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Tests of Between-Subjects Effects

Measure:MEASURE_1

Transformed Variable:Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Intercept	28374,981	1	28374,981	2139,161	,000	,881
wasassignedtothefollowingtreatmentgroup	500,049	1	500,049	37,698	,000	,115
Error	3833,451	289	13,265			

Table 64:Repeated measures ANOVA for pain (VAS)

Within-Subjects Factors

Measure:MEASURE_1

time	Dependent Variable
1	VAS
2	VAS2
3	VAS3
4	VAS4
5	VAS5

Between-Subjects Factors

		Value Label	N
was assigned to the following treatment group	1	PAST	143
	2	STO	148

Box's Test of Equality of Covariance Matrices[a]

Box's M	27,321
F	1,788
df1	15
df2	335421,923
Sig.	,030

Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal across groups.

a. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Multivariate Tests[b]

Effect		Value	F	Hypothesis df	Error df	Sig.	Partial Eta Squared
time	Pillai's Trace	,474	64,387[a]	4,000	286,000	,000	,474
	Wilks' Lambda	,526	64,387[a]	4,000	286,000	,000	,474
	Hotelling's Trace	,901	64,387[a]	4,000	286,000	,000	,474
	Roy's Largest Root	,901	64,387[a]	4,000	286,000	,000	,474
time * wasassignedtothefollowingtreatmentgroup	Pillai's Trace	,215	19,584[a]	4,000	286,000	,000	,215
	Wilks' Lambda	,785	19,584[a]	4,000	286,000	,000	,215
	Hotelling's Trace	,274	19,584[a]	4,000	286,000	,000	,215
	Roy's Largest Root	,274	19,584[a]	4,000	286,000	,000	,215

a. Exact statistic

b. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Mauchly's Test of Sphericity[b]

Measure:MEASURE_1

Within Subjects Effect	Mauchly's W	Approx. Chi-Square	df	Sig.	Epsilon[a]		
					Greenhouse-Geisser	Huynh-Feldt	Lower-bound
time	,382	276,455	9	,000	,660	,669	,250

Tests the null hypothesis that the error covariance matrix of the orthonormalized transformed dependent variables is proportional to an identity matrix.

a. May be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed in the Tests of Within-Subjects Effects table.

b. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Tests of Within-Subjects Effects

Measure:MEASURE_1

Source		Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
time	Sphericity Assumed	34801,532	4	8700,383	141,842	,000	,329
	Greenhouse-Geisser	34801,532	2,639	13186,613	141,842	,000	,329
	Huynh-Feldt	34801,532	2,675	13010,272	141,842	,000	,329
	Lower-bound	34801,532	1,000	34801,532	141,842	,000	,329
time * wasassignedtothefollowingtreatmentgroup	Sphericity Assumed	10479,016	4	2619,754	42,710	,000	,129
	Greenhouse-Geisser	10479,016	2,639	3970,594	42,710	,000	,129
	Huynh-Feldt	10479,016	2,675	3917,496	42,710	,000	,129
	Lower-bound	10479,016	1,000	10479,016	42,710	,000	,129
Error(time)	Sphericity Assumed	70907,577	1156	61,339			
	Greenhouse-Geisser	70907,577	762,716	92,967			

	Huynh-Feldt	70907,577	773,054	91,724			
	Lower-bound	70907,577	289,000	245,355			

Tests of Within-Subjects Contrasts

Measure:MEASURE_1

Source	time	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
time	Level 1 vs. Level 2	10474,144	1	10474,144	94,684	,000	,247
	Level 2 vs. Level 3	3988,383	1	3988,383	60,439	,000	,173
	Level 3 vs. Level 4	1420,402	1	1420,402	23,839	,000	,076
	Level 4 vs. Level 5	1054,325	1	1054,325	15,463	,000	,051
time * wasassignedtothefollowingtreatmentgroup	Level 1 vs. Level 2	2654,351	1	2654,351	23,995	,000	,077
	Level 2 vs. Level 3	836,713	1	836,713	12,679	,000	,042
	Level 3 vs. Level 4	746,175	1	746,175	12,524	,000	,042
	Level 4 vs. Level 5	567,727	1	567,727	8,326	,004	,028
Error(time)	Level 1 vs. Level 2	31969,876	289	110,622			
	Level 2 vs. Level 3	19071,273	289	65,991			
	Level 3 vs. Level 4	17219,172	289	59,582			
	Level 4 vs. Level 5	19705,063	289	68,184			

Levene's Test of Equality of Error Variances[a]

	F	df1	df2	Sig.
VAS	,165	1	289	,685
VAS2	1,362	1	289	,244
VAS3	2,294	1	289	,131
VAS4	,159	1	289	,691
VAS5	,018	1	289	,892

Tests the null hypothesis that the error variance of the dependent variable is equal across groups.

a. Design: Intercept + wasassignedtothefollowingtreatmentgroup
Within Subjects Design: time

Tests of Between-Subjects Effects

Measure:MEASURE_1

Transformed Variable:Average

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	Partial Eta Squared
Intercept	288766,117	1	288766,117	2477,815	,000	,896
wasassignedtothefollowingtreatmentgroup	4751,665	1	4751,665	40,773	,000	,124
Error	33680,237	289	116,541			

Table 65: Visit 1 - Question: In general, would you say your health is....

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Excellent	0	0.0	0.0	0.0
	Very good	8	5.3	5.3	5.3
	Good	46	30.7	30.7	36.0
	Fair	79	52.7	52.7	88.7
	Poor	17	11.3	11.3	100.0
	Total	150	100.0	100.0	
STO	Excellent	0	0.0	0.0	0.0
	Very good	6	4.0	4.0	4.0
	Good	51	34.0	34.0	38.0
	Fair	75	50.0	50.0	88.0
	Poor	18	12.0	12.0	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
In general, would you say your health is ...	dimension1 PAST	150	151.07	22660.50
	STO	150	149.93	22489.50
	Total	300		

Test Statistics[a]

	In general, would you say your health is ...
Mann-Whitney U	11164.500
Wilcoxon W	22489.500
Z	-.125
Asymp. Sig. (2-tailed)	.901

a. Grouping Variable: was assigned to the following treatment group

Table 66: Visit 1 - Question: **Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	54	36.0	36.0	36.0
	Limited a little	80	53.3	53.3	89.3
	Not limited at all	16	10.7	10.7	100.0
	Total	150	100.0	100.0	
STO	Limited a lot	58	38.7	38.7	38.7
	Limited a little	76	50.7	50.7	89.3
	Not limited at all	16	10.7	10.7	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much? dimension1	PAST	150	152.29	22843.00
	STO	150	148.71	22307.00
	Total	300		

Test Statistics[a]

	Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?
Mann-Whitney U	10982.000
Wilcoxon W	22307.000
Z	-.397
Asymp. Sig. (2-tailed)	.691

a. Grouping Variable: was assigned to the following treatment group

Table 67: Visit 1 - Question: **Does your health now limit you in climbing several flights of stairs?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	76	50.7	50.7	50.7
	Limited a little	71	47.3	47.3	98.0
	Not limited at all	3	2.0	2.0	100.0
	Total	150	100.0	100.0	
STO	Limited a lot	83	55.3	55.3	55.3
	Limited a little	65	43.3	43.3	98.7
	Not limited at all	2	1.3	1.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
Does your health now limit you in climbing several flights of stairs?	dimension1	PAST	150	154.18	23126.50
		STO	150	146.82	22023.50
		Total	300		

Test Statistics[a]

	Does your health now limit you in climbing several flights of stairs?
Mann-Whitney U	10698.500
Wilcoxon W	22023.500
Z	-.843
Asymp. Sig. (2-tailed)	.399

a. Grouping Variable: was assigned to the following treatment group

Table 68: Visit 1 - Question: During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	42	28.0	28.0	28.0
	No	108	72.0	72.0	100.0
	Total	150	100.0	100.0	
STO	Yes	49	32.7	32.7	32.7
	No	101	67.3	67.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious? dimension1	PAST	150	151.00	22650.00
	STO	150	150.00	22500.00
	Total	300		

Test Statistics[a]

	During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?
Mann-Whitney U	11175.000
Wilcoxon W	22500.000
Z	-.115
Asymp. Sig. (2-tailed)	.908

a. Grouping Variable: was assigned to the following treatment group

Table 69: Visit 1 - Question: **During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	46	30.7	30.7	30.7
	No	104	69.3	69.3	100.0
	Total	150	100.0	100.0	
STO	Yes	43	28.7	28.7	28.7
	No	107	71.3	71.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?	dimension1	PAST	150	149.00	22350.00
		STO	150	152.00	22800.00
		Total	300		

Test Statistics[a]

	During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?
Mann-Whitney U	11025.000
Wilcoxon W	22350.000
Z	-.379
Asymp. Sig. (2-tailed)	.705

a. Grouping Variable: was assigned to the following treatment group

Table 70: Visit 1 - Question: **During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	73	48.7	48.7	48.7
	No	77	51.3	51.3	100.0
	Total	150	100.0	100.0	
STO	Yes	74	49.3	49.3	49.3
	No	76	50.7	50.7	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious? dimension1	PAST	150	151.00	22650.00
	STO	150	150.00	22500.00
	Total	300		

Test Statistics[a]

	During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?
Mann-Whitney U	11175.000
Wilcoxon W	22500.000
Z	-.115
Asymp. Sig. (2-tailed)	.908

a. Grouping Variable: was assigned to the following treatment group

Table 71: Visit 1 - Question: During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	75	50.0	50.0	50.0
	No	75	50.0	50.0	100.0
	Total	150	100.0	100.0	
STO	Yes	70	46.7	46.7	46.7
	No	80	53.3	53.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?	dimension1	PAST	150	148.00	22200.00
		STO	150	153.00	22950.00
		Total	300		

Test Statistics[a]

	During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?
Mann-Whitney U	10875.000
Wilcoxon W	22200.000
Z	-.577
Asymp. Sig. (2-tailed)	.564

a. Grouping Variable: was assigned to the following treatment group

Table 72: Visit 1 - Question: **During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Not at all	0	0.0	0.0	0.0
	Slightly	24	16.0	16.0	16.0
	Moderately	83	55.3	55.3	71.3
	Quite a bit	43	28.7	28.7	100.0
	Extremely	0	0.0	0.0	100.0
	Total	150	100.0	100.0	
STO	Not at all	0	0.0	0.0	0.0
	Slightly	18	12.0	12.0	12.0
	Moderately	71	47.3	47.3	59.3
	Quite a bit	59	39.3	39.3	98.7
	Extremely	2	1.3	1.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?	dimension1	PAST	150	140.51	21077.00
		STO	150	160.49	24073.00
		Total	300		

Test Statistics[a]

	During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?
Mann-Whitney U	9752.000
Wilcoxon W	21077.000
Z	-2.198
Asymp. Sig. (2-tailed)	.028

a. Grouping Variable: was assigned to the following treatment group

Table 73: Visit 1 - Question: **How much time during the past 4 weeks have you feel calm and peaceful?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	5	3.3	3.3	3.3
	Most of the time	14	9.3	9.3	12.7
	A good bit of the time	33	22.0	22.0	34.7
	Some of the time	71	47.3	47.3	82.0
	A little of the time	26	17.3	17.3	99.3
	None of the time	1	.7	.7	100.0
	Total	150	100.0	100.0	
STO	All of the time	1	.7	.7	.7
	Most of the time	26	17.3	17.3	18.0
	A good bit of the time	26	17.3	17.3	35.3
	Some of the time	55	36.7	36.7	72.0
	A little of the time	40	26.7	26.7	98.7
	None of the time	2	1.3	1.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks have you feel calm and peaceful?	dimension1	PAST	150	146.91	22036.00
		STO	150	154.09	23114.00
		Total	300		

Test Statistics[a]

	How much time during the past 4 weeks have you feel calm and peaceful?
Mann-Whitney U	10711.000
Wilcoxon W	22036.000
Z	-.754
Asymp. Sig. (2-tailed)	.451

a. Grouping Variable: was assigned to the following treatment group

Table 74: Visit 1 - Question: How much time during the past 4 weeks did you have a lot of energy?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	5	3.3	3.3	3.3
	Most of the time	11	7.3	7.3	10.7
	A good bit of the time	32	21.3	21.3	32.0
	Some of the time	63	42.0	42.0	74.0
	A little of the time	35	23.3	23.3	97.3
	None of the time	4	2.7	2.7	100.0
	Total	150	100.0	100.0	
STO	All of the time	2	1.3	1.3	1.3
	Most of the time	8	5.3	5.3	6.7
	A good bit of the time	20	13.3	13.3	20.0
	Some of the time	78	52.0	52.0	72.0
	A little of the time	39	26.0	26.0	98.0
	None of the time	3	2.0	2.0	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks did you have a lot of energy? dimension1	PAST	150	142.93	21439.50
	STO	150	158.07	23710.50
	Total	300		

Test Statistics[a]

	How much time during the past 4 weeks did you have a lot of energy?
Mann-Whitney U	10114.500
Wilcoxon W	21439.500
Z	-1.615
Asymp. Sig. (2-tailed)	.106

a. Grouping Variable: was assigned to the following treatment group

Table 75: Visit 1 - Question: **How much time during the past 4 weeks did you feel down?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	0	0.0	0.0	0.0
	Most of the time	12	8.0	8.0	8.0
	A good bit of the time	32	21.3	21.3	29.3
	Some of the time	57	38.0	38.0	67.3
	A little of the time	35	23.3	23.3	90.7
	None of the time	14	9.3	9.3	100.0
	Total	150	100.0	100.0	
STO	All of the time	1	.7	.7	.7
	Most of the time	19	12.7	12.7	13.3
	A good bit of the time	21	14.0	14.0	27.3
	Some of the time	58	38.7	38.7	66.0
	A little of the time	43	28.7	28.7	94.7
	None of the time	8	5.3	5.3	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks did you feel down?	dimension1	PAST	150	151.19	22678.50
		STO	150	149.81	22471.50
		Total	300		

Test Statistics[a]

	How much time during the past 4 weeks did you feel down?
Mann-Whitney U	11146.500
Wilcoxon W	22471.500
Z	-.144
Asymp. Sig. (2-tailed)	.886

a. Grouping Variable: was assigned to the following treatment group

Table 76: Visit 1 - Question: During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities like visiting with friends, relatives, etc. ?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	0	0.0	0.0	0.0
	Most of the time	22	14.7	14.7	14.7
	A good bit of the time	27	18.0	18.0	32.7
	Some of the time	59	39.3	39.3	72.0
	A little of the time	20	13.3	13.3	85.3
	None of the time	22	14.7	14.7	100.0
	Total	150	100.0	100.0	
STO	All of the time	1	.7	.7	.7
	Most of the time	22	14.7	14.7	15.3
	A good bit of the time	35	23.3	23.3	38.7
	Some of the time	54	36.0	36.0	74.7
	A little of the time	23	15.3	15.3	90.0
	None of the time	15	10.0	10.0	100.0
	Total	150	100.0	100.0	

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks did you feel down?	dimension1	PAST	150	151.19	22678.50
		STO	150	149.81	22471.50
		Total	300		

Test Statistics[a]

	How much time during the past 4 weeks did you feel down?
Mann-Whitney U	11146.500
Wilcoxon W	22471.500
Z	-.144
Asymp. Sig. (2-tailed)	.886

a. Grouping Variable: was assigned to the following treatment group

Table 77: Frequency tables Visit 2

Question: In general, would you say your health is....

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Excellent	2	1.3	1.3	1.3
	Very good	14	9.3	9.4	10.7
	Good	82	54.7	55.0	65.8
	Fair	38	25.3	25.5	91.3
	Poor	13	8.7	8.7	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Excellent	1	.7	.7	.7
	Very good	8	5.3	5.3	6.0
	Good	64	42.7	42.7	48.7
	Fair	64	42.7	42.7	91.3
	Poor	13	8.7	8.7	100.0
	Total	150	100.0	100.0	

Question: **Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	23	15.3	15.4	15.4
	Limited a little	93	62.0	62.4	77.9
	Not limited at all	33	22.0	22.1	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Limited a lot	39	26.0	26.0	26.0
	Limited a little	91	60.7	60.7	86.7
	Not limited at all	20	13.3	13.3	100.0
	Total	150	100.0	100.0	

Question: **Does your health now limit you in climbing several flights of stairs?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	38	25.3	25.5	25.5
	Limited a little	105	70.0	70.5	96.0
	Not limited at all	6	4.0	4.0	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Limited a lot	69	46.0	46.0	46.0
	Limited a little	78	52.0	52.0	98.0
	Not limited at all	3	2.0	2.0	100.0
	Total	150	100.0	100.0	

Question: During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	87	58.0	58.4	58.4
	No	62	41.3	41.6	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Yes	61	40.7	40.7	40.7
	No	89	59.3	59.3	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	87	58.0	58.4	58.4
	No	62	41.3	41.6	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Yes	59	39.3	39.3	39.3
	No	91	60.7	60.7	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	111	74.0	74.5	74.5
	No	38	25.3	25.5	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Yes	85	56.7	56.7	56.7
	No	65	43.3	43.3	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	114	76.0	76.5	76.5
	No	35	23.3	23.5	100.0
	Total	149	99.3	100.0	
	Missing data	1	.7		
STO	Yes	78	52.0	52.0	52.0
	No	72	48.0	48.0	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Not at all	2	1.3	1.3	1.3
	Slightly	55	36.7	36.9	38.3
	Moderately	68	45.3	45.6	83.9
	Quite a bit	23	15.3	15.4	99.3
	Extremely	1	.7	.7	100.0
	Total	149	99.3	100.0	
		1	.7		
STO	Not at all	2	1.3	1.3	1.3
	Slightly	32	21.3	21.3	22.7
	Moderately	73	48.7	48.7	71.3
	Quite a bit	39	26.0	26.0	97.3
	Extremely	4	2.7	2.7	100.0
	Total	150	100.0	100.0	

Question: **How much time during the past 4 weeks have you feel calm and peaceful?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	9	6.0	6.0	6.0
	Most of the time	29	19.3	19.5	25.5
	A good bit of the time	46	30.7	30.9	56.4
	Some of the time	56	37.3	37.6	94.0
	A little of the time	8	5.3	5.4	99.3
	None of the time	1	.7	.7	100.0
	Total	149	99.3	100.0	
		1	.7		
STO	All of the time	5	3.3	3.3	3.3
	Most of the time	25	16.7	16.7	20.0
	A good bit of the time	35	23.3	23.3	43.3
	Some of the time	56	37.3	37.3	80.7
	A little of the time	28	18.7	18.7	99.3
	None of the time	1	.7	.7	100.0
	Total	150	100.0	100.0	

Question: **How much time during the past 4 weeks did you have a lot of energy?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	7	4.7	4.7	4.7
	Most of the time	22	14.7	14.8	19.5
	A good bit of the time	52	34.7	34.9	54.4
	Some of the time	55	36.7	36.9	91.3
	A little of the time	12	8.0	8.1	99.3
	None of the time	1	.7	.7	100.0
	Total	149	99.3	100.0	
		1	.7		
STO	All of the time	15	10.0	10.0	10.0
	Most of the time	44	29.3	29.3	39.3
	A good bit of the time	65	43.3	43.3	82.7
	Some of the time	25	16.7	16.7	99.3
	A little of the time	1	.7	.7	100.0
	None of the time	150	100.0	100.0	
	Total				

Question: **How much time during the past 4 weeks did you feel down?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	2	1.3	1.3	1.3
	Most of the time	5	3.3	3.4	4.7
	A good bit of the time	20	13.3	13.4	18.1
	Some of the time	39	26.0	26.2	44.3
	A little of the time	52	34.7	34.9	79.2
	None of the time	31	20.7	20.8	100.0
	Total	149	99.3	100.0	
		1	.7		
STO	All of the time	2	1.3	1.3	1.3
	Most of the time	13	8.7	8.7	10.0
	A good bit of the time	33	22.0	22.0	32.0
	Some of the time	45	30.0	30.0	62.0
	A little of the time	38	25.3	25.3	87.3
	None of the time	19	12.7	12.7	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities like visiting with friends, relatives, etc. ?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	0	0.0	0.0	0.0
	Most of the time	7	4.7	4.7	4.7
	A good bit of the time	22	14.7	14.8	19.5
	Some of the time	42	28.0	28.2	47.7
	A little of the time	52	34.7	34.9	82.6
	None of the time	26	17.3	17.4	100.0
	Total	149	99.3	100.0	
		1	.7		
STO	All of the time	1	.7	.7	.7
	Most of the time	14	9.3	9.3	10.0
	A good bit of the time	35	23.3	23.3	33.3
	Some of the time	56	37.3	37.3	70.7
	A little of the time	24	16.0	16.0	86.7
	None of the time	20	13.3	13.3	100.0
	Total	150	100.0	100.0	

Table 78: Frequency tables Visit 3

Question: In general, would you say your health is....

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Excellent	4	2.7	2.8	2.8
	Very good	22	14.7	15.4	18.2
	Good	79	52.7	55.2	73.4
	Fair	30	20.0	21.0	94.4
	Poor	8	5.3	5.6	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Excellent	0	0.0	0.0	0.0
	Very good	11	7.3	7.3	7.3
	Good	77	51.3	51.3	58.7
	Fair	51	34.0	34.0	92.7
	Poor	11	7.3	7.3	100.0
	Total	150	100.0	100.0	

Question: **Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	13	8.7	9.1	9.1
	Limited a little	86	57.3	60.1	69.2
	Not limited at all	44	29.3	30.8	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Limited a lot	38	25.3	25.3	25.3
	Limited a little	93	62.0	62.0	87.3
	Not limited at all	19	12.7	12.7	100.0
	Total	150	100.0	100.0	

Question: **Does your health now limit you in climbing several flights of stairs?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	22	14.7	15.4	15.4
	Limited a little	104	69.3	72.7	88.1
	Not limited at all	17	11.3	11.9	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Limited a lot	62	41.3	41.3	41.3
	Limited a little	83	55.3	55.3	96.7
	Not limited at all	5	3.3	3.3	100.0
	Total	150	100.0	100.0	

Question: During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	100	66.7	69.9	69.9
	No	43	28.7	30.1	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	65	43.3	43.3	43.3
	No	85	56.7	56.7	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	97	64.7	67.8	67.8
	No	46	30.7	32.2	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	63	42.0	42.0	42.0
	No	87	58.0	58.0	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	119	79.3	83.2	83.2
	No	24	16.0	16.8	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	80	53.3	53.3	53.3
	No	70	46.7	46.7	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	115	76.7	80.4	80.4
	No	28	18.7	19.6	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	75	50.0	50.0	50.0
	No	75	50.0	50.0	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Not at all	7	4.7	4.9	4.9
	Slightly	70	46.7	49.0	53.8
	Moderately	53	35.3	37.1	90.9
	Quite a bit	13	8.7	9.1	100.0
	Extremely	0	0.0	0.0	
	Total	143	95.3	100.0	
		7	4.7		
STO	Not at all	4	2.7	2.7	2.7
	Slightly	29	19.3	19.3	22.0
	Moderately	76	50.7	50.7	72.7
	Quite a bit	40	26.7	26.7	99.3
	Extremely	1	.7	.7	100.0
	Total	150	100.0	100.0	

Question: **How much time during the past 4 weeks have you feel calm and peaceful?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	13	8.7	9.1	9.1
	Most of the time	43	28.7	30.1	39.2
	A good bit of the time	42	28.0	29.4	68.5
	Some of the time	36	24.0	25.2	93.7
	A little of the time	7	4.7	4.9	98.6
	None of the time	2	1.3	1.4	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	2	1.3	1.3	1.3
	Most of the time	29	19.3	19.3	20.7
	A good bit of the time	47	31.3	31.3	52.0
	Some of the time	52	34.7	34.7	86.7
	A little of the time	19	12.7	12.7	99.3
	None of the time	1	.7	.7	100.0
	Total	150	100.0	100.0	

Question: **How much time during the past 4 weeks did you have a lot of energy?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	11	7.3	7.7	7.7
	Most of the time	39	26.0	27.3	35.0
	A good bit of the time	39	26.0	27.3	62.2
	Some of the time	42	28.0	29.4	91.6
	A little of the time	11	7.3	7.7	99.3
	None of the time	1	.7	.7	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	0	0.0	0.0	0.0
	Most of the time	17	11.3	11.3	11.3
	A good bit of the time	47	31.3	31.3	42.7
	Some of the time	64	42.7	42.7	85.3
	A little of the time	19	12.7	12.7	98.0
	None of the time	3	2.0	2.0	100.0
	Total	150	100.0	100.0	

Question: **How much time during the past 4 weeks did you feel down?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	2	1.3	1.4	1.4
	Most of the time	2	1.3	1.4	2.8
	A good bit of the time	12	8.0	8.4	11.2
	Some of the time	37	24.7	25.9	37.1
	A little of the time	51	34.0	35.7	72.7
	None of the time	39	26.0	27.3	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	1	.7	.7	.7
	Most of the time	10	6.7	6.7	7.3
	A good bit of the time	24	16.0	16.0	23.3
	Some of the time	43	28.7	28.7	52.0
	A little of the time	39	26.0	26.0	78.0
	None of the time	33	22.0	22.0	100.0
	Total	150	100.0	100.0	

Question: **During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities like visiting with friends, relatives, etc. ?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	2	1.3	1.4	1.4
	Most of the time	5	3.3	3.5	4.9
	A good bit of the time	15	10.0	10.5	15.4
	Some of the time	33	22.0	23.1	38.5
	A little of the time	63	42.0	44.1	82.5
	None of the time	25	16.7	17.5	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	0	0.0	0.0	0.0
	Most of the time	14	9.3	9.3	9.3
	A good bit of the time	31	20.7	20.7	30.0
	Some of the time	50	33.3	33.3	63.3
	A little of the time	35	23.3	23.3	86.7
	None of the time	20	13.3	13.3	100.0
	Total	150	100.0	100.0	

Table 79: Frequency tables Visit 4

Question: In general, would you say your health is....

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Excellent	7	4.7	4.9	4.9
	Very good	33	22.0	23.1	28.0
	Good	70	46.7	49.0	76.9
	Fair	26	17.3	18.2	95.1
	Poor	7	4.7	4.9	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Excellent	0	0.0	0.0	0.0
	Very good	16	10.7	10.8	10.8
	Good	79	52.7	53.4	64.2
	Fair	40	26.7	27.0	91.2
	Poor	13	8.7	8.8	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	12	8.0	8.4	8.4
	Limited a little	76	50.7	53.1	61.5
	Not limited at all	55	36.7	38.5	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Limited a lot	28	18.7	18.9	18.9
	Limited a little	103	68.7	69.6	88.5
	Not limited at all	17	11.3	11.5	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **Does your health now limit you in climbing several flights of stairs?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	22	14.7	15.4	15.4
	Limited a little	94	62.7	65.7	81.1
	Not limited at all	27	18.0	18.9	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Limited a lot	55	36.7	37.2	37.2
	Limited a little	90	60.0	60.8	98.0
	Not limited at all	3	2.0	2.0	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	110	73.3	76.9	76.9
	No	33	22.0	23.1	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	68	45.3	45.9	45.9
	No	80	53.3	54.1	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	102	68.0	71.3	71.3
	No	41	27.3	28.7	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	63	42.0	42.6	42.6
	No	85	56.7	57.4	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	125	83.3	87.4	87.4
	No	18	12.0	12.6	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	81	54.0	54.7	54.7
	No	67	44.7	45.3	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	122	81.3	85.3	85.3
	No	21	14.0	14.7	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	Yes	83	55.3	56.1	56.1
	No	65	43.3	43.9	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Not at all	23	15.3	16.1	16.1
	Slightly	65	43.3	45.5	61.5
	Moderately	46	30.7	32.2	93.7
	Quite a bit	9	6.0	6.3	100.0
	Extremely	0	0.0	0.0	
	Total	143	95.3	100.0	
		7	4.7		
STO	Not at all	6	4.0	4.1	4.1
	Slightly	29	19.3	19.6	23.6
	Moderately	74	49.3	50.0	73.6
	Quite a bit	36	24.0	24.3	98.0
	Extremely	3	2.0	2.0	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **How much time during the past 4 weeks have you feel calm and peaceful?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	17	11.3	11.9	11.9
	Most of the time	50	33.3	35.0	46.9
	A good bit of the time	30	20.0	21.0	67.8
	Some of the time	30	20.0	21.0	88.8
	A little of the time	12	8.0	8.4	97.2
	None of the time	4	2.7	2.8	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	7	4.7	4.7	4.7
	Most of the time	29	19.3	19.6	24.3
	A good bit of the time	42	28.0	28.4	52.7
	Some of the time	53	35.3	35.8	88.5
	A little of the time	16	10.7	10.8	99.3
	None of the time	1	.7	.7	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **How much time during the past 4 weeks did you have a lot of energy?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	16	10.7	11.2	11.2
	Most of the time	47	31.3	32.9	44.1
	A good bit of the time	37	24.7	25.9	69.9
	Some of the time	34	22.7	23.8	93.7
	A little of the time	9	6.0	6.3	100.0
	None of the time	0	0.0	0.0	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	0	0.0	0.0	0.0
	Most of the time	20	13.3	13.5	13.5
	A good bit of the time	49	32.7	33.1	46.6
	Some of the time	62	41.3	41.9	88.5
	A little of the time	15	10.0	10.1	98.6
	None of the time	2	1.3	1.4	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **How much time during the past 4 weeks did you feel down?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	1	.7	.7	.7
	Most of the time	3	2.0	2.1	2.8
	A good bit of the time	10	6.7	7.0	9.8
	Some of the time	32	21.3	22.4	32.2
	A little of the time	51	34.0	35.7	67.8
	None of the time	46	30.7	32.2	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time	2	1.3	1.4	1.4
	Most of the time	5	3.3	3.4	4.7
	A good bit of the time	21	14.0	14.2	18.9
	Some of the time	47	31.3	31.8	50.7
	A little of the time	40	26.7	27.0	77.7
	None of the time	33	22.0	22.3	100.0
	Total	148	98.7	100.0	
		2	1.3		

Question: **During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities like visiting with friends, relatives, etc. ?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	3	2.0	2.1	2.1
	Most of the time	3	2.0	2.1	4.2
	A good bit of the time	10	6.7	7.0	11.2
	Some of the time	33	22.0	23.1	34.3
	A little of the time	49	32.7	34.3	68.5
	None of the time	45	30.0	31.5	100.0
	Total	143	95.3	100.0	
		7	4.7		
STO	All of the time				
	Most of the time	12	8.0	8.1	8.1
	A good bit of the time	30	20.0	20.3	28.4
	Some of the time	53	35.3	35.8	64.2
	A little of the time	35	23.3	23.6	87.8
	None of the time	18	12.0	12.2	100.0
	Total	148	98.7	100.0	
		2	1.3		

Table 80: Visit 5 - Question: In general, would you say your health is....

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Excellent	6	4.0	4.1	4.1
	Very good	57	38.0	39.0	43.2
	Good	52	34.7	35.6	78.8
	Fair	24	16.0	16.4	95.2
	Poor	7	4.7	4.8	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Excellent	0	0.0	0.0	0.0
	Very good	18	12.0	12.2	12.2
	Good	76	50.7	51.4	63.5
	Fair	41	27.3	27.7	91.2
	Poor	13	8.7	8.8	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
In general, would you say your health is …	dimension1	1	146	122.57	17894.50
		2	148	172.10	25470.50
		Total	294		

Test Statistics[a]

	In general, would you say your health is …
Mann-Whitney U	7163.500
Wilcoxon W	17894.500
Z	-5.295
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 81: Visit 5 - Question: **Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	8	5.3	5.5	5.5
	Limited a little	77	51.3	52.7	58.2
	Not limited at all	61	40.7	41.8	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Limited a lot	24	16.0	16.2	16.2
	Limited a little	106	70.7	71.6	87.8
	Not limited at all	18	12.0	12.2	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much? dimension1	1	146	172.84	25235.00
	2	148	122.50	18130.00
	Total	294		

Test Statistics[a]

	Does your health now limit you in moderate physical efforts such as moving a table, pushing the vacuum cleaner, bowling or playing golf? If so, how much?
Mann-Whitney U	7104.000
Wilcoxon W	18130.000
Z	-5.909
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 82: Visit 5 - Question: **Does your health now limit you in climbing several flights of stairs?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Limited a lot	22	14.7	15.1	15.1
	Limited a little	92	61.3	63.0	78.1
	Not limited at all	32	21.3	21.9	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Limited a lot	46	30.7	31.1	31.1
	Limited a little	98	65.3	66.2	97.3
	Not limited at all	4	2.7	2.7	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group	N	Mean Rank	Sum of Ranks
Does your health now limit you in climbing several flights of stairs?	dimension1 1	146	168.83	24649.00
	2	148	126.46	18716.00
	Total	294		

Test Statistics[a]

	Does your health now limit you in climbing several flights of stairs?
Mann-Whitney U	7690.000
Wilcoxon W	18716.000
Z	-5.050
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 83: Visit 5 - Question: During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	113	75.3	77.4	77.4
	No	33	22.0	22.6	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Yes	74	49.3	50.0	50.0
	No	74	49.3	50.0	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?	dimension1	1	146	127.23	18575.00
		2	148	167.50	24790.00
		Total	294		

Test Statistics[a]

	During the past 4 weeks, have you accomplished less than you would like as a result of your physical health?
Mann-Whitney U	7844.000
Wilcoxon W	18575.000
Z	-4.873
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 84: Visit 5 - Question: **During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	102	68.0	69.9	69.9
	No	44	29.3	30.1	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Yes	67	44.7	45.3	45.3
	No	81	54.0	54.7	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?	dimension1	1	146	129.30	18878.00
		2	148	165.45	24487.00
		Total	294		

Test Statistics[a]

	During the past 4 weeks, were you limited in the kind of work or other regular activities you do as a result of your physical health?
Mann-Whitney U	8147.000
Wilcoxon W	18878.000
Z	-4.257
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 85: Visit 5 - Question: **During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	128	85.3	87.7	87.7
	No	18	12.0	12.3	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Yes	90	60.0	60.8	60.8
	No	58	38.7	39.2	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?	dimension1	1	146	127.62	18633.00
		2	148	167.11	24732.00
		Total	294		

Test Statistics[a]

	During the past 4 weeks, have you accomplished less than you would like to as a result of any emotional problems, such as feeling depressed or anxious?
Mann-Whitney U	7902.000
Wilcoxon W	18633.000
Z	-5.251
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 86: Visit 5 - Question: **During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Yes	120	80.0	82.2	82.2
	No	26	17.3	17.8	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Yes	87	58.0	58.8	58.8
	No	61	40.7	41.2	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?	dimension1	1	146	130.18	19006.00
		2	148	164.59	24359.00
		Total	294		

Test Statistics[a]

	During the past 4 weeks, did you not do work or other regular activities as carefully as usual as a result of any emotional problems such as feeling depresses or anxious?
Mann-Whitney U	8275.000
Wilcoxon W	19006.000
Z	-4.389
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 87: Visit 5 - Question: **During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	Not at all	28	18.7	19.2	19.2
	Slightly	72	48.0	49.3	68.5
	Moderately	39	26.0	26.7	95.2
	Quite a bit	7	4.7	4.8	100.0
	Extremely	0	0.0	0.0	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	Not at all	8	5.3	5.4	5.4
	Slightly	29	19.3	19.6	25.0
	Moderately	80	53.3	54.1	79.1
	Quite a bit	29	19.3	19.6	98.6
	Extremely	2	1.3	1.4	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?	dimension1	1	146	112.24	16386.50
		2	148	182.29	26978.50
		Total	294		

Test Statistics[a]

	During the past 4 weeks, how much did pain interfere with your normal work, including both work outside the home and housework?
Mann-Whitney U	5655.500
Wilcoxon W	16386.500
Z	-7.490
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 88: Visit 5 - Question: **How much time during the past 4 weeks have you feel calm and peaceful?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	32	21.3	21.9	21.9
	Most of the time	47	31.3	32.2	54.1
	A good bit of the time	24	16.0	16.4	70.5
	Some of the time	25	16.7	17.1	87.7
	A little of the time	14	9.3	9.6	97.3
	None of the time	4	2.7	2.7	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	All of the time	3	2.0	2.0	2.0
	Most of the time	31	20.7	20.9	23.0
	A good bit of the time	45	30.0	30.4	53.4
	Some of the time	53	35.3	35.8	89.2
	A little of the time	15	10.0	10.1	99.3
	None of the time	1	.7	.7	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks have you feel calm and peaceful?	dimension1	1	146	124.55	18185.00
		2	148	170.14	25180.00
		Total	294		

Test Statistics[a]

	How much time during the past 4 weeks have you feel calm and peaceful?
Mann-Whitney U	7454.000
Wilcoxon W	18185.000
Z	-4.723
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 89: Visit 5 - Question: **How much time during the past 4 weeks did you have a lot of energy?**

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	25	16.7	17.1	17.1
	Most of the time	54	36.0	37.0	54.1
	A good bit of the time	33	22.0	22.6	76.7
	Some of the time	24	16.0	16.4	93.2
	A little of the time	9	6.0	6.2	99.3
	None of the time	1	.7	.7	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	All of the time	1	.7	.7	.7
	Most of the time	23	15.3	15.5	16.2
	A good bit of the time	50	33.3	33.8	50.0
	Some of the time	56	37.3	37.8	87.8
	A little of the time	15	10.0	10.1	98.0
	None of the time	3	2.0	2.0	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks did you have a lot of energy?	dimension1	1	146	115.53	16867.50
		2	148	179.04	26497.50
		Total	294		

Test Statistics[a]

	How much time during the past 4 weeks did you have a lot of energy?
Mann-Whitney U	6136.500
Wilcoxon W	16867.500
Z	-6.612
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 90: Visit 5 - Question: How much time during the past 4 weeks did you feel down?

Treatment group	Parameter	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	1	.7	.7	.7
	Most of the time	0	0.0	0.0	.7
	A good bit of the time	10	6.7	6.8	7.5
	Some of the time	24	16.0	16.4	24.0
	A little of the time	60	40.0	41.1	65.1
	None of the time	51	34.0	34.9	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	All of the time	0	0.0	0.0	0.0
	Most of the time	9	6.0	6.1	6.1
	A good bit of the time	23	15.3	15.5	21.6
	Some of the time	42	28.0	28.4	50.0
	A little of the time	35	23.3	23.6	73.6
	None of the time	39	26.0	26.4	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks did you feel down?	dimension1	1	146	166.11	24251.50
		2	148	129.15	19113.50
		Total	294		

Test Statistics[a]

	How much time during the past 4 weeks did you feel down?
Mann-Whitney U	8087.500
Wilcoxon W	19113.500
Z	-3.876
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

Table 91: Visit 5 - Question: **During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities like visiting with friends, relatives, etc. ?**

Treatment group	**Parameter**	Frequency	Percent	Valid Percent	Cumulative Percent
PAST	All of the time	0	0.0	0.0	0.0
	Most of the time	3	2.0	2.1	2.1
	A good bit of the time	5	3.3	3.4	5.5
	Some of the time	37	24.7	25.3	30.8
	A little of the time	37	24.7	25.3	56.2
	None of the time	64	42.7	43.8	100.0
	Total	146	97.3	100.0	
		4	2.7		
STO	All of the time	1	.7	.7	.7
	Most of the time	15	10.0	10.1	10.8
	A good bit of the time	24	16.0	16.2	27.0
	Some of the time	55	36.7	37.2	64.2
	A little of the time	35	23.3	23.6	87.8
	None of the time	18	12.0	12.2	100.0
	Total	148	98.7	100.0	
		2	1.3		

Ranks

	was assigned to the following treatment group		N	Mean Rank	Sum of Ranks
How much time during the past 4 weeks did you feel down?	dimension1	1	146	166.11	24251.50
		2	148	129.15	19113.50
		Total	294		

Test Statistics[a]

	How much time during the past 4 weeks did you feel down?
Mann-Whitney U	8087.500
Wilcoxon W	19113.500
Z	-3.876
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: was assigned to the following treatment group

15 REFERENCE LIST

PENDLETON A, ARDEN N, DOUGADOS M, DOHERTY M, BANNWARTH B, BIJLSMA JWJ ET AL. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Including Therapeutic Trials (ESCISIT). ANN RHEUM DIS 2000;59: 936-944

2. LEQUESNE M, BRANDT K, BELLAMY N, MOSKOWITZ R, MENKES CJ, PELLETIER JP, ALTMAN RD - Guidelines for testing Slow Acting Drugs in OsteoArthritis. J RHEUMATOL, 1994, 21, suppl 41, 65-73.

3. DOUGADOS M, DEVOGELAER JP, ANNEFELD M, AVOUAC B, BOUVENOT G, COOPER C ET AL (The Members of the Group for the Respect of Ethics and Excellence in Science). - Recommendations for the registration of drugs used in the treatment of osteoarthritis. ANN RHEUM DIS 1996 ; 55 :552-7.

4. BELLAMY N, KIRWAN J, ALTMAN R, BOERS M, BRANDT KD, BROOKS P, DOUGADOS M, LEQUESNE M, STRAND V, TYGWELL P. - Recommendations for a score set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Results of consensus development at OMERACT III. J RHEUMATOL 1997 ; 24 : 799- 804.

5. ALTMAN R, BRANDT K, HOCHBERG M, MOSKOWITZ R, BELLARNY N, BLOCH DA ET AL. - Design and conduct of clinical trials in patients with osteoarthritis : Recommendations from a task force of the Osteoarthritis Research Society. Results of a Workshop. OSTEOARTHRITIS CART. 1996, 4 : 217-43.

6. LEQUESNE M - Les anti-arthrosiques symptomatiques d'action lente : un nouveau concept thérapeutique? REV RHUM 1994; 61 : 75-9.

7. MAUVIEL A, DAIREAUX M, HARTMANN DJ, GALERA P, LOYAUX G, PUJOL JP - Effets des insaponifiables d'avocat et de soja (PIAS) sur la production de collagène par des cultures de synoviocytes, chondrocytes articulaires et fibroblastes dermiques. REV RHUM MAL OSTEOARTIC 1987 ; 56 : 207-11.

8. LOYAU G, PUJOL JP, MAUVIEL A - Effet des insaponifiables d'avocat/soja (Piasclédine°) sur l'activité coliagénolytique de culture de synoviocytes rhumatoides humains et de chondrocytes articulaires de lapin traités par l'interleukine 1. REV RHUM MAL OSTEOARTIC 1991, 58: 241-5.

9. MAZIÈRES B, TEMPESTA C, TIECHARD M, VAGUIER G - Pathologic and biochemical effects of a lipidic avocado and soja extract (LASE) on an expérimental post-

contusive model of OA (abstract). - OSTEOARTHRITIS CARTIL 1993 ; 1 : 46.

10. HENROTIN YE, LABASSE AH, JASPAR JM, DE GROOTE DD, ZHENG SX, GUILLOU GB, REGINSTER JYL. - Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. CLINICAL RHEUM 1998, 17: 31-9.

11. BOUMEDIÈNE K, BOGDANOWICZ P, FELISAZ N, GALERA P, PUJOI JP - Avocado/soya unsaponifiables enhance expression of transforming growth factor and plasminogen activator inhibitor-1 in cultured articular chondrocytes. ARTHRITIS RHEUM 1999; 39: S227.

12. BLOTMAN F, MAHEU E, WULWIK A, CASPARD H, LOPEZ A. - Mid-term efficacy and safety of avocado and soya unsaponifiables (ASU) in the treatment of knee and hip osteoarthritis : results of a three- month prospective, randomized, double-blind, placebo-controlled, parallel groups, multicenter clinical trial. REV RHUM (Engl Ed) 1997; 64 : 825-34.

13. MAHEU E, MAZIÈRES B, LE LOËT X, LOYAU G, VALAT JP, GROUIN JM, BOURGEOIS P, ROZENBERG S. - Symptomatic efficacy of avocado/ soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. A prospective, randomized, double- blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month follow-up demonstrating a persistent effect. ARTHRITIS RHEUM 1998 ; 41 : 81-91.

14. ALTMAN R, ASCH E, BLOCH D, BOLE G, BORENSTEIN D, BRANDT K, CHRISTY W, COOKE TD, GREENWALD R, HOCHBERG M, HOWELL D, KAPLAN D, KOOPMAN W, LONGLEY S, MANKIN H, MCSHANE DJ, MEDSGER T, MEEMAN R, MIKKELSEN W, MOSKOWITZ R, MURPHY W, ROTHSCHILD B, SEGAL M, SOKOLOFF L, WOLFE F - Development of criteria for the classification and reporting of osteoarthritis. ARTHRITIS AND RHEUMATISM 1986; 29 - 1039-49.

15. KELLGREN JH, LAURENCE JS. - Radiological assessment of osteoarthritis. ANN. RHEUM. Dis. 1957 ; 16: 494-501

16. HUTCHINSON TA, SHAHAN DR, ANDERSON ML: DRUGDEX® SYSTEM. MICROMEDEX Inc., Englewood, Colorado

17. PETERSON AM, NAU DP, CRAMER JA, ET AL. A checklist for medication compliance and persistence studies using retrospective databases. VALUE HEALTH 2006;10:3-12.

18. LEQUESNE M, DOUGADOS M, ABITEBOUL M, ET AL: How to evaluate the long-term course of osteoarthritis: Tests for trials of fundamental treatments. REV RHUM MAL OSTEOARTIC 1990; 57(9) part 2: 24S-31S. (article in French)

19. WARE JE, KOSINSKI M, AND KELLER SD A 12-Item Short-Form Health Survey construction of scales and preliminary tests of reliability and validity. MED CARE 1996 Mar; 34 (3): 220-33

20. LEQUESNE M, MERY C, SAMSON M, GERARD P - Indexes of severity for osteoarthritis of the hip and knee. SCAND J RHEUMATOL, 1987 ; 65 : 85-9.

21. HUSKISSON E.C. Measurement of pain. LANCET 1974 ; November 9:1127-31

22. PAVELKA K, COSTE P, GEHER P, KREJCI G: Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin. Rheumatol (2010) 29:659-670

23. JORDAN K.M. et al. EULAR resommendations 2003 : an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145 – 1155.

24. LEQUESNE M, MAHEU E, CADET C, DREISER RL. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002; 47:50-8.